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Scope of the Thesis 
The endocytic pathway is essential for the defence against pathogens. Various pathogens 
are internalized some of its proteins (antigens) are subsequently degraded while transported 
through the endocytic pathway. In this way, small immuno genetic peptides are generated 
which are ultimately loaded onto MHC class II molecules in the specialized MHC class II-
containing compartments (MIIC). At the same time MHC class II molecules are synthesized 
in the ER and targeted via the Golgi Apparatus to the MIIC. This lysosomal-related organelle 
forms the ideal environment for loading of the antigenic peptides onto MHC class II 
molecules. After loading, MHC class II molecules are transported to the plasma membrane 
where the peptide-MHC class II complex is presented to CD4+ T cells.  
The first part of the introduction gives a general overview of the process of MHC class II 
loading with peptides. The involvement of HLA-DM and -DO are discussed as well as the 
possible use of MHC class II-peptides in immunotherapy for cancer. The second part of the 
introduction deals with the current finding that Rab proteins are not only found associated 
with the fusion machinery of intracellular vesicles, but are often linked to motor proteins as 
well.  
In Chapter 2 we look in closer detail to the transport of the MIIC. By labeling the β-chain 
of the class II DR1 with GFP, we were able to follow the MIIC in living cells. Striking is the 
bi-directional transport of these compartments. We determined that this bi-directionality was 
facilitated by the alternating actions of two microtubule-based motors, kinesin and dynein. 
The regulation of this transport occurs via the small GTPase Rab7 and its effector RILP, 
which is described in Chapter 3.  RILP, upon binding to active Rab7, is able to recruit the 
minus-end motor complex dynein-dynactin onto lysosomal compartments. Thereby transport 
towards the microtubule-organizing center (MTOC) is stimulated. As a result, lysosomal 
compartments form a dense cluster around the MTOC. Recently we found a natural occurring 
splice variant of RILP, lacking exon VII, which is unable to recruit the dynein-dynactin motor 
complex. The characteristics of this variant and its implication for the current understanding 
of RILP functioning are outlined in Chapter 4. 
MIIC are not the only lysosomal compartments moving in a bi-directional fashion through 
the cell. Conventional lysosomes and late endosomes, and phagosomes also move bi-
directional via the action of kinesin and dynein along the microtubules. Chapter 5 describes 
how stimulation of minus-end transport by expression of RILP, can lead to the killing of 
Salmonella bacteria. Normally Salmonella survives in a so-called Salmonella-containing 
vacuole (SCV) by actively preventing fusion with mature, degradative lysosomes. We now 
show that upon expression of RILP, dynein is massively recruited onto the SCV which largely 
stimulates fusion with mature lysosomes. As a result, intracellular Salmonella survival 
decreases dramatically. 
In melanocytes, a specialized lysosomal compartment exists besides the conventional 
lysosomes, the melanosome. Melanosomes are the factories in which melanin is synthesized 
and stored. Upon stimulation with hormones or UV light, melanocytes secrete their 
melanosomes, which are taken up by the neighboring keratinocytes and provide color in hair 
and skin. Chapter 6 deals with two GTPases and two motor proteins active in the transport of 
melanosomes. Whereas Rab7 acts in a more early stage, regulating the microtubule-based 
dynein transport via RILP, Rab27a acts at later stages capturing the melanosomes in the 
peripheral actin via the actin-based Myosin Va motor. 
 Chapter 7 summarizes the findings in the previous chapters and describes the general 
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A brief introduction in the process of antigen presentation 
MHC class II molecules present fragments from proteins degraded in the endocytic 
pathway (Cresswell, 2000; Wubbolts and Neefjes, 1999) (figure 1). MHC class II molecules 
are composed of an α and β chain that assemble in the ER into an αβ heterodimer. 
Subsequently, a third chain, the invariant chain or Ii, interacts with this heterodimer to form a 
heterotrimer. In fact, a trimer of this heterotrimer is formed resulting in a nonameric complex 
(Cresswell, 1994; Marks et al., 1990; Roche et al., 1991). Ii acts as a sort of a pseudosubstrate 
by allowing a small segment (called CLIP for Class II-associated Ii peptide) to enter the 
peptide-binding groove of MHC class II. Moreover, Ii is necessary for transport out of the ER 
as illustrated in mice lacking Ii which show a reduced surface expression of MHC class II 
(Bikoff et al., 1993; Viville et al., 1993).  
Whereas most proteins are transported via the Golgi directly to the plasma membrane, Ii 
targets MHC class II molecules from the trans-Golgi network to late endosomal structures, 
collectively called MIIC for MHC class II-containing compartments (Neefjes et al., 1990). In 
the MIIC all the requirements for efficient peptide loading of MHC class II are concentrated. 
First, proteases that degrade Ii until only the CLIP fragment is left in the peptide binding 
groove of MHC class II molecules (Neefjes and Ploegh, 1992). Second, proteases, reductases 
and unfoldases that process antigenic fragments that have entered the cell by receptor-
mediated or fluid-phase endocytosis (Lennon-Dumenil et al., 2002). Finally, HLA-DM which 
mediates the exchange of the CLIP fragment for fragments generated from the endocytosed 
antigens (Sanderson et al., 1994). The activity of HLA-DM in turn can be controlled by a 
chaperone-of-chaperones called HLA-DO (Denzin et al., 1997; Liljedahl et al., 1996; van 
Ham et al., 1997). Thus, in these specialised MIIC the unique combination of dedicated 
(endosomal) chaperones and proteolytic activity supports proper antigen loading of MHC 
class II molecules. Loaded MHC class II molecules are subsequently transported to the 
plasma membrane for presentation of endocytosed antigens to CD4+ T cells (Germain and 











Fig. 1 Peptide loading of MHC class II and MHC class I molecules. 
MHC class II molecules (MHCII) are assembled as dimers in the endoplasmic reticulum (ER) with help of the 
specialized chaperone invariant chain (Ii), which in addition occupies the peptide-binding groove. Three of these 
MHC class II/ Ii complexes together form a nonameric complex that is transported to the MHC class II 
containing compartments (MIIC). Here the invariant chain is degraded by cathepsins and proteases until only 
the part occupying the peptide-binding groove is left, which is called CLIP. In these compartments MHCII also 
encounters antigenic peptide fragments derived from proteins degraded in the endocytic track. CLIP is then 
exchanged for one of these fragments with help of the chaperone HLA-DM, and the peptide loaded MHCII is 
transported to the plasma membrane for presentation to the immune system.  
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The invariant chain, a transporting pseudopeptide  
As discussed above, MHC class II molecules can encounter at least three different 
specialised chaperones during its existence. The formation of the MHC class II αβ 
heterodimer is the first step in the formation of the MHC class II complex in the ER and is 
assisted by various common chaperones like BiP and PDI (Bonnerot et al., 1994; Cotner and 
Pious, 1995; Nijenhuis and Neefjes, 1994; Schaiff et al., 1992). Rapidly after this assembly 
step, the first dedicated chaperone Ii is co-assembled (Cresswell, 1994; Marks et al., 1990; 
Roche et al., 1991). Ii is usually expressed in molar excess over MHC class II αβ 
heterodimers and is retained in the ER. Whereas Ii supports exit of MHC class II αβ 
heterodimers from the ER, the reverse is also the case. MHC class II αβ heterodimers are 
required for release of Ii from the ER (Bikoff et al., 1993; Marks et al., 1990; Viville et al., 
1993).  
Ii is a type II transmembrane glycoprotein containing a short amino-terminal cytoplasmic 
domain, a single transmembrane domain, a domain that occupies the peptide-binding groove 
of MHC class II (called Class-II-associated Ii peptide or CLIP), and a carboxyl-terminal 
trimerisation motif (figure 2). Ii forms trimers that interact with dimers of MHC class IIαβ in 
the ER (Cresswell, 1994; Marks et al., 1990; Roche et al., 1991) (figure 1). The interaction of 
Ii with MHC class II is necessary for proper folding and supports transport of MHC class II 
molecules (Anderson and Miller, 1992; Cresswell, 1996; Marks et al., 1995a; Viville et al., 
1993) from the ER to endosomal structures (Bikoff et al., 1993).  
 Ii, however, not only functions as a mediator in transport. Early in assembly, the CLIP 
segment of Ii enters the MHC class II peptide-binding groove. This acts as a pseudopeptide 
preventing premature loading of MHC class II with peptides that have entered the ER for 
binding to MHC class I molecules (Busch et al., 1996). In addition, peptide (or 
pseudopeptide) binding is required to pass the ‘ER quality control system’ for transport to the 
endocytic pathway (Bikoff et al., 1993; Viville et al., 1993). After ER exit the vast majority of 
MHC class II/Ii complexes enters the endocytic pathway (Neefjes et al., 1990), although a 
small percentage is transported directly to the plasma membrane via the secretory pathway 
(Lamb et al., 1991) followed by rapid internalisation and sorting into the endocytic pathway 





Fig. 2 Structural overview of the p31 isoform of the human invariant chain. 
Invariant chain is a type II transmembrane glycoprotein containing a short amino-terminal cytoplasmic domain, 
a single transmembrane domain (TM), a domain that occupies the peptide-binding groove of MHC class II 
(called Class-II-associated Ii peptide or CLIP), and a carboxyl-terminal trimerisation motif. The cytoplasmic 
domain contains two di-leucine motifs that are essential for sorting and intracellular trafficking. A destruction 
box motif (RXXL) near the transmembrane region appears to be involved in nuclear NF-κB signaling. Also 
depicted is the p41 isoform that harbors an additional 64 amino acid Thyroglobulin domain (TGD) known to 
regulate cathepsin L activity. 
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The cytoplasmic domain of Ii contains two di-leucine motifs (figure 2), which are 
necessary for sorting of MHC class II molecules to the MIIC and also for internalisation from 
the plasma membrane (Bakke and Dobberstein, 1990; Lotteau et al., 1990; Nijenhuis et al., 
1994; Odorizzi et al., 1994; Pieters et al., 1993; Pond et al., 1995). There is some debate about 
how the MHC class II complexes traffic to the MIIC. Some reports describe trafficking via 
early endosomes to MIIC (Brachet et al., 1999; Pond and Watts, 1999), but most show direct 
targeting from the trans-Golgi network to the MIIC (Benaroch et al., 1995; Davidson, 1999; 
Neefjes et al., 1990; Peters et al., 1991). In all cases the MHC class II complexes are targeted 
to the pre-lysosomal MIIC compartment.  
 
Processing of the invariant chain 
Once inside the endocytic pathway, Ii is degraded by various proteases in a processive 
manner. Ii degradation is essential for transport of antigen loaded MHC class II molecules 
from the MIIC to the plasma membrane. Although cathepsin B and D were originally claimed 
to be responsible for degradation of Ii, this concept was left when it was observed that Ii 
degradation proceeded normally in mice lacking these proteases (Deussing et al., 1998; 
Villadangos et al., 1997). Instead, Ii degradation involves more specific proteases like 
cathepsin S and L. Inhibition of cathepsin S impaired MHC class II antigen presentation and 
Ii degradation (Riese et al., 1998; Riese et al., 1996). A marked tissue specific expression 
profile is observed for the cathepsins. In macrophages cathepsin S is up- and cathepsin L is 
down-regulated upon interferon γ stimulation (Beers et al., 2003). Whereas peripheral antigen 
presenting cells contain relatively high cathepsin S levels (Beers et al., 2003; Honey et al., 
2001), cathepsin L appears to be crucial for Ii degradation in cortical tissue endothelial cells 
(Honey et al., 2002; Nakagawa and Rudensky, 1999). Thus, cathepsin S and L are both 
important with partially overlapping activities for Ii degradation, although other (currently 
unknown) proteases will be involved in other steps of this degradation.  
In conclusion, several proteases are required for one simple but crucial act, the removal 
of a transporting chaperone 1-3 hours after assembly of the MHC class II/Ii nonamer. This is 
critical for the exchange of remaining CLIP fragments for antigenic peptides and for the 
transport of MHC class II to the plasma membrane.  
 
The invariant chain, more than just a MHC class II chaperone 
Invariant chain does not merely function as a MHC class II chaperone preventing peptide 
loading in the ER, stimulating exit from the ER and modulating antigenic peptide loading, but 
it may have additional functions as well. The development from immature to mature B-cells is 
impaired in Ii-deficient mice. These B-cells arrest in an immature stage (Kenty and Bikoff, 
1999; Shachar and Flavell, 1996). The N-terminal cytoplasmic domain of Ii is required for B-
cell maturation, since expression of only this domain suffices to stimulate B-cell maturation 
(Matza et al., 2002b). The Ii cytosolic domain diffuses from MIIC into the nucleus where it is 
supposed to activate NF-κB signalling which then results in B-cell maturation (Matza et al., 
2002a).  
 
HLA-DM, editor for antigenic peptide loading of MHC class II molecules 
The need for additional chaperones in the loading of MHC class II molecules with 
peptides was not obvious. Only after a thorough analysis of B cell lines with deletions in the 
MHC locus at chromosome 6, it became apparent that additional proteins were required for 
successful peptide loading of MHC class II molecules. The genes were subsequently 
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identified as HLA-DMA and HLA-DMB which assemble into HLA-DM (H2-M in mice), a 
non-polymorphic type I membrane protein with high similarity in sequence and structure to 
MHC class II molecules (Cho et al., 1991; Fling et al., 1994; Kelly et al., 1991; Mellins et al., 
1991; Morris et al., 1994). After assembly in the ER, HLA-DM is transported to MIIC 
through a tyrosine-based targeting signal in the cytoplasmic tail of HLA-DMB (Copier et al., 
1996; Marks et al., 1995b). Although HLA-DM accumulates in MIIC, it probably recycles via 
the plasma membrane by efficient re-internalisation mediated by the tyrosine-motif in the 
HLA-DMB tail (Arndt et al., 2000; van Lith et al., 2001). 
HLA-DM deficient cells and mice express surface MHC class II molecules loaded with 
the Ii-degradation fragment CLIP instead of antigenic peptides (Ceman et al., 1994; Fling et 
al., 1994; Fung-Leung et al., 1996; Martin et al., 1996; Miyazaki et al., 1996; Morris et al., 
1994; Riberdy et al., 1992). Thus, although some spontaneous exchange of CLIP for antigenic 
fragments can occur in the acidic MIIC (Avva and Cresswell, 1994), efficient exchange 
requires HLA-DM to release CLIP and low affinity peptides, while allowing high affinity 
peptides to remain associated (Denzin and Cresswell, 1995; Kropshofer et al., 1996; Lovitch 
et al., 2003; Sherman et al., 1995; Sloan et al., 1995; van Ham et al., 1996; Weber et al., 
1996). Further in vitro experiments showed that the interaction between HLA-DM and MHC 
class II molecules and the ‘activity’ of HLA-DM were facilitated by acidic pH, as found in the 
MIIC (Kropshofer et al., 1997; Sanderson et al., 1996; Ullrich et al., 1997; vogt et al., 1997). 
HLA-DM appears to stabilize MHC class II molecules devoid of peptide to allow binding of 
high affinity peptides and at the same time, as a true chaperone, prevents the aggregation of 
‘empty’ MHC class II molecules (Denzin et al., 1996; Kropshofer et al., 1997).  
The structure of HLA-DM reveals a molecule with a high structural identity to MHC 
class II molecules (figure 3). One major difference is the absence of a MHC class II peptide-
binding groove in HLA-DM, which renders it unable to bind peptides (and the invariant 
chain) (Fremont et al., 1998; Mosyak et al., 1998). A co-crystal of HLA-DM and MHC class 
II molecules has not been generated, but mutational studies have revealed areas in the top part 
(peptide-binding groove) of MHC class II and HLA-DM as interacting segments (Pashine et 
al., 2003; Stratikos et al., 2002). MHC class II molecules are highly polymorphic and 
different MHC class II alleles present different fragments from the same antigen. Still, Ii as 
well as HLA-DM are non-polymorphic and interact with all polymorphic MHC class II alleles 
(Robinson et al., 2001). As a consequence, the binding affinity of CLIP for MHC class II 
Fig. 3 The structure of HLA-DM 
shows high structural identity to MHC 
class II molecules.  
The structures of a MHC class II 
molecule (in this case HLA-DR3) and 
HLA-DM are projected above the 
membrane. The transmembrane regions 
of both molecules are undefined and not 
depicted. Note the absence of an open 
peptide-binding groove in HLA-DM, 
which prohibits peptide binding. 
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molecules differs for the different MHC class II haplotypes, possibly resulting in a different 
dependency on HLA-DM (Doebele et al., 2003). Whether this results in differences in peptide 
loading of MHC class II remains unclear. 
 
HLA-DO, the chaperone of chaperones  
As described, efficient loading of MHC class II with specific antigenic peptides is tightly 
regulated by the chaperones Ii and HLA-DM. More recently the attention shifted to another 
MHC class II look-a-like, also encoded in the MHC locus. Two genes encoding for HLA-
DOA and HLA-DOB were identified that assemble into a HLA-DO (or H2-O the murine 
homologue of HLA-DO) heterodimer (Tonnelle et al., 1985; Young and Trowsdale, 1990). 
Like HLA-DM, HLA-DO has a very high sequence identity to HLA-DR molecules, which 
suggests that they arose from recent gene duplication (van Lith et al., 2002). HLA-DO is also 
a non-polymorphic heterodimer with lysosomal targeting sequences located in the 
cytoplasmic tail of HLA-DOB (van Lith et al., 2001). Unlike HLA-DMB, HLA-DOB 
contains two putative targeting signals, a di-leucine motif and a tyrosine-based motif (van 
Lith et al., 2001).  
Whereas HLA-DM is always co-expressed with MHC class II molecules in APCs, HLA-
DO is only expressed on a subset of thymic medullary epithelium and in immature B cells 
(Douek and Altmann, 1997; Karlsson et al., 1991; Tonnelle et al., 1985). Moreover, both 
HLA-DO and HLA-DM are rapidly down-regulated upon activation of B cells (Roucard et al., 
2001). A stable interaction is formed between HLA-DO and HLA-DM, and targets HLA-DO 
to the MIIC (Liljedahl et al., 1996). Upon deletion of its targeting signals, HLA-DO is still 
targeted to the MIIC via HLA-DM (van Lith et al., 2001). Subsequently, the HLA-DM/DO 
heterotetramer recycles between MIIC and the plasma membrane although it accumulates in 
MIIC (van Lith et al., 2001).  
HLA-DO acts as a negative regulator of HLA-DM since MHC class II molecules loaded 
with the CLIP fragment appeared at the plasma membrane in response to ectopic expression 
of HLA-DO or overexpression of H2-O in transgenic mice (Brocke et al., 2003; Denzin et al., 
1997; van Ham et al., 2000; van Ham et al., 1997). Mice deficient for H2-O have only mild 
phenotypes, including an increase in antibody titer in plasma suggesting that B cell 
proliferation is less tightly controlled (Liljedahl et al., 1998; Perraudeau et al., 2000). Further 
studies revealed that HLA-DO altered the pH sensitivity of HLA-DM in supporting peptide 
loading of MHC class II molecules in vitro. Apparently, HLA-DO acts as a pH sensor 
restricting HLA-DM activity to more acidic (late endosomal) structures (van Ham et al., 
2000). The function of HLA-DO is not fully understood, the assumption is that the activity of 
B cells should be tightly controlled, implying that antigenic peptide loading of MHC class II 
should primarily occur with antigens recognized by surface immunoglobulins. The activity of 
HLA-DO skews peptide loading to the late endosomal structures where B cell receptor-
mediated antigens are processed. HLA-DO may thus play a critical role in controlling B cell 
activation by regulating the activity of HLA-DM.  
 
From the MIIC to the plasma membrane 
Obviously, proper loading with antigenic peptides in the MIIC is not sufficient for 
successful MHC class II antigen presentation. Therefore, MHC class II molecules first have to 
be transported to the plasma membrane. Transport of MHC class II has been studied using 
combinations of electron microscopy and real-time imaging of GFP-tagged MHC class II 
molecules. MIIC move along microtubules from the Golgi area around the microtubule 
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organising center (MTOC) toward the plasma membrane (Wubbolts et al., 1996). This 
transport is similar to late endosomal and lysosomal transport and occurs in a bi-directional 
manner and in a stop-and-go fashion along the microtubules, mediated by the alternate 
activities of the dynein/dynactin and kinesin motor proteins (Wubbolts et al., 1999). What 
controls these motor protein activities is largely unclear but dynein/dynactin-mediated 
transport toward the minus-end involves at least the activity of the small GTPase Rab7 and its 
effector protein RILP (Jordens et al., 2001).  
Finally, the MIIC reaches the end of the microtubule at the cortical actin cytoskeleton just 
underneath the plasma membrane. How this last step occurs is unclear, but ultimately the 
MIIC fuses with the plasma membrane, as shown by electron microscopy (Raposo et al., 
1996; Wubbolts et al., 1996). At the plasma membrane, part of the intracellular content (the 
internal vesicles in a multivesicular body) is secreted in the form of so-called exosomes 
(Raposo et al., 1996; Zitvogel et al., 1998). The majority of the internal structures of the MIIC 
probably fuse back to the plasma membrane followed by rapid internalisation of the late 
endocytic MIIC proteins via their internalisation signals (Arndt et al., 2000; van Lith et al., 
2001). Subsequently, these proteins are transported back to the MIIC through the endocytic 
pathway. Since only part of the MHC class II molecules can be internalised, MHC class II 
accumulates at the plasma membrane (Pinet et al., 1995; Reid and Watts, 1990). 
After internalisation, a fraction of the MHC class II molecules is recycled back to the 
plasma membrane. In monocytes, the reappearance of MHC class II at the plasma membrane 
is controlled by interleukin 10 (Koppelman et al., 1997). Treatment with IL-10 results in a 
strong reduction of surface MHC class II molecules possibly by affecting the Rab7 pathway, 
which in turn controls dynein motor-mediated MIIC transport (our unpublished results). This 
is the first example of regulation of MHC class II responses by manipulation of the last step in 
intracellular transport of MHC class II molecules to the cell surface. 
An alternative route of MHC class II molecules from the MIIC to the plasma membrane 
has been proposed for dendritic cells (Boes et al., 2002; Chow et al., 2002; Kleijmeer et al., 
2001). Upon activation of DCs, the MIIC appears to alter its morphology resulting in the 
formation of long tubular structures extending into the periphery. Live imaging of these cells 
revealed that these class II-positive structures, similar to the conventional MIIC, move in a 
microtubule-dependent manner (Boes et al., 2002). Probably in response to the gross 
alteration of the cytoskeleton of activated dendritic cells, the MHC class II molecules move 
more in the direction of the contact site with a specific T cell. Surprisingly, no accumulation 
of GFP-tagged MHC class II molecules was observed in the ‘immunological synapse’ 
between the DC and the T cell (Boes et al., 2002). The exact function of this directed 
transport of MIIC-derived tubules after DC activation still has to be revealed.  
Thus two modes of transport of MHC class II molecules from MIIC to the plasma 
membrane have been reported; direct transport and fusion of MIIC with the plasma membrane 
and the formation of tubular structures. In either case, transport requires motor-based 
microtubule transport likely to be mediated by dynein/dynactin and kinesin motor proteins, 
with the small GTPase Rab7 as one of the controllers of this transport step.  
 
Interfering with antigen presentation by MHC class II molecules 
 
Promoting antigen presentation 
The pathway of antigen presentation by MHC class II molecules outlined above shows 
that it requires a ‘multi-enzyme’ process involving various chaperones, acidic pH and 
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proteases at different stages of biosynthesis. Obviously, affecting one or more of these 
enzymes can positively or negatively influence antigen presentation. For instance, MHC class 
II antigen presentation can be improved when antigens are more efficiently acquired and 
targeted to MIIC. Macrophages and monocytes, in contrast to B cells, are able to internalise 
large volumes. This implies that many antigenic fragments have to compete for access to 
MHC class II molecules in the MIIC. More selective uptake of antigen using surface 
immunoglobulins in B cells (Lanzavecchia, 1985; Rock et al., 1984; Siemasko and Clark, 
2001), Fc-receptors on macrophages and DCs (Fanger et al., 1997; Guyre et al., 1997) or 
mannose-receptors on DCs (Engering et al., 1997) will strongly improve antigen presentation 
by MHC class II molecules (Lanzavecchia, 1996). Cells may also alter the conditions for 
antigen presentation in MIIC. Best studied are DCs that acidify the MIIC upon activation 
(Trombetta et al., 2003), and B cells that down-regulate HLA-DO upon activation (Roucard et 
al., 2001). In both cases, antigen presentation by MHC class II molecules is more efficient.  
 
Inhibiting antigen presentation 
If activation of MHC class II antigen presentation is an option, the reverse is almost 
certainly true as well. For instance, Th2 cell activity controlling immune responses can inhibit 
class II antigen presentation. Another manner to inhibit MHC class II responses is by 
interfering with endosomal proteases, as was first shown by using leupeptin. Leupeptin is a 
protease inhibitor that inhibits complete degradation of Ii (Cresswell et al., 1990; Neefjes and 
Ploegh, 1992). Since Ii degradation is a prerequisite for transport of MHC class II molecules 
to the cell surface, these inhibitors are negative regulators of class II presentation (Amigorena 
et al., 1995; Brachet et al., 1997; Neefjes and Ploegh, 1992). Naturally occurring protease 
inhibitors exist as well. Cystatin is a reversible inhibitor of cysteine proteases like the 
cathepsins. Cystatin family members are expressed in a tissue-specific manner and can 
modulate cathepsin activities and thereby inhibit antigen presentation by MHC class II 
molecules (Pierre and Mellman, 1998), although this is still somewhat controversial.   
Pathogens are known to use a similar system to inhibit MHC class II presentation, as has 
been reported for two filarial nematodes, Onchocerca volvulus and Acanthocheilonema viteae 
(Hartmann et al., 1997; Schonemeyer et al., 2001). Both nematodes produce cystatin-like 
molecules that have an immunosuppressive activity by inhibiting cathepsin S and L. 
Moreover, Bm-CPI-2 is a cystatin homologue secreted by the parasite Brugia malayi that also 
interferes with MHC class II processing by inhibiting multiple cysteine proteases (Manoury et 
al., 2001).  
Intracellular growing bacteria use different strategies to prevent presentation by MHC 
class II molecules. These pathogens include Salmonella Typhimurium, Mycobacterium 
Tuberculosis and Mycobacterium Leprae, which usually reside in the endo/phagosomal 
pathway. Some of these pathogens are able to modulate the endo/lysosomal compartments. 
Salmonella injects several effector proteins into the host cytosol, which prevents fusion of the 
phagosome with mature lysosomes (Holden, 2002). Recently it has been found that one of the 
bacterial effectors is a PI3P phosphatase (Hernandez et al., 2004) that has been implicated in 
inhibition of the formation of internal structures within the MIIC (Fernandez-Borja et al., 
1999) and antigen presentation by MHC class II molecules (Song et al., 1997). Thus 
Salmonella might interfere with MHC class II presentation in multiple ways. It escapes the 
degradation in the mature lysosomes thereby limiting the amount of Salmonella-derived 
antigens. Secondly, by preventing the formation of internal membranes, Salmonella might 
reduce the peptide loading efficiency by preventing efficient interactions between MHC class 
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II and HLA-DM (Zwart et al., 2005). Nature has thus developed a complicated system to 
allow presentation of antigenic fragments generated in the endosomal track. It has also 
developed multiple ways to manipulate this process, not only exploited by pathogens, but also 
by tumours as will be discussed below. 
 
 
MHC class II molecules in oncogenesis 
Most tumours do not express MHC class II molecules. Exceptions are -obviously- B cell 
leukemia like chronic lymphocytic leukemia, Burkitt lymphoma, EBV-induced B cell Non-
Hodgkin Lymphoma, follicular lymphoma and Kahler’s disease (Guy et al., 1986). In 
addition, melanoma can express MHC class II molecules (Zeng et al., 2000), although often in 
a rather heterologous manner, and Glioma type 1 tumours also constitutively express MHC 
class II (Takamura et al., 2004). Furthermore, interferon γ and possibly other factors can 
induce MHC class II expression on Glioma type 2 and many other tumours including cervix 
tumours (Santin et al., 1998) and bladder cancer (Champelovier et al., 2003). In most cases, 
not only MHC class II molecules are expressed but also the accessory proteins required for 
efficient transport (Ii) and peptide loading (HLA-DM) (Siegrist et al., 1995).  
MHC class II-restricted presentation of exogenous antigens can easily be observed ex 
vivo by EBV-transformed B cells (Nijenhuis et al., 1994) and melanoma cells (van Ham et al., 
2000) implying that the MHC class II system ‘works’ correctly and efficiently in these 
tumours. In addition, MHC class II molecules can present ‘tumour-specific antigens’ like 
Epstein Barr viral (EBV) antigen EBNA-1 (Voo et al., 2002) and melanoma-specific antigens 
like tyrosinase and gp100 (Parkhurst et al., 2003; Topalian et al., 1994). Still, an efficient host 
response is obviously lacking when a tumour appears and selective outgrowth of tumour-
specific CD4+ T cells has not been reported in patients, even though these T cells can be 
expanded in vitro. Apparently tumour factors prevent expansion of these cells.  
Interestingly, some tumours that express MHC class II also express inhibitors for the 
MHC class II antigen presentation process. Most notably is the inhibitor for HLA-DM, HLA-
DO, in B cell leukemia. Whether this reflects a differentiation difference (HLA-DO is best 
expressed in immature B cells) or an active attempt to inhibit antigen presentation by MHC 
class II, is unclear. Other tumours secrete inhibitory cytokines like IL-10 to suppress MHC 
class II and other responses, which is particularly clear for melanomas (Dummer et al., 1996) 
and EBV-induced B cell tumours (Benjamin et al., 1992). The EBV genome encodes a 
homologous protein for IL-10 (BCRF1; (Moore et al., 1991; Vieira et al., 1991)) that may 
also inhibit T cell responses, although this is not fully established. Other tumours, like 
neuroblastoma, actively down regulate expression of MHC class II by silencing the CTIIA 
promoter (Croce et al., 2003). 
Patients selectively lacking expression of MHC class II molecules (and not MHC class I) 
exist. These bare lymphocyte syndrome patients usually have genetic defects in the 
transcription machinery regulating expression of MHC class II molecules and its accessory 
proteins HLA-DM and the invariant chain (Mach et al., 1994). Defects have been reported for 
the transcription factor CIITA (Steimle et al., 1993). Although these patients are prone to 
many infections, no increased rate of tumour formation has been reported. Similarly, no 
increased tumour incidence is observed in mice deficient for MHC class II molecules, DM or 
Ii. These observations suggest that class II plays no active role in the tumour formation. 
However, this does not exclude a relevant role of MHC class II molecules in anti-tumour 
responses. First, MHC class II molecules are essential for the induction of proper CTL 
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responses (Ossendorp et al., 1998). These are most likely not the MHC class II molecules 
expressed on tumours but merely MHC class II molecules expressed on professional antigen 
presenting cells, like DCs. These cells probably internalise apoptotic bodies or necrotic debris 
from tumour cells and present fragments to the CD4+ T cells, which then stimulate cytotoxic 
T cell proliferation (Ossendorp et al., 1998). State of the art tumour vaccination strategies 
therefore include -beside antigens for MHC class I molecules- antigens for presentation by 
MHC class II molecules. These antigens can be targeted into the MHC class II pathway using 
Fc-receptor-mediated uptake (You et al., 2001), via the mannose receptor (van Bergen et al., 
1999), or (although this pathway is more undefined) directly used in the form of exosomes 
(Zitvogel et al., 1998). The stimulation of both the MHC class I and MHC class II pathway 




Most attention in immunotherapy of cancer has been on MHC class I molecules, but the 
concepts with respect to the source of targets (antigens) is very similar for MHC class II 
molecules. In fact, using antigen presentation by MHC class II may even have a number of 
profound advantages. First of all, any therapy is more selective since MHC class II molecules 
are only expressed on a restricted number of tissues. In addition, delivery systems for 
antigenic fragments to MHC class II molecules are considerably simpler compared to MHC 
class I. Antigens do not have to be delivered into the cytoplasm but simply opsonised to enter 
the endocytic track for efficient loading onto MHC class II. Finally, whereas MHC class I 
molecules interact only with short peptides that do not allow further modifications, MHC 
class II molecules bind peptides in a different way, as peptides associated to MHC class II 
molecules extent out of the peptide-binding groove (Stern et al., 1994). Modifications can 
safely be introduced in these extensions without affecting the immunogenicity. Yet, the 
pharmacodynamics and stability of the peptides can be strongly affected. However, these 
modifications do allow further improvement in targeting the peptides to the correct cells by 
using for example the mannose receptor on DCs (Tan et al., 1997), and may be critical for 
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Rab proteins, connecting transport and vesicle fusion 
 
 





Arp1  actin-related protein 1 
DIC   dynein intermediate chain  
KHC   kinesin heavy chain  
KIF   kinesin superfamily protein 
MTOC  microtubule organising centre 
PI(3)P  phosphatidylinositol 3-phosphate 
RB6K  Rabkinesin-6 
MKlp2  mitotic kinesin-like protein 2 
RILP   Rab7 interacting lysosomal protein  
SCV  Salmonella-containing vacuole 
  




Small GTPases of the Rab family control timing of vesicle fusion. Fusion of two vesicles 
can only occur when they have been brought into close contact. Transport by microtubule- or 
actin-based motor proteins will facilitate this process in vivo. Ideally, transport and vesicle 
fusion are linked activities. Active, GTP-bound Rab proteins dock on specific compartments 
and are therefore perfect candidates to control transport of the different compartments. 
Recently, a number of Rab proteins were identified that control motor protein recruitment to 
their specific target membranes. By cycling through inactive and active states Rab proteins 
are able to control motor protein-mediated transport and subsequent fusion of intracellular 
structures both in a spatial and timed manner.  
 
Rab proteins and their interacting partners 
Over 60 mammalian Rab proteins have been identified and each Rab protein regulates a 
distinct intracellular transport step [1,2] through its temporal and spatial association with 
various interacting proteins. One group of interacting proteins comprises the regulatory 
proteins. These include Guanine Exchange Factors (GEFs), GTPase Activating Proteins 
(GAPs), GDP Dissociation Inhibitors (GDIs) and GDP Displacement Factors (GDFs). 
Together these proteins control the switch between active GTP-bound and inactive GDP-
bound Rab proteins. Moreover, they might be involved in targeting the Rab proteins to their 
specific membrane [3], a process which is still poorly understood.  
The second group of interacting partners are the effector proteins, a rapidly expanding list 
of proteins that specifically interact with active, GTP-bound Rab proteins [4]. One Rab 
protein can interact with multiple effector proteins that either function in a larger complex or 
provide the basis for distinct downstream functions. However, effector proteins can also be 
shared between related Rab proteins, providing concerted action of different Rab proteins 
within one pathway [5-7].  
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Rab proteins are recognized for their key roles in both membrane transport and fusion. 
Whereas the role of Rab proteins in vesicle fusion is relatively well understood [8], the exact 
role of Rab proteins in transport was obscure until recently. This review will focus on the 
emerging role of Rab proteins in vesicle transport with multiple examples of Rabs controlling 
motor protein recruitment and activation on defined vesicles (Table 1) (Figure 2).  
 
Intracellular transport  
The presence of many different intracellular compartments requires a high order of 
regulation of transport to ensure delivery at the correct destination. Two networks support 
motor protein-driven intracellular transport, the microtubule and the actin network. In animal 
cells, microtubules provide high-speed, long-range transport, whereas the actin network 
usually facilitates slower and short-range local transport events. Actin-mediated transport 
occurs via the members of the myosin family [9]. Myosins consist of a motor head, a neck 
and a variable tail domain that mediates interaction with specific cargoes [10]. Besides 
myosin II, a number of unconventional myosins are involved in organelle transport. These 
include I, V, VI and VII, of which the class V myosins are the most efficient and processive 
members [11,12].  
 Most intracellular transport, however, occurs via the microtubule network. Two families of 
motor proteins use microtubules, kinesins and dyneins [13,14]. There are 14 defined families 
of kinesin motors based on phylogenetic tree analyses [15]. Most kinesin motors transport 
cargo towards the plus-end of the microtubules located in the cell periphery, with a few 
exceptions [15]. Kinesins have a domain structure relatively similar to myosins. They consist 
of a heavy chain (KHC) and a light chain (KLC). Conventional KHCs have three subdomains: 
the globular motor head, a stalk and a globular tail domain. The non-motor domains are 
thought to be involved in cargo and microtubule binding, and regulation of the motor unit [16-
18].  
There are only two dynein motor isoforms mediating vesicular transport. These are 
cytoplasmic dynein 1 and cytoplasmic dynein 2, of which the latter is mainly involved in 
intraflagellar movement but also functions in Golgi organisation [19,20]. Dynein 1 (further on 
referred to as dynein) is the commonly known dynein involved in many cellular processes 
[21]. Dynein only mediates cargo transport towards the minus-end located at the Microtubule 
Organising Centre (MTOC) [22-24]. Dynein motors are massive multimeric complexes 
composed of two bulky heavy chains and a variety of accessory subunits including two 
intermediate chains (DICs), four light intermediated chains, and several light chains. The 
heavy chains form the motor domains, whereas the accessory subunits are involved in the 
interaction with the cargo and regulatory proteins [21]. Via the intermediate chains, dynein 
interacts with its activator, dynactin [25,26]. Dynactin is a multisubunit complex composed of 
p150glued, p62, p50dynamitin, Arp11, Arp1, β-actin, CapZ α/β, p27, p25, and p24 that links 
dynein to most cargoes [27].  
How motor proteins find their correct vesicular destination is still unclear. Several kinesins 
directly interact with their specific cargoes via their variable tail domains or their associated 
light chains, which have been shown to interact with multiple membrane-associated proteins 
[28,29]. Recently, the group of Gelfand identified at least three different dynein light 
intermediate chains, of which one is involved in the targeting of dynein to melanosomes [30]. 
Although some direct dynein-cargo interactions has been described, efficient dynein 
processivity and membrane recruitment requires dynactin [31,32]. Dynactin by itself is unable 
to directly interact with lipids in membranes, but via Arp1 dynactin can interact with the 
spectrin network on vesicular membranes [33-35]. Moreover, Muresan et al. showed that 
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spectrin specifically interacts with acidic phospholipids, indicating that the lipid composition 
of the membrane might be important for the association of motor proteins [35].  
Both, plus-end and minus-end directed motors can be present on the same cargo [36-38]. 
As a result, many intracellular vesicles like endosomes, lysosomes, secretory vesicles, 
melanosomes, peroxisomes and mitochondria move along microtubules in a bidirectional 
manner [37-42]. However, these organelles are never observed to be torn apart by two 
oppositely directed motor proteins. A recent study on bidirectional transport by dynein and 
kinesin-1 motors of peroxisomes, revealed that opposite motor activities do not act 
simultaneously, but are temporarily controlled [37]. Apparently there is an agreement between 
the motors on when to be active (Figure 1). 
 
Rab proteins controlling motor proteins  
As has been described, Rab proteins would be ideal to regulate specific recruitment of 
motor proteins to defined vesicles, because they mark all the different compartments. The first 
indications that Rab proteins might be directly linked to the cytoskeleton came from Peranen 
et al. and Deretic et al. [43,44]. They observed a striking actin localisation and actin-mediated 
movement of Rab8-positive vesicles, which was largely dependent on Rab8 activity. Since 
then, a growing number of examples were reported of Rab proteins controlling recruitment of 





Figure 1. Many cargoes move in a bidirectional manner due to the presence of both kinesin and dynein/dynactin 
on the same cargo. The alternating activities of the motors determine the direction.  
 
Golgi-associated Rab6 and its associated motors 
The first description of a Rab protein directly coupling to a motor protein was when Goud 
and co-workers identified a new kinesin-like protein as an effector of Golgi-associated Rab6, 
Rabkinesin-6 (RB6K) [45]. RB6K specifically interacted with GTP-Rab6 and overexpression 
resulted in dispersion of the Golgi towards the plus-end of microtubules. Interestingly, RB6K 
has two microtubule-binding sites; one in the N-terminal motor domain and one in the Rab6-
binding C-terminus. The functional relevance of these two microtubule-binding sites became 
apparent when RB6K was shown to be crucial for cytokinesis and was highly upregulated 
during mitosis [46-48]. In addition to its localisation to the central spindle, the motor domain 
of RB6K is highly similar to the mitotic kinesin MKLP1, and is therefore reclassified as 
MKLP2. During the cell cycle, RB6K/MKLP2 localisation is independent of Rab6, which is 
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in contradiction with its role in Golgi transport and some controversy exists about the latter 
function. However, RB6K/MKLP2 might have different interaction partners during the 
various stages of the cell cycle. 
Other Rab6 effector proteins were subsequently identified. Short et al. and Matanis et al. 
isolated two related dynactin-binding proteins, BicD1 and BicD2 that interacted with GTP-
Rab6 [49,50]. BicD2, as well as BicD1, bind to p50dynamitin [51] and thereby link Rab6 to the 
dynein/dynactin complex. Overexpression of the Rab6-binding C-terminal portion of BicD2 
significantly diminished minus-end transport of Rab6-positive vesicles, most likely by 
uncoupling the motor from Rab6 [49]. In addition, a link between Rab6 and the dynactin 
subunit p150Glued was observed in vitro [50], but the functional relevance of these two modes 
of interaction remains elusive. 
Thus active Rab6 can interact with both kinesin (RB6K/MKLP2) and the dynein/dynactin 
complex, thereby regulating both plus-end and minus-end transport of Golgi compartments. 
Still, directional transport of Golgi vesicles occurs, which cannot occur by simultaneous 
activity of the two oppositely directed motor proteins. How the relative activities of both 



















      
Rab4 KIF3B EE IP  (55) 
 LIC EE Y2H  (61) 
Rab5 DIC EE IP  (57) 
 KIF16B EE no PI3K (62) 
Rab6 p150GLUED Golgi Y2H BicD1/2 (49;50) 
 p50dynamitin Golgi pull down  (50) 
 RB6K/MKLP2 Golgi Y2H, pull 
down 
 (45) 
      
Rab7 Dynein/dynactin LE/Lys unknown RILP (64) 
      




      
Rab11 MyoVb recycling  
compartment
Y2H  (85) 
   Y2H FIP2 (86) 
Rab27a MyoVa melanosome Y2H, IP Melanophilin/Slac2 (74-78) 
 MyoVIIa melanosome pull down MyRIP (80;81) 
 
DIC, dynein intermediate chain; FIP-2, family interacting protein-2; IP, immuno precipitation; LIC,  




Table 1 :  Rab GTPases interacting with motor proteins  
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Rab4 and Rab5 regulating exo- and endocytosis via coordinated interactions with kinesin 
and dynein motors 
The transport of the insulin-responsive glucose transporter GLUT4 in 3T3-1L adipocytes, 
illustrates the interplay between Rab proteins and motors. GLUT4 proteins are translocated 
from the perinuclear area to the plasma membrane following insulin stimulation due to both 
enhanced exocytosis and reduced endocytosis [52-54]. Imamura et al. identified Rab4 as a 
main regulator of exocytosis of GLUT4 [55]. They found an interaction between active GTP-
Rab4 and KIF3B, a kinesin-2 family member. Insulin activates Rab4 in a PI3K- and PKCγ-
dependent manner, which in turn enhances its association to KIF3B. In addition, insulin 
increased binding of KIF3B to microtubules, again dependent on PI3K- and PKCγ activity. 
Since phosphorylation of kinesin has been suggested to affect microtubule-binding, it is 
possible that KIF3B is a target of these kinases [56].    
The other component of the GLUT4 cycle, endocytosis, is controlled by Rab5. Huang et al. 
showed that dynein could be co-isolated with Rab5 [57]. Upon stimulation with insulin, they 
observed a significant decrease in the levels of GTP-Rab5, which resulted in a concomitant 
reduction in dynein association and inhibition of minus-end transport. In addition, insulin 
decreased the interaction of dynein with microtubules in a PI3K-dependent manner. Again 
this might be mediated by phosphorylation of the dynein/dynactin complex, which has 
previously been shown to negatively regulate its microtubule-binding capacity [58]. 
Involvement of a large group of kinases (>207) in endo- and exocytosis is further supported 
by a recent RNAi screen by Zerial and co-workers [59]. How these kinases might affect motor 
protein-based transport remains elusive. 
Thus, the insulin-stimulated increase of active GTP-Rab4 leads to enhanced recruitment 
(by co-isolation experiments) and activity of KIF3B resulting in enhanced plus-end directed 
transport (i.e. exocytosis). However, insulin-dependent phosphorylation events also inactivate 
Rab5 and diminish dynein/dynactin function thereby inhibiting minus-end transport (i.e. 
endocytosis). By these means, insulin stimulation results in efficient delivery of GLUT4 at the 
plasma membrane. 
Earlier, Nielsen et al showed that Rab5 activity is required for minus-end directed transport 
of early endosomes isolated from A431 cells. But surprisingly, antibodies directed against the 
dynein motor did not affect minus-end transport. In contrast, MC44 antibodies directed 
against multiple KHCs blocked both minus-end and plus-end transport of early endosomes 
[60]. This suggests a link between Rab5 and a minus-end directed kinesin motor protein. 
Moreover, yeast-two hybrid data indicate that Rab4 interacts with the dynein light 
intermediate chain (LIC) [61]. Apparently, Rab proteins can adapt to the diverse motor 
requirements of distinct (sub)compartments in different cell types but various interactions still 
have to be confirmed by techniques other than yeast two-hybrid and co-isolation experiments.  
Rab5 creates a membrane-patch for KIF16B motor association 
Whereas the previous examples described direct interactions between microtubule-based 
motor proteins and Rab proteins, Zerial and colleagues recently showed that Rab5 can create a 
local environment for motor recruitment without the need for a direct interaction. They 
identified a new kinesin family member, KIF16B, which was recruited to early endosomes in 
a Rab5-dependent manner [62]. KIF16B can be classified as a plus-end directed kinesin-3 
family member [15]. Together with Unc104, another kinesin-3, it is the only known kinesin 
that contains a lipid-binding domain. Hoepfner et al. showed that KIF16B interacts with 
PI(3)P-loaded vesicles via its C-terminal PhoX homology (PX) domain. Vps34 is a PI3-
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kinase and an effector protein of Rab5, and is responsible for the local production of PI(3)P 
on the endosomal membrane. Rab5 thus regulates KIF16B recruitment by creating a PI(3)P-
containing microdomain suitable for KIF16B binding, thereby stimulating plus-end transport 
of the endosomes. However, Rab5 and PI3-kinase activity also appeared to regulate minus-
end transport of early endosomes [60], therefore the question remains how the opposite 
activities are temporarily controlled by the same Rab5 protein and possibly the same PI3-
kinase.  
 
Rab7 and its effector RILP regulate dynein/dynactin-motor recruitment to late endosomes 
Rab7 is present on late endosomal and lysosomal structures that –like other structures- 
move along microtubules in a bidirectional manner due to the alternating activities of dynein 
and kinesin motors [42]. Rab7 requires its effector protein Rab7-interacting lysosomal protein 
(RILP) [63,64] to recruit the dynein/dynactin motor to late endosomes and lysosomes 
resulting in accumulation of these structures at the extreme minus end of microtubules, the 
MTOC [64]. Overexpression of the (dominant-negative) C-terminal Rab7-binding portion of 
RILP prevents recruitment of the dynein/dynactin complex [64] and results in the relocation 
of late endosomal compartments towards the cell periphery by kinesin [63,64]. A direct 
interaction of the dynein/dynactin motor with either Rab7 or RILP was not seen.  
Lebrand et al. have shown that the lipid composition of late endosomes is of major 
importance for the membrane localisation of Rab7 [65]. Interestingly, spectrin is also found 
on Rab7-containing compartments and is required for the perinuclear retention of these 
compartments, thereby making spectrin a potential mediator of motor recruitment 
(unpublished observations). Thus, lipids and possibly spectrin might play a role in Rab7-
mediated motor recruitment.  
Interestingly, Vps34 and its adaptor protein p150 also forms a complex with inactive GDP-
bound Rab7 [66]. Rab7 activation results in the release of Vps34, which raises the possibility 
that Vps34 is cycling between early and late endosomes. Collectively, these data suggests that 
recruitment of the dynein/dynactin motor to late endosomal compartments might be the 
consequence of a Rab7/RILP mediated alteration of the late endosomal membrane (by 
affecting the lipid composition resulting in spectrin binding –for example) analogous to the 
recruitment of KIF16B to early endosomes by Rab5/Vps34 [62].  
The control of myosin motors by Rab proteins 
 There are also many examples of Rab proteins interacting with the actin-based myosin 
motors (for review [67]). The earliest finding with respect to these interactions was the 
association of Rab27a with the actin-based motor myosin Va [68]. This link became apparent 
with the similar phenotypes of two coat color mutants in mice, dilute and ashen, which have 
mutations in respectively the MYOVA and the RAB27A genes [69,70]. As a result, 
melanocytes of these mutant mice show a striking depletion of melanin-loaded melanosomes 
in their dendrites [71,72]. A third color coat mutant, leaden, has a defective gene encoding for 
Melanophilin/Slac-2a [73], a Rab27a effector that was later identified as the MyoVa receptor 
by several groups [74-78]. Recently, Rab27a was also found to interact with another myosin 
motor, MyoVII [79] in retina pigment epithelial (RPE) cells. This interaction was dependent 
on a different Rab27a effector, MyRIP [80,81], which illustrates the cell type specific 
interactions between Rab proteins, their effectors and motors. 
 Two other Rabs have been shown to couple to myosins, Rab11 and Rab8. Rab11 is 
associated to the recycling compartment and regulates recycling of the transferrin receptor 
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and several G protein-coupled receptors [82-84]. A direct interaction was found between 
Rab11 and myosin Vb via a yeast two-hybrid screen [85], yet the Rab11 effector ‘Rab11 
family interacting protein-2’ (FIP-2) also interacts with myosin Vb [86]. Rab8 regulates the 
biosynthetic pathway from the Golgi towards the plasma membrane [87,88]. Recently, 
myosin VI has been observed to directly interact with optineurin [89], an interaction partner 
of Rab8 [90], which may explain the Rab8-dependent actin-based movements observed 
earlier [43,44].  
 
In conclusion, these data illustrate how various Rab proteins recruit -either directly or 
indirectly- specific microtubule- or actin-based motor proteins to their target membranes. The 
factors regulating the GTPase cycle of Rab proteins (but also other proteins like kinases and 
probably also phosphatases) then control the timing of motor activities on specific vesicles. 
 
Rab proteins combining two activities: transport and vesicle fusion 
Rab proteins are best known for their role in regulating most -if not all- intracellular fusion 
and fission events [2,8,91]. They can create membrane subdomains via their interaction with 
various effector proteins in order to sort cargo [5,92]. In addition, Rab proteins play a major 
role in the process prior to fusion with the target membrane by recruiting tethering and 
docking factors [8]. Rab proteins are thus able to connect membrane fission/fusion and 
transport, and, given their defined intracellular location, provide specificity. 
Wolkoff and co-workers already showed five years ago, in an in vitro reconstituted system, 
that fission of early endosomes requires the action of microtubule-based motor proteins [93]. 
They observed bidirectional movement of vesicles, which was blocked by a general antibody 
against the kinesin heavy chain. Inhibiting Rab4 activity on these endosomes stimulated 
minus-end transport by the minus-end directed kinesin protein KIF2C and increased the 
fission events in vitro, consistent with Rab4 acting as a switch between plus- and minus-end 
transport. 
The interaction of Rab5 with Vps34 that leads to local early endosomal production of 
PI(3)P is another illustrative example of a direct link between transport and fusion. Local 
increase of PI(3)P not only leads to the recruitment of KIF16B, but also attracts FYVE-
domain containing proteins like EEA1 which are part of the docking and fusion machinery 
[94]. 
Another example, of a Rab protein controlling fusion via motor proteins is found in the 
phagocytic pathway. Phagosomes are lysosome-related organelles and largely regulated by 
both Rab5 and Rab7 [95,96]. In the end stage of the phagocytic pathway pathogens are 
degraded in the phagolysosomes due to the fusion with lysosomes and the introduction of 
various hydrolases [97,98]. Salmonella is one of the pathogens that is able to survive 
intracellular in a so-called Salmonella-containing vacuole (SCV). Like nascent phagosomes, 
the SCV acquires Rab7, which is required for its maturation [99]. But the SCV is able to 
prevent its fusion with mature lysosomes. Recently, Guignot et al. have shown that both 
kinesin and dynein motor activities are required for the formation and maintenance of the 
SCV [100]. Interestingly, by increasing the amount of the Rab7 effector RILP on SCVs or 
nascent phagosomes, the motor balance can be shifted towards dynein/dynactin, which 
subsequently leads to enhanced fusion with mature lysosomes [101,102]. As a result 
intracellular Salmonella replication is blocked [102]. 
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Thus Rab proteins orchestrate membrane fusion not only by recruiting the components of 
the fusion machinery, but also by controlling the process prior to fusion, motor-based vesicle 
transport. This once again proves Rab proteins are master regulators of intracellular 






































Figure 2. Microtubule- and actin-based motor proteins involved in Rab-dependent motility. Red and blue 
indicate respectively minus-end and plus-end directed motors. See text for details. 
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Opposing motor activities of dynein and kinesin determine 
retention and transport of MHC class II-containing 
compartments 
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Echeverri, Richard B. Vallee and Jacques Neefjes
 
 





MHC class II molecules exert their function at the cell surface by presenting to T cells 
antigenic fragments that are generated in the endosomal pathway. The class II molecules are 
targetted to early lysosomal structures, termed MIIC, where they interact with antigenic 
fragments and are subsequently transported to the cell surface. We previously visualised 
vesicular transport of MHC class II-containing early lysosomes from the microtubule 
organising centre (MTOC) region towards the cell surface in living cells. Here we show that 
the MIIC move bidirectionally in a ‘stop-and-go’ fashion. Overexpression of a motor head-
deleted kinesin inhibited MIIC motility, showing that kinesin is the motor that drives its plus 
end transport towards the cell periphery. Cytoplasmic dynein mediates the return of vesicles 
to the MTOC area and effectively retains the vesicles at this location, as assessed by 
inactivation of dynein by overexpression of dynamitin. Our data suggest a retention 
mechanism that determines the perinuclear accumulation of MIIC, which is the result of 
dynein activity being superior over kinesin activity. The bidirectional nature of MIIC 
movement is the result of both kinesin and dynein acting reciprocally on the MIIC during its 
transport. The motors may be the ultimate targets of regulatory kinases since the protein 
kinase inhibitor staurosporine induces a massive release of lysosomal vesicles from the 




MHC (Major Histocampatbility Complex) class II molecules associate with antigenic 
fragments in endocytic compartments where antigen degradation occurs (Watts, 1997). In 
most cell types antigen loading occurs in late endocytic, early lysosomal structures, called 
MIIC (MHC classII-containing compartment), to which class II molecules are targeted by the 
associated invariant chain (Ii; Cresswell, 1994; Wolf et al., 1996). Ii is degraded in a stepwise 
manner upon arrival in these structures (Blum et al., 1988; Nguyen and Humphreys, 1989; 
Pieters et al., 1991) but an Ii fragment, termed CLIP (carboxyterminal Ii leupeptin-induced 
peptide), escapes full degradation by occupying the class II peptide binding groove (Avva et 
al., 1994; Ghosh et al., 1995). This fragment is exchanged for other peptides by a specific 
chaperone called HLA-DM (Jensen, 1998) which is also found in MIIC (Karlsson et al., 1994; 
Sanderson et al., 1994; Fernandez-Borja et al., 1996; Pierre et al., 1996; Robbins et al., 1996).  
If peptide loading occurs mainly in MIIC, how are the peptide-loaded class II complexes 
transported to the cell surface? We have previously visualised vesicular transport of MIIC 
Chapter 2 
 46 
towards the cell surface using cells expressing class II tagged with the Green Fluorescent 
Protein (GFP; Heim and Tsien, 1996). The GFP-tagged class II molecules functioned 
identically to endogenous class II in assembly, peptide loading, intracellular transport and 
distribution (Wubbolts et al., 1996). Fluorescent class II molecules accumulate in structures 
localised in a perinuclear area around the Golgi and the microtubule organising centre 
(MTOC). The structures contain markers for class II-containing early lysosomal vesicles 
(MIIC; Peters et al., 1991), like HLA-DM, CD63, mature cathepsin D and acidic peptidases, 
while they lack the late endosomal marker mannose 6-phosphate receptor (Fernandez-Borja et 
al., 1996; Wubbolts et al., 1996; van Ham et al., 1997). Occasionally, a MIIC is released from 
the MTOC region and moves towards the plasma membrane. How the MIIC are retained in 
the perinuclear area and which factors determine their release are currently unknown and are 
studied here.  
The regulation of class II transport may have many characteristics of the transport of 
specialised vesicular structures such as cytolytic granules, melanosomes or other storage 
vesicles (Griffiths and Argon, 1995; Gruenberg and Kreis, 1995). However, vesicular 
transport of class II in most cells, including Mel JuSo cells, does not seem to be tightly 
regulated, yet appears to be constitutive. In some cell types, examples of regulation in class II 
transport have been reported. Inhibition of Ii degradation inhibits class II loading and delays 
surface expression of newly synthesised class II molecules (Neefjes and Ploegh, 1992; 
Zachgo et al., 1992) and alters intracellular distribution of class II in dendritic cells (Pierre 
and Mellman, 1998). Differentiation of dendritic cells affects intracellular distribution of class 
II (Sallusto and Lanzavecchia, 1994; Cella et al., 1997) and its transport through endosomes 
(Pierre et al., 1997). Moreover, treatment of monocytes with IL-10 inhibits arrival of newly 
synthesised class II to the plasma membrane and maintains endocytosed class II 
intracellularly (Koppelman et al., 1997). In all cases the molecular effector mechanisms 
underlying these effects are unknown.  
Many intracellular vesicles are transported along polarised cytoskeletal elements, 
microtubules, by utilising molecular motor proteins (reviewed in Vallee and Scheetz, 1996; 
Hirokawa, 1998). Kinesin moves towards the fast growing end (or plus end), away from the 
MTOC, and cytoplasmic dynein moves towards the minus end. The amino-terminal globular 
domains of the motors are involved in the binding to microtubules (Vale and Fletterick, 1997; 
Woehlke et al., 1997), with dynein having a finger-like protrusion from the large globule that 
interacts with the microtubules (Gee et al., 1998). In the case of dynein, vesicle binding is 
thought to be mediated by the interaction of the dynein intermediate chains (ICs) with the 150 
kDa Glued subunit of a linker complex, dynactin (Vaughan and Vallee, 1995; Waterman-
Storer et al., 1995). Overexpression of the 50 kDa ‘dynamitin’ subunit of the dynactin 
complex was found to dissociate the complex. Under these conditions dynein was released 
from its cargo sites (Echeverri et al., 1998), resulting in inhibition of minus end-directed 
vesicle transport (Burkhardt et al., 1997). In the case of kinesin, cargo binding has been 
reported to occur through a membrane surface protein, kinectin (Toyoshima et al., 1992; 
Futterer et al., 1995; Kumar and Schertz, 1995). Cargo binding is thought to occur through the 
carboxy-terminal end of the kinesin heavy chain, possibly with the participation of the kinesin 
light chains.  
Here we show that transport of MIIC is dependent on microtubular integrity. MIIC move in 
a ‘stop-and-go’ fashion in both the plus and the minus end directions along microtubules. 
Overexpression of kinesin heavy chain (KHC) lacking the motor domain blocks normal MIIC 
movement in the periphery, suggesting that kinesin is the motor that drives plus end motility. 
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Blocking dynein function, by overexpression of dynamitin, abrogates retention of the class II-
containing lysosomes in the MTOC region unless kinesin is inactivated as well. This suggests 
that the normal intracellular distribution of class II structures, with the bulk of MIIC 
accumulated in the MTOC area and few transporting vesicles in the periphery, is mediated by 
the action of two opposing motors. Retaining MIIC in the MTOC area is an active process 
and requires dynein activity to be superior over kinesin activity on its membranes. Treatment 
of cells with the protein kinase inhibitor staurosporine induces the dispersion of MIIC, which 
could imply that phosphorylation events alter the delicate equilibrium of the motors acting on 
the membranes resulting in loss of retention of the vesicles. The change in direction of MIIC 
transport and its stop-and-go nature may reflect frequent exchange of vesicle-bound motors 
during the transport process.  
Materials and Methods  
 
Cell culture  
Mel JuSo cells were maintained at 37°C in 5% CO2 in standard culture conditions (Iscoves 
medium, 2 mM glutamine, 100 i.u./ml penicillin, 100 µg/ml streptomycin). Medium for 
transfectants was supplemented with 500 µg/ml G418 (all obtained from Gibco). Cells were 
seeded on 24 mm glass coverslips at least 2 days before the experiment in medium lacking 
G418 and were transferred to a 37°C incubator without CO2 at least 1 hour before the 
experiment. During the experiments cells were cultured in Iscoves medium in a coverslip 
holder (Ince et al., 1985), which was kept at 37°C. To disrupt microtubules, cells were treated 
with nocodazole (10 µg/ml, Biomol, USA) for 7 minutes. Cells were cultured in the presence 
of staurosporine (1 µM, Biomol, USA) for 10-20 minutes at 37°C and analysed either directly 
by confocal laser scanning microscope (CLSM) or after fixation in ice-cold methanol for 2 
minutes prior to immunodetection of markers proteins.  
 
Antibodies  
The following antibodies were used: rabbit polyclonal anti-Ii C terminus (ICC5, provided 
by Dr Morton; Morton et al., 1995), mouse monoclonal anti-Ii (VicY1, provided by Dr 
Knapp, Vienna; Quaranta et al., 1984), rabbit polyclonal anti-CD63 (Vennegoor et al., 1985), 
rabbit polyclonal anti-HLA-DMA (FS2; Sanderson et al., 1994), rabbit polyclonal anti-
mannose 6-phosphate receptor (M6PR, provided by Dr B. Hoflack, Lille; Hoflack and 
Kornfeld, 1985), mouse monoclonal anti-TfR (B3/25, Boehringer-Mannheim), rabbit 
polyclonal anti-TGN (TGN46, a kind gift of Dr Ponnamballan; Prescott et al., 1997) and 
mouse monoclonal anti-dynamitin (H50.1; Echeverri et al., 1998). Antibodies were diluted in 
phosphate-buffered saline containing 0.5% BSA. Texas Red-conjugated goat anti-rabbit 
antibodies were purchased from Molecular Probes (Molecular Probes, Leiden).  
 
Cloning  
pCMVβ (Clontech) was modified by linker addition (5′ GGCCGAATTCGGTACCCGG-
GAGATCTATCGATATCGC / 5′ GGCCGCGATATCGATAGATCTCCCGGGTACCGAA-
TTC) into the NotI site. Kinesin cDNA (kindly provided by Dr R. Vale; Navone et al., 1992) 
was transferred from pSP72 (Promega) to pcDNA3 (Invitrogen) by BamHI/EcoRI digest. The 
kinesin motor deletion mutant was generated by addition of a linker (5′ 
GATCCTTGTCCCAGCCATGGCGTT / 5′ AACGCCATGGCTGGGACAAG), which was 
ligated into HpaI/BamHI-digested pcDNA3kinesin. The kinesin mutant was recloned into the 
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pCMVβ vector using the BamHI/NotI sites. The NLS-GFP construct was generated by the 
addition of the nuclear localisation sequence of Xenopus nucleoplasmin (NLS, 
KRPAATKKAGQAKKKK) upstream of the EGFP cDNA (Clontech) and a downstream SalI 
site, using PCR. The PCR product was SalI-digested and cloned into the EcoRV/XhoI sites of 
pcDNA3. Dynamitin cDNA was obtained in the expression vector pCMVβ (Echeverri et al., 
1998).  
 
Image acquisition and analyses  
Confocal images were collected by a Biorad MRC600 (Biorad, Hercules, CA) equipped 
with an Argon/Krypton laser and a heated culture chamber (Ince et al., 1985). Single channel 
green fluorescence was detected at λ >515 nm after excitation with λ 488 nm. For dual 
analyses green fluorescence was detected at λ 520-560 nm and red fluorochromes were 
detected at λ >585 nm after excitation with λ 488 nm and 568 nm, respectively. Timed lapse 
recordings were analysed as described (Wubbolts et al., 1996). Briefly, 36 images taken every 
5 seconds were superimposed and the first image was subtracted. The resulting image was 
colour coded and merged with the first image. Velocities were calculated using NIH image by 
collecting pixel positions of peripheral class II-containing structures in the image series (with 
minor alterations of the kinematics and Biorad import macros from the NIH image homepage: 
http://rsb.info.nih.gov/nih-image). In Fig. 1A pixel positions were plotted as x-y diagrams in 
Microsoft Excel and positioned over the inverted first image of the series. Histograms of Fig. 
2 were generated by calculating distances between the position of MIIC in successive images. 
Pixel values were converted into distances using the magnification factor of the microscope 
and the CLSM settings (Biorad) rendering 19 velocity values per trail of 20 images. 
Frequencies of individual velocities in the data set were plotted as percentage of the maximal 
occurrence. Note that this analysis intrinsically results in underestimated speed values, since 
movement in the z-direction is not taken into account.  
 
Microinjection  
Cells were microinjected on a heated xy-stage of a Zeiss-Anxiovert 135M microscope 
equipped with an Eppendorf manipulator 5171/transjector 5246 system. Routinely, 50-100 
cells were injected intranuclearly with a mix of the cDNA encoding NLS-GFP (1 ng/µl) and 
the cDNAs indicated (0.1-0.2 µg/µl) in a solution of 120 mM potassium glutamate, 40 mM 
KCl, 1 mM MgCl2, 1 mM EGTA, 200 µM CaCl2, 10 mM Hepes and 40 mM mannitol, pH 
7.2. After injection, cells were cultured at 37°C, and after 3-5 hours either living cells were 
analysed by CLSM or cells were fixed with 3.7% formaldehyde, permeabilized (by 0.1% 




MHC class II-containing vesicles move bidirectionally in a ‘stop-and-go’ fashion  
We have previously visualised transport of class II-containing structures in living cells 
using GFP-tagged class II molecules. Most of these accumulated in a perinuclear area, where 
the Golgi and MTOC reside, and some were moving in the periphery. The class II-containing 
structures were transported towards the cell surface without intersecting earlier endocytic 
compartments (Wubbolts et al., 1996).  
 
                                                                                                                    Chapter 2 
 49
Intracellular accumulation of MIIC in the perinuclear region suggests that a rate-limiting 
process in the transport of these structures is taking place. We observed living cells at a high 
magnification to study the details of transport of individual MIIC by collecting images of cells 
every 3 seconds. Fig. 1A shows cells (only half cells are depicted and the position of the 
nucleus is indicated by ‘n’) in which representative movement patterns of two individual 
vesicles are shown. Every point within the trail represents the position of the vesicle in 
successive images (Fig. 1A). Vesicles move in a ‘stop-and-go’ fashion (arrows indicate the 
vesicle position in the first image and asterisks are placed where the spacing between points 
are small indicating ‘stops’). Strikingly, peripheral vesicles frequently return to the MTOC 
area (grey trail). Furthermore, vesicles are seen that move away from the perinuclear sphere, 
stop, and return again (and vice versa, as exemplified by the white trail). While approximately 
20% of the fluorescent structures are located in peripheral regions only a portion show rapid 
movement over long distances (1-5% of total, i.e. 3-5 vesicles per minute). At MTOC and 
peripheral locations ‘steady state’ pools of MIIC seem to be present while the rapid moving 
pool shuttles between these two locations.  
Bidirectional movement occurs in the MTOC area as well (Fig. 1B). Minor oscillations 
continuously occur, with occasionally an MIIC escaping at high speed (indicated by the arrow 
at t=3 seconds), and rapidly returning to approximately the same position at t=9 seconds. 
Images are generated using a frame-averaging method and the ‘trail’ formed at t=3 seconds 
represents rapid movement of the vesicle during image capture (a similar effect is seen to a 
lesser extent at t=6 seconds).  
Thus, class II-containing structures move in a ‘stop-and-go’ fashion in two directions, away 
from the MTOC region and returning to this area. Apparently, both the direction and speed of 
class II-containing vesicles during transport can be modified along the transport route.  
 
MIIC move along microtubules  
Since most vesicular transport is supported by microtubules, we analysed movement of 
MIIC before and after incubating the class II/GFP-expressing cells with the microtubule-
depolymerizing agent nocodazole. Images were collected every 3 seconds for a period of 1 
minute and the speed of individual movements was calculated (Fig. 2). In untreated cells 
MIIC move with velocities up to 0.8 µ m/s (upper panels), while nocodazole treatment 
abrogates the rapid movement (lower panels). This is also represented by the nocodazole-
treated cells leaving only small and undirected changes in the class II vesicle positions (data 
not shown). 
Thus, movement of the early lysosomal class II-containing structures is bidirectional and 
requires intact microtubules. This suggests that oppositely directed microtubule-dependent 
motors act on the transporting MIIC and therefore should ultimately determine the kinetics of 













 Fig. 1. MHC class II-containing MIIC move bidirectionally.  
(A) Confocal analyses of living cells at 37°C. MHC class II/GFP-tagged transfectants show accumulated 
vesicles in a region around the MTOC and few transporting vesicles in the periphery. The position of the nucleus 
is indicated by ‘n’, approximate cell borders are indicated by the dotted lines. 20 images were acquired at 
intervals of 5 seconds. Vesicle position coordinates were collected as described in Materials and methods and 
plotted as x-y diagrams. Plots were positioned over an image of the timed series. Vesicle positions in the first 
image are indicated by arrows. The grey trail shows apparent undirected movement until the 14
th 
image, after 
which it is transported rapidly to the MTOC region near the nucleus. In white another vesicle is followed that 
returns to the MTOC area (images 1-5) and immediately moves to the periphery again. At the images 7-12 only 
minor changes in the vesicle position occur (stops, indicated by asterisk) but movement resumes at image 13. (B) 
A perinuclear area is shown at high magnification at 0, 3, 6 and 9 seconds, one vesicle which initially is in a 
cluster is released (at t=3 and 6 seconds) but returns to the cluster within the next 3 seconds. At t=3 seconds 
(and to a lesser extent at t =6 seconds) a trail of the rapidly moving vesicle is generated by the filter technique 
applied during image capture. Bars 5 µm.  
 
 




Kinesin mediates plus end-directed transport of class II-containing structures  
To test whether the ubiquitously expressed kinesin (Navone et al., 1992) is the plus end-
directed motor involved in transport of MIIC, kinesin mutants were generated and 
overexpressed in the class II-GFP transfectants by nuclear microinjection of cDNAs. The 
motor domain of kinesin was deleted (aa 1-334, ΔM-KHC; Kozielski et al., 1997; Vale and 
Fletterick, 1997; Woehlke et al., 1997) to produce a motor that should be unable to drive 
vesicle movement, while it would still bind cargo. Upon overexpression, ΔM-KHC should 
interfere with endogenous kinesin function in a dominant-negative fashion.  
cDNA encoding the marker protein GFP attached to the nuclear localisation signal (NLS) of 
Xenopus nucleoplasmin (NLS-GFP) was used to locate injected cells and verify their 
viability. NLS-GFP was efficiently targetted to the nucleus and therefore did not interfere 
with the visualisation of class II/GFP-containing structures. Microinjecting low amounts (1 
ng/µl) of NLS-GFP cDNA yielded cells with a detectable green nucleus as early as 1.5 hours 
after injection. Cells coinjected with the cDNA of NLS-GFP and a cDNA encoding the 
kinesin mutant (present in 200-fold excess) coexpressed both proteins as assessed by 
immunostaining (data not shown). The migration of class II vesicles was subsequently 
recorded in living cells after microinjection (Fig. 3). Movement was analysed by the 
projection procedure described above: the first image of the series shown (left panels) and the 
movement over 3 minutes is shown as trails (right panel). Microinjection of empty vector (V) 
and overexpression of wild-type kinesin (KHC) resulted in no obvious effects on distribution 
and mobility of MIIC, since similar trails are formed in the injected and surrounding cells. 
Fig.2. MIIC movement but not perinuclear accumulation 
requires intact microtubules. Sequential images of the 
same cells cultured at 37°C were taken for 1 minute, 
every 3 seconds before and after treatment with 
nocodazole (10 µg/ml 7 minutes at 37°C). The first image 
of the series is color coded green and movement over a 
60 second period is color coded red. Movement was 
visualised by subtracting the first image from the 
superimposed images. From these images data sets were 
collected. Vesicle pixel coordinates were extracted and 
speeds were calculated for every movement within trails 
(114 and 152 events for control and nocodazole-treated 
cells, respectively) and the frequencies of speed intervals 
were plotted. The procedure is described in the Materials 
and methods. Nocodazole treatment eliminated rapid 
movement of the vesicles and only undirected oscillations 




The introduction of kinesin with a deletion of the motor head (ΔM-KHC) strongly inhibited 
movement of MIIC, leaving only minor vesicle oscillations in the injected cells similar to 
those observed in cells with disrupted microtubules (Fig. 2). Injecting the motorhead-deleted 
construct did not affect fluid phase uptake and internalisation followed for up to 30 minutes 
(data not shown), a period in which late endosomes are accessed (Tulp et al., 1996). These 




Fig. 3. Kinesin is the plus end motor that drives movement of MIIC. MHC class II/GFP transfectants were 
injected with both NLS-GFP (1 ng/µl) and kinesin mutant cDNAs (0.6 µg/µl) 5 hours prior to analyses. Injected 
cells are identified by the fluorescent appearance of the nucleus. Early lysosomes are labeled by the class II/GFP 
chimeric molecules. Movement analyses were performed by collecting images every 5 seconds for 3 minutes. 
Panels on the left depict the first image of the series (for MHC class II and NLS-GFP). Right panels show vesicle 
movement shown as trails. Microinjecting empty vector (V) and overexpression of wild-type kinesin (KHC) did 
not affect movement. In contrast, overexpression of the kinesin lacking the motor head domain (ΔM-KHC) 
inhibited movement of MIIC in the living cells, leaving only small trails in the injected cells. The boundaries of 
the cells are indicated by the dotted lines. Bar, 10 µm.  
 
 
Dynein directs minus end movement and is essential for perinuclear retention of MIIC  
MIIC are transported in a bidirectional fashion (Fig. 1). Kinesin is apparently involved in 
the plus end transport. The minus end-directed motor dynein may be responsible for the 
transport along the microtubules in the opposite direction. Dynein activity can be inhibited by 
overexpression of a 50 kDa protein called dynamitin, resulting in dissociation of the dynactin 
complex, thereby rendering a dynein motor that is no longer able to associate with its cargo 
(Burkhardt et al., 1997; Echeverri et al., 1998). cDNA of dynamitin was coinjected with 
cDNA of NLS-GFP and the effect on MIIC movement was analyzed (Fig. 4A, class II/GFP). 
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Overexpression of dynamitin resulted in a major redistribution of MIIC. In injected cells, 
labelled vesicles no longer accumulated in the MTOC region but are relocated to the tips of 
the cells just beneath the plasma membrane. Apparently, intracellular retention of MIIC is 
critically dependent on dynein activity. MIIC remained in the tips of cells when cells were 
cultured for longer periods after injection. This indicates that at least one other rate-limiting 
process should be taking place in the periphery before plasma membrane embedding of class 




Fig. 4. Dynamitin overexpression causes redistribution MIIC from the MTOC region to the tips of cells. 
Transfected cells were microinjected with cDNAs of dynamitin (0.2 µg/µl) and NLS-GFP (1 ng/µl; B, top: 5 
ng/µl) and living cells were analyzed by CLSM 3 hours after microinjection. Injected cells are marked by the 
appearance of fluorescent nuclei (left panels) or by ‘i’. The position of the plasma membrane is indicated by the 
dotted lines. (A) Control cells show accumulation of class II in perinuclear vesicles (living cells, class II/GFP). 
Dynamitin overexpression causes redistribution of virtually all class II vesicles to the tip of the cells and loss of 
perinuclear vesicle accumulation. (A) Dynamitin protein was immunodetected (A, p50) as well as marker 
proteins for trans-Golgi network (A, TGN46), late endosomes (A, M6PR). Late endosomes are relocated 
whereas the TGN is not. Dynamitin gradually relocates MIIC to the tips of cells. Mel JuSo cells were injected 
with cDNA of dynamitin mixed with NLS-GFP and fixed after 1, 2 and 3.5 hours of culture at 37°C. The early 
MIIC marker, Ii was immunodetected (B) and injected cells are shown (indicated by the fluorescent nuclei). Note 
the massive tip accumulation at 3.5 hours, which is only partial at 2 hours after microinjection. Antibodies used 
are TGN46, M6PR and H50.1. Bars 10 µm. 
 
Relocation of vesicles as a result of dynamitin overexpression not only affected MIIC, but 
also late endosomes (positive for M6PR) in the injected cells, which also appeared relocated 
(Fig. 4A). The trans-Golgi network (TGN) disperses after overnight expression of dynamitin 
(Burkhardt et al., 1997), but was not fragmented 3 hours after injection of dynamitin cDNA 
(Fig. 4B, TGN46).  
To study the kinetics of the relocation process we analyzed fixed cells 1, 2 and 3.5 hours 
after injection, with the MIIC marker Ii (Fig. 4B, Ii). After 1 hour injected protein can be 
readily detected (by dynamitin immunodetection) (data not shown, see also NLS-GFP), but no 
effects are seen on the MIIC distribution. The relocation is only partial at 2 hours but is 
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complete at 3.5 hours. These results showed that abrogation of minus end-directed dynein 
activity mediates rapid relocation of vesicles from the MTOC towards the plus end of 
microtubules and that dynein is involved in retaining MIIC in this area.  
 
Dynamitin-induced relocalization of class II-containing structures is mediated by 
kinesin  
Retention and transport of MIIC thus appears to be dependent on the activity of two motor 
proteins, dynein and kinesin, acting in opposite directions. Maintaining dynamitin-induced 
dispersal was shown to require microtubules (Burkhardt et al., 1997). To directly show that 
kinesin drives plus end movement of MIIC upon dynein inactivation, the relocation of 
vesicles caused by dynamitin overexpression was studied in the presence or absence of 
overexpressed wild-type (KHC) or motor head-deleted (ΔM-KHC) kinesin (Fig. 5). Kinesin 
cDNA had to be microinjected in excess since it required higher concentrations than 
dynamitin to exert its effect.  
 
 
Fig.5. Relocation of MIIC upon 
dynamitin overexpression is mediated 
by kinesin. Class II/GFP transfectants 
were injected with cDNA mixtures of 
dynamitin and empty vector, wild-type 
KHC or ΔM-KHC. Cells were cultured 
at 37°C for 5 hours, fixed and 
dynamitin was immunodetected. 
Overexpression of dynamitin causes 
relocation of the class II vesicles 
(dynamitin panels). Coexpressing wild-
type kinesin with dynamitin still shows 
the effect of redistribution of class II 
vesicles (dynamitin+KHC) whereas the 
dynamitin-induced redistribution of 
MIIC is abrogated by coexpression of 
mutant kinesin (dynamitin+ΔM-
KHC).cDNA concentrations: dynamitin 
(60 ng/µl), wt (0.6 µg/µl), ΔM (0.6 
µg/µl). Bar 10 µm.  
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Therefore, the minimal concentration of dynamitin cDNA that still induced relocation of 
MIIC in 5 hours was determined (Fig. 5, dynamitin). This concentration of dynamitin cDNA 
was coinjected with excess cDNA encoding the kinesin mutant and cells were analysed after 5 
hours culture at 37°C. Injection of the dynamitin cDNA induced relocation, but obvious tip 
accumulation was not yet observed. Coexpression of the wild-type kinesin protein did not 
alter the distribution (Fig. 5, dynamitin+KHC). However, coexpression of kinesin lacking the 
motor domain resulted in a clear abrogation of the dynamitin-induced relocation of MIIC 
while dynamitin was expressed at equal levels (Fig. 5, dynamitin+ΔM-KHC). Light 
fluorescent reticulated staining seen in the injected cell may reflect class II trapped in the ER, 
since ER-to-Golgi transport is dynein-dependent and intra-Golgi transport is kinesin-
dependent as well (Lippincott-Schwartz et al., 1995). MIIC were still located in the 
perinuclear region, as was the case for control cells and cells expressing the kinesin proteins 
only. This indicated that the redistribution of MIIC upon dynein inhibition was mediated by 
kinesin. Apparently, dynein activity determines retention of the class II-containing structures 
in the MTOC area. Upon inactivation of dynein it is the kinesin motor that transports MIIC to 
the periphery. 
 
Staurosporine causes redistribution of MIIC  
Apparently, both kinesin and dynein are able to affect MIIC retention. They could be the 
ultimate targets for regulatory processes in class II transport, either by altering motor activity 
or by modulating vesicle binding. To study the regulation of MIIC transport, we tested 
whether pharmacological agents could affect the distribution of class II vesicles. Agents that 
increase intracellular Ca
2+ 
levels (thapsigargin, ionomycin) do not show effects on the class II 
distribution. AlF4, a compound that activates GTP binding proteins, also had no detectable 
effect (data not shown). Not surprisingly, the MIIC transport requires ATP, since NaN3/2-
deoxyglucose treatment of the cells blocked movement of MIIC, in line with transport along 
microtubules propelled by motor proteins (data not shown). Treatment of cells with the 
protein kinase inhibitor staurosporine (1 µM) rapidly increased MIIC appearance in the 
periphery (Fig. 6B), while tyrosine kinase inhibitors (genistein, herbimycin A and tyrphostins 
25/47) did not induce these effects. As suggested by the relatively high concentration 
necessary to mediate redistribution, the effect of staurosporine most probably was not due to 
an inhibition of (classical) PKCs (IC50 in the nM range) since long-term TPA pre-treatment 
did not mimic the staurosporine effect.  
Cells treated with staurosporine show increased numbers of MIIC in the periphery within 15 
minutes while the perinuclear area shows fewer fluorescent vesicles, suggesting that the 
retention of vesicles is inhibited, similar to the effect seen in dynamitin-overexpressing cells. 
Pretreating the cells with nocodazole followed by staurosporine treatment prevented the 
redistribution of perinuclear vesicles, suggesting that intact microtubules are required for the 
redistribution of class II vesicles seen after treatment with the drug (Fig. 6D). These results 






Fig. 6. Staurosporine induces microtubule-dependent redistribution of MIIC. Living class II/GFP 
transfectants were observed by CLSM before (A) and after (B) treatment with staurosporine (1 µM) for 20 
minutes at 37°C. Staurosporine treatment causes redistribution of the class II vesicles. Pre-treatment with 
nocodazole (C, 5 µg/ml, 30 minutes) blocked staurosporine-mediated redistribution (D). Note that staurosporine 
treatment decreases perinuclear accumulation of class II vesicles in the cells and increases the number of 
peripheral vesicles. Bars 10 µm. 
 
To study whether only MIIC were affected by the staurosporine treatment, several markers 
for intracellular compartments were immunodetected before (Fig. 7C) and after staurosporine 
treatment (Fig. 7st). The location of trans-Golgi network (TGN), early endosomal 
compartments (labelled by the transferrin receptor, TfR) and late endosomes (marked by 
mannose 6-phosphate receptor, M6PR) are not detectably affected by staurosporine. In 
contrast, the lysosomal markers (CD63 and lamp-1 (not shown)) and the MIIC markers 
invariant chain (Fig. 7ICC) and DM (Fig. 7DMA) relocated after staurosporine treatment, 
resulting in peripheral accumulation of MIIC vesicles. Since staurosporine affects lysosomal-
like compartments while the TGN, early and late endosomes are not affected, a protein 
kinase-dependent event is probably required for the regulation of vesicular transport of MIIC 
and lysosomes.  
 
Discussion  
MHC class II molecules tagged with GFP accumulate in early lysosomal-like structures 
(termed MIIC; Peters et al., 1991), which are localised at the indented side of the nucleus. We 
have previously shown that the class II/GFP chimeric molecules expressed in Mel JuSo cells 
codistributed with endogenous class II molecules and were able to bind peptide similar to 
endogenous class II expressed in the Mel JuSo cell line (Wubbolts et al., 1996). Subcellular 
fractionation studies of Mel JuSo cells have shown that class II is concentrated in 
multivesicular MIIC compartments containing HLA-DM, fluid phase markers, both immature 
and mature cathepsin D and acidic peptidase activity (Sanderson et al., 1994; Fernandez-Borja 
et al., 1996; van Ham et al., 1997). Mature lysosomes contained HLA-DM and mature 
cathepsin D but not class II (Fernandez-Borja et al., 1996).  




Fig. 7. Effect of staurosporine on intracellular compartments. Cells were cultured in the absence (C) or 
presence of staurosporine (st, 1 µM for 20 minutes), fixed, and markers for the trans-Golgi compartment 
(TGN46), early endosomes (TfR), late endosomes (M6PR), class II vesicles (DMA and ICC) and lysosomes 
(CD63) were immunolocalized. The positions of trans-Golgi compartments (TGN) and earlier endosomal 
structures (TfR, M6PR) are unaffected but MIIC are redistributed. Bar 10 µm.  
Transport of class II-containing structures has been studied by following the class II/GFP-
labelled vesicles in real time. Here, we have analyzed the transport of class II structures in 
living cells in detail. MIIC are accumulated in a region around the MTOC and the Golgi 
complex, located proximal to the nucleus. Occasionally, an MIIC is released from this area 
and transported via microtubules away from the MTOC. However, the release is not definite 
and vesicles often return to their original location by oppositely directed movement. Moving 
MIIC in the periphery do not lose fluorescence or reduce in size, indicating that the integrity 
of MIIC is maintained during transport. The bidirectional nature of MIIC transport suggests 
that regulatory events for release from or return to the MTOC region can be made all along 
the vesicular transport route.  
Molecular motors have been shown to be important in many processes including the 
transport and distribution of intracellular organelles, proteins and the motility of cells 
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(reviewed in Goodson et al., 1997). Many plus end-directed, microtubule-dependent motors 
have been identified with different cargo specificity and tissue expression (Hirokawa, 1998). 
The ubiquitously expressed kinesin has been shown to function in a wide variety of organelle 
transport processes (Goodson et al., 1997) including lysosomes (Hollenbeck and Swanson, 
1990; Swanson et al., 1992; Perou and Kaplan, 1993; Nakata and Hirokawa, 1995; Rodriguez 
et al., 1996).  
We overexpressed a dominant-negative mutant of kinesin to study its involvement in class 
II transport. Nuclear microinjection of cDNA results in rapid expression (here 3-6 hours after 
injection) of the encoded protein, allowing a study of effects of potentially lethal proteins. We 
conclude that kinesin is involved in MIIC transport to the plus end of microtubules since 
overexpression of kinesin lacking the motor domain inhibited movement of MIIC whereas no 
effect was observed upon overexpression of wild-type kinesin. Velocities observed for the 
MIIC transport (with maximal measured speeds of 0.8 µm/second) are comparable with 
speeds obtained for kinesin-mediated motility and correspond to approximately 100 steps of 
the motor per second (Schnitzer and Block, 1997).  
MIIC move towards the minus end of the microtubular track as well, an activity that can be 
driven by the motor protein dynein (Paschal et al., 1987; Schroer et al., 1989; Holzbaur and 
Vallee, 1994). Dynein function has been implicated in endosomal transport (Aniento et al., 
1993; Oda et al., 1995) and in one study, dynein was shown to be associated, not necessarily 
functionally, with lysosomes (Lin et al., 1996). Overexpression of dynamitin, a subunit of the 
multiprotein complex dynactin that links dynein to its cargo, dissociates this complex and 
consequently inhibits dynein-mediated movement (Echeverri et al., 1998) and results in the 
redistribution of various subcellular structures including lysosomes (Burkhardt et al., 1997).  
The retrograde transport of MIIC requires the action of dynein, as inhibition of its activity 
in class II/GFP transfectants by overexpression of dynamitin abrogated fast MIIC movement 
(data not shown) and virtually all MTOC-accumulated vesicles were relocated to the tips of 
the cells. This shows that dynein inhibition affects the plus end transport as well, a feature that 
is described for microtubule-based transport mechanisms (Hamm-Alvarez et al., 1993). This 
is supported by the kinetics of the relocation process, which is complete only 3.5 hours after 
microinjection of dynamitin cDNA. However, kinesin activity is required for the relocation 
process (Fig. 5). The data imply that dynamitin overexpression interferes with the transport 
process itself by, for example, reducing the amount of steps an MIIC-bound kinesin molecule 
is able to make.  
Apparently, the retention of MIIC in a perinuclear region requires functional dynein while 
the opposing action of kinesin mediates the transport of the released structures and maintains 
them in the tip. This is supported by the simultaneous expression of dynamitin and mutant 
kinesin. Expression of mutant kinesin was able to block the relocation of MIIC to the tips of 
the cells when dynamitin is expressed as well.  
We suggest that the retention and bidirectional transport of MIIC is a result of the 
continuous action of two oppositely directed motors, kinesin and dynein. Bidirectional 
movement has been reported for other types of vesicle transport, for example in secretory 
vesicular transport such as the triggered release of melanophore pigment granules by 
hormones (Haimo and Rozdzial, 1989; Rogers et al., 1997) or for maturing phagosomes 
(Blocker et al., 1997). In vitro, purified kinesin and dynein have been shown to confer 
bidirectional movement to squid axon microtubules (Vale et al., 1992). The rapid change of 
direction in the MIIC transport suggests that both motors can be efficiently exchanged from 
the vesicle surface or remain associated and be alternately (in)activated.  
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In conclusion, the fate of MIIC in the MTOC region is determined by both kinesin and 
dynein action and the control of MIIC transport to the periphery may ultimately result in 
either activation of kinesin and/or inactivation of dynein, by for example dissociation of the 
dynactin complex. Alternatively, the affinity for the motor proteins to bind their receptors 
(Toyoshima et al., 1992; Futterer et al., 1995; Yu et al., 1995; Leung et al., 1996) on the MIIC 
is altered, resulting in dislocation of dynein and increased binding of kinesin. The 
accumulation of MIIC in the tips of dynamitin-overexpressing cells just beneath the plasma 
membrane suggest that at these locations another rate-limiting event occurs in the transport of 
MIIC and cell surface deposition of class II molecules.  
How activities of motor proteins or their binding affinities to cargo can be regulated is 
unclear. Multiple mechanisms have been proposed, many of which involve phosphorylation 
events on serine/threonine residues of either the kinesin and associated proteins (Hollenbeck, 
1993; Lee and Hollenbeck, 1995; Lindesmith et al., 1997), or dynein/dynactin (Lin et al., 
1994; Farshori and Holzbaur, 1997), or both (Hamm-Alvarez et al., 1993). Microtubule-
associated proteins (MAPs) have been suggested to compete for motor binding to 
microtubules in a phosphorylation-dependent manner as well (Lopez and Scheetz, 1993; 
Hagiwara et al., 1994; Sato-Harada et al., 1996). We have tested a variety of pharmacological 
compounds to interfere with the retention process in MIIC transport by analyzing 
morphological changes in the distribution of the vesicles. The protein kinase inhibitor 
staurosporine rapidly induces the depletion of perinuclear vesicles, while simultaneously 
many peripheral vesicles appear. Staurosporine appears to be more selective for MIIC and 
lysosomes than dynamitin overexpression, which affects the distribution of many other 
compartments as well (Burkhardt et al., 1997). Interestingly, other tyrosine kinase inhibitors 
(herbimycin A, genistein, tyrphostins 47 and 26), myosin light chain kinase inhibitors (ML-7 
and KT5926) and long term pre-treatment with TPA, which inhibits classical PKCs, did not 
mimic the effect seen in staurosporine-treated cells (data not shown). A cytosolic factor 
important for in vitro minus-end movement of phagosomes was found to be sensitive to 
staurosporine inhibition as well (yet sensitive in the nM range). Interestingly, this factor could 
be immunodepleted from cytosol with antibodies recognising Arp1, a subunit of the dynactin 
complex (Blocker et al., 1997).  
Recently, the first indications for regulation of class II transport have been obtained, in 
particular dendritic cells (DC) alter the distribution of class II molecules upon maturation 
(Sallusto and Landzavecchia, 1994; Nijman et al., 1995; Cella et al., 1997; Pierre et al., 1997) 
and IL-10 rapidly inhibits transport of both internalised and the newly synthesised molecules 
from class II compartments to the plasma membrane (Koppelman et al., 1997). Recent studies 
suggest a role for the invariant chain in the regulation of intracellular positioning of class II 
(Anderson and Roche, 1998; Pierre and Mellman, 1998). Effective breakdown of this class II 
specific chaperone (Cresswell, 1996) by cathepsin S (Reise et al., 1996; Deussing et al., 1998) 
confers location of class II to earlier endosomal locations than lysosomes in maturing 
dendritic cells (Pierre and Mellman, 1998). Moreover, Ii is phosphorylated in a staurosporine-
sensitive manner which also delayed endosomal targeting of class II molecules (Spiro and 
Quaranta, 1989; Anderson and Roche, 1998). Although the exact molecular basis for these 
effects remains unclear, they ultimately should interfere with the motors involved in transport 
of class II vesicles to the plasma membrane.  
The targets of dynamitin as well as staurosporine may be the protein(s) that ultimately 
regulate class II release and transport and may be controlled by the maturation of lysosomes 
and signal transduction cascades initiated by, for example, IL10. The involvement of two 
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opposite-directed motor proteins in class II transport may be a general mechanism for 
regulating intracellular organisation and transport of various compartments, including the 
maturation of phagosomes in macrophages (Blocker et al., 1997). Remarkably, retention of 
MIIC in the MTOC region is apparently an active process and requires the continuous activity 
of dynein motors. The molecular basis for the control of the respective motor activities will 
further add to our understanding of the timing and regulation of class II transport upon 
dendritic cell maturation, by IL-10 signalling and potentially many other factors that modulate 
vesicular transport in cells.  
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The Rab7 effector protein RILP controls lysosomal transport by 
inducing the recruitment of dynein-dynactin motors 
 
Ingrid Jordens, Mar Fernandez-Borja, Marije Marsman, Simone Dusseljee, Lennert Janssen, Jero 
Calafat, Hans Janssen,Richard Wubbolts and Jacques Neefjes. 
 
 
Many intracellular compartments, including MHC class II-containing lysosomes [1], 
melanosomes [2], and phagosomes [3], move along microtubules in a bidirectional manner 
and in a stop-and-go fashion due to the alternating activities of a plus-end directed kinesin 
motor and a minus-end directed dynein-dynactin motor [4]. It is largely unclear how motor 
proteins are targeted specifically to different compartments. Rab GTPases recruit and/or 
activate several proteins involved in membrane fusion and vesicular transport [5, 6]. They 
associate with specific compartments after activation, which makes Rab GTPases ideal 
candidates for controlling motor protein binding to specific membranes. We and others [7] 
have identified a protein, called RILP (for Rab7-interacting lysosomal protein), that interacts 
with active Rab7 on late endosomes and lysosomes. Here we show that RILP prevents further 
cycling of Rab7. RILP expression induces the recruitment of functional dynein-dynactin 
motor complexes to Rab7-containing late endosomes and lysosomes. Consequently, these 
compartments are transported by these motors toward the minus end of microtubules, 
effectively inhibiting their transport toward the cell periphery. This signaling cascade may be 














Figure 1. RILP expression results in a collapse of 
lysosomes around the MTOC. The effect of RILP on 
the late endosomal/lysosomal distribution was 
analyzed by immunoelectron microscopy. (a) A 
micrograph of the MTOC region of a control cell and 
(b) the same region in a cell overexpressing RILP. 
Anti-tubulin labeled with 10 nm gold, and anti-RILP 
labeled with 15 nm gold. Golgi (G) and MTOC are 
indicated. Arrows indicate MVB. Note the cluster of 
MVB around the MTOC in cells expressing RILP. Bar 
200 nm. (c) Living Mel JuSo cells microinjected with 
cDNA encoding RILP were followed over a 120 s 
period at 37°C using time series (60 images at 2 s 
intervals) by CLSM. The microinjected cell was 
marked, and lysosomes were visualized by 
LysoTracker Red. An injected cell and a control cell 
are shown. The collected images are projected (color-
coded red) followed by subtraction of the initial 
image (color-coded green). This procedure allows the 
visualization of movement as red trails. The 
projection is merged onto the initial image. Bar, 10 
μm.   
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Results and Discussion 
 
 
RILP requires GTP-Rab7 for clustering of late endosomes and lysosomes around the 
MTOC  
Rab7 specifically associates with late endosomal/lysosomal compartments [8–11] and 
might thus regulate motor protein recruitment to these compartments. In order to identify 
Rab7 binding proteins involved in this process, an Epstein-Barr virus-transformed human B 
lymphocyte cDNA library was screened by a yeast two-hybrid assay. A protein was isolated 
that specifically interacted with active, GTP bound Rab7Q67L but not with inactive, GDP 
bound Rab7T22N (see Supplementary material, Figure S1). The same protein (called RILP) 
was isolated by Cantalupo et al. [7]. When overexpressed by nuclear microinjection of cDNA 
in Mel JuSo cells expressing MHC class II-GFP, RILP induced a collapse of class II-
containing lysosomal compartments (Figure S2a). This effect could be inhibited by 
coexpression of dominant-negative Rab7T22N (Figure S2a). Expression of the C-terminal 
half of RILP (denoted ΔN) resulted in a phenotype opposite to that of full-length RILP; the 
class II-containing lysosomes were dispersed instead of clustered (Figure S2b). In fact, 
expression of ΔN could prevent the action of full-length RILP, as shown by coexpression 
experiments (Figure S2c). Apparently, ΔN competes with both endogenous and ectopically 
expressed RILP for binding to active Rab7Q67L, resulting in lysosome dispersion.  
To analyze the RILP-induced lysosomal cluster in more detail, RILP was expressed in Mel 
JuSo cells by retroviral transduction. Cryosections of RILP-transduced cells were labeled with 
anti-RILP (large gold) and anti-tubulin (small gold) antibodies (Figure 1a,b). In control cells, 
lysosomal multivesicular bodies (MVB) are located at some distance to the MTOC (indicated 
by arrows in Figure 1a). In cells transduced with virus encoding RILP, slightly swollen MVB 
that were positive for RILP were densely clustered around the MTOC (Figure 1b).  
The RILP-induced cluster of lysosomes is gradually formed within 1 hr after RILP 
injection (Figure S3), and during this process, the lysosomes still moved bidirectionally. To 
test whether the clustered lysosomes were still motile, cDNA encoding RILP was introduced 
via microinjection along with a marker. The lysosomes were visualized by LysoTracker Red 
[12]. Two hours after injection, the motility of the collapsed lysosomes was assayed for 2 min 
by time-lapse microscopy. Collected images were projected. The first image was color-coded 
green, and the motility, seen in the projection as trails, was color-coded red (Figure 1c). 
Peripheral lysosomes were highly motile in control cells. In contrast, cells expressing RILP 
showed no motility of the clustered lysosomes. These results suggest that RILP expression 
results in a GTP-bound Rab7-dependent accumulation of late endosomes and lysosomes 
around the MTOC and abrogates plus-end directed movement. 
 
 
RILP arrests Rab7 in the vesicle bound, activated state  
Rab7 cycles between a GTP-bound active and a GDP-bound inactive state and between the 
membrane and the cytosol. The GDP-bound form mainly localizes to the cytoplasm, whereas 
the GTP-bound form associates to membranes [8, 9]. It is, however, unclear where the exact 
GDP/GTP exchange takes place. To visualize the effect of RILP on the Rab7 cycle in vivo, 
Mel JuSo cells were stably transfected with both GFP-tagged wild-type Rab7 and active 
Rab7Q67L. Both wild-type and active Rab7 localized to late endosomal and lysosomal 
compartments (Figure 2a). To determine the Rab7 cycle, we performed FRAP (fluorescence 
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recovery after photobleaching) experiments on living GFP-Rab7 and GFP-Rab7Q67L 
transfectants. A small portion of the fluorescent vesicles was bleached, and the recovery of 
fluorescence was followed by time-lapse microscopy [13]. To enable detection of bleached 
vesicles that lost the GFP signal, cells were incubated with LysoTracker Red (data not shown; 
[12]). Recovery of fluorescence can only occur when membrane-bound Rab7 dissociates from 
the membrane upon GTP-hydrolysis and is replaced by GFP-Rab7 from the cytosol. 
Therefore, the fluorescence recovery represents the Rab7 cycle. The recovery of fluorescence 
in the bleach spot was plotted (Figure 2b), thereby allowing the determination of the recovery 
time (t1/2; the time in which 50% of the fluorescence in the bleach spot was recovered) and 
the mobile fraction (the percentage of maximally recovered GFP-Rab7). The t1/2 of the GFP-
Rab7 cycle in vivo was approximately 52 s (Figure 2b,c). Note that there is no full recovery of 
the initial fluorescence; approximately 31% of the GFP-Rab7 was found in an immobile 
fraction. Consistently, GTP-bound Rab7Q67L showed a slower recovery with a t1/2 of 156 s 
(Figure 2b,c).  
When RILP was expressed in GFP-Rab7 cells, clustering of the Rab7-positive lysosomes 
occurred within 1 hr, while expression of ΔN resulted in dispersion of lysosomes (Figure 2a, 
middle and bottom panels). FRAP experiments revealed that both RILP and ΔN dramatically 
decreased the fluorescence recovery of GFP-Rab7 on vesicles (Figure 2a–c), indicated by a 
markedly increased immobile fraction. An accurate t1/2 could not be determined. Identical 
results were obtained for vesicles at the edge of the RILP-induced cluster as well as for single 
vesicles, or when RILP or ΔN was introduced in cells expressing GFP-Rab7Q67L (data not 
shown). Because RILP and ΔN interact with the GTP-bound form of Rab7 (see 
Supplementary material and [7]), these data suggest that both RILP and ΔN lock Rab7 in the 
activated state. To further test this, GFP-Rab7 was expressed in the presence or absence of 
RILP in [
32
P]orthophosphate Cos7 cells. Rab7 was isolated and analyzed by TLC (Figure S5).  
RILP co-expression resulted in an increase of GTP bound Rab7, which indeed suggests 
that RILP arrests Rab7 in the active, vesicle bound state. Various other GTPases have been 
described that are maintained in the GTP bound state by their effector proteins [14, 15]. Such 
complexes require additional proteins to inactivate the GTPase-effector interaction in order 
for the GTPase cycle to proceed [16]. Therefore, it is likely that the protein(s) controlling 
release of RILP from Rab7 is involved in the regulation of vesicle movement in the opposite 
direction, as illustrated by the phenotype of ΔN. 
 
 
RILP induces the recruitment of functional dynein/dynactin complexes to lysosomes  
The observed RILP-induced clustering could be the result of either inhibition of plus-end 
directed transport by kinesin or activation of minus-end directed transport by the dynein-
dynactin complex. To discriminate between these possibilities, cells expressing RILP were 
stained for two endogenous subunits of the dynein-dynactin complex and the kinesin heavy 
chain (KHC). Endogenous DHC and the dynactin subunits p150
glued 
(Figure 3a), p50dynamitin, 
and arp1 (data not shown) but not kinesin (Figure 3a) were recruited to the clustered 
lysosomes in cells overexpressing RILP. In cells expressing ΔN, the dispersed lysosomes did 
not label for endogenous p150
glued 











































Figure 2. RILP and ΔN lock Rab7 in the vesicle-bound, activated state. (a) Representative examples of GFP-
Rab7 cells overexpressing either RILP or ΔN as indicated, shown in a glow-over/-under representation. The 
cells are shown before (prebleach), immediately after, and at three time points after the bleach, as indicated. 
The bleached area is depicted by a green circle, and the vesicles were identified by LysoTracker Red (data not 
shown). The nucleus (N) and the cell boundaries are indicated. The bar equals 10 μm. (b) Representative 
recovery curves of fluorescence in the bleached spot. The fluorescence (F) was related to the initial 
fluorescence (set at 100%) and corrected for loss of fluorescence due to bleaching and the scanning procedure. 
The different colors represent the different conditions tested. (c) Quantification of the recovery time (t1/2) and 
mobile fraction (M) deduced from the recovery curves including the standard deviation. GFP-Rab7Q67L 
recovers three times slower than wild-type GFP-Rab7. No accurate determination can be made of the t1/2 of 
RILP- and  ΔN-expressing cells. Both RILP and ΔN strongly reduce the mobile fraction of GFP-Rab7.  
 






















Figure 3. RILP induces recruitment of dynein-dynactin complexes to lysosomal compartments. (a) Mel JuSo 
cells were microinjected with cDNA encoding RILP and fixed. Injected cells were identified by RILP detection or 
by an injection marker. In the panels showing the localization of CD63, the RILP-expressing cells are marked by 
an asterisk in the nucleus. Fixed cells were labeled with anti-RILP and anti-dynactin subunit p150
glued 
(top 
panels), anti-CD63 and anti-dynein heavy chain (DHC) (middle panels), or anti-CD63 and anti-ubiquitous 
kinesin heavy chain (KHC) antibodies (bottom panels). Both endogenous p150
glued 
and DHC are highly enriched 
on the RILP-induced lysosomal clusters. The bars equal 10 μm. (b) Mel JuSo cells were microinjected with 
cDNA encoding ΔN, fixed, and stained with antibodies against ΔN (left) and the dynactin subunit p150
glued 
(right). ΔN induced a lysosomal redistribution to the tip of the cell and did not cause an accumulation of the 
dynactin subunits on the lysosomes. The bar equals 10 μm. (c) Control cells and cells superinfected with virus 
encoding RILP or ΔN (indicated as - and +, respectively) were homogenized, and membrane and supernatant 
fractions were separated by high-speed centrifugation. Equal amounts of total protein were separated by 10% 
SDS-PAGE and analyzed by immunoblotting with the antibodies indicated. The dynein-dynactin subunit 
p50dynamitin is highly enriched in the membrane fraction of RILP-expressing cells, but not in the ΔN-expressing 
cells.  
 
To biochemically confirm that the RILP induced dynein-dynactin complex recruitment 
onto membranes, RILP or ΔN was expressed after transient retroviral transduction. Control 
cells and cells infected with RILP or ΔN were homogenized, and membranes were separated 
from the supernatant by high-speed centrifugation. Equal amounts of total protein from the 
fractions were analyzed by SDS-PAGE and immunoblotted (Figure 3c). RILP was mainly 
present in the supernatant fractions but also in the membrane fraction, whereas ΔN was 
predominantly present in the membrane fraction. This is consistent with the distributions 
observed by CLSM (Figure S2b). RILP did not affect membrane recruitment of Rab7 and 
tubulin, but the dynein-dynactin subunits p50dynamitin (Figure 3c), p150
glued
, and the dynein 
intermediate chain (DIC) (data not shown) were highly enriched in the membrane fraction of 
RILP-expressing cells. ΔN did not affect the distribution of any of the proteins tested. These 
results indicate that the N-terminal half is required for dynein-dynactin motor recruitment, 
whereas the C-terminal half of RILP binds to activated Rab7 on late endosomes and 
lysosomes.  
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To dissect lysosomal clustering from dynein-dynactin motor recruitment, RILP was 
expressed in cells treated with the microtubule-disrupting agent nocodazole (Figure 4a). As a 
result, the class II-containing lysosomes were dispersed but still recruited the dynactin 
complex (stained by p150
glued
). This suggests that RILP-induced dynein motor recruitment 
preceded lysosomal clustering around the MTOC. To determine whether the recruited dynein-
dynactin complexes mediated RILP-induced clustering of late endosomes and lysosomes, 
dynein function was disrupted by overexpression of p50dynamitin [17, 18]. This resulted in the 
relocation of lysosomes containing RILP, p50dynamitin, and class II from the perinuclear area to 
a peripheral location (Figure 4b). Thus, RILP induces the recruitment of functional dynein-
dynactin complexes to late endosomal/lysosomal compartments resulting in minus-end 
directed transport and accumulation of these compartments around the MTOC.  
RILP might act as a receptor for the dynein-dynactin complex. To test this, we have 
attempted to show a direct interaction between RILP and the motor complex by yeast two-
hybrid assay, chemical crosslinking, and coimmunoprecipitation. However, none of these 
assays revealed a direct interaction between RILP and the subunits of the dynein-dynactin 
motor complex. To obtain a more detailed picture of the localization of RILP with respect to 
the motor, we performed cryo-electron microscopy. Endogenous motor proteins were 
undetectable by electron microscopy; therefore, RILP was coexpressed with vsv-tagged 
p50dynamitin (see also Figure 4b). Whereas Rab7 and RILP often colocalized, no such 
colocalization was found for RILP and p50dynamitin (Figure S7). These data suggest, but do 
not exclude, that RILP does not directly interact with the dynein-dynactin motor.  
 
Figure 4. RILP-induced dynein-dynactin motor recruitment precedes minus-end transport. (a) Mel JuSo class 
II-GFP cells were treated with 10 μg/ml nocodazole for 20 min before injection with cDNA encoding RILP and 
were subsequently cultured in the presence of nocodazole for 1 hr. Cells were fixed and stained for p150
glued
. The 
cell injected with RILP is indicated by an asterisk. (b) A mixture of cDNA encoding RILP and an 8-fold excess of 
cDNA encoding vsv-tagged p50dynamitin was microinjected into Mel JuSo class II-GFP cells (left panel). 
p50dynamitin was visualized by anti-vsv (right panel) and RILP by anti-RILP (middle panel). The position of the 
plasma membrane and the nucleus (N) are indicated. The class II-containing lysosomes do not cluster in the 
perinuclear region, but were dispersed into the periphery. The RILP-induced collapse of the lysosomal 
compartments apparently requires dynein activity. The bar equals 10 μm.  
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How does Rab7/RILP induce selective dynein-dynactin recruitment? Most likely, RILP or 
RILP-regulated proteins “modify” the cytosolic phase of late endosomes and lysosomes, such 
that dynein-dynactin is recruited. This might be preceded by the binding of a member of the 
spectrin family, which acts as an intermediate structure between membranes and the dynactin 
subunit arp1 [19, 20] (recruited upon RILP expression; data not shown). Subsequently, the 
dynein-dynactin motor complex will be constructed on the spot. Whether Rab7/RILP recruits 
other motor proteins besides dynein-dynactin remains to be established. Other Rab family 
members are linked to motor proteins as well. Rab6 directly interacts with a kinesin family 
member [21], whereas Rab5 has been found to couple to a yet-unidentified minus-end 
directed motor activity [22]. Rab27 has been shown to regulate transport of melanosomes and 
cytolytic granules by recruitment of the actin-based motor myosin Va [23]. Thus, in addition 
to controlling vesicle fusion, Rab proteins appear to regulate motor protein recruitment. The 
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Supplementary material  
 
Plasmids, two-hybrid screening, and identification of RILP  
Wild-type (wt) and mutant Rab7 cDNAs (kind gift of P. Chavier [S1, S2]) and wt and 
mutant Rab5 (kindly provided by M. Zerial [S3, S4]) were subcloned into the QA pCDNA3 
(Invitrogen) with a myc tag for immuno detection. For the yeast two-hybrid screen, Rab5 and 
Rab7 constructs were subcloned in the yeast expression vector pGBT9 (Stratagene) after 
elimination of the CAAX-boxes by PCR. For GFP-tagging, the ATG start codon of Rab7 and 
Rab7Q67L was eliminated by PCR and the fragments were cloned in pEGFP C1 (Clontech). 
cDNA encoding p50dynamitin [S5] and ΔN were subcloned into the eukaryotic expression vector 
pCMVβ with an N-terminal vsv-tag [S6]. Full-length RILP was subcloned into pCDNA3 
(Invitrogen) with and without myc-tag. Myc-tagging did not effect the localization of RILP. 
All PCR products were sequence verified. A cDNA library of Epstein-Barr virus-transformed 
human B lymphocytes was used for the screen (kindly provided by Dr. S.J. Elledge). The 
clone was obtained via the NCBI EST database, which extended the original ΔN (199–401 
amino acids) toward the 5’-end. Automatic sequencing revealed a putative initiator ATG 
codon followed by a coding sequence of 1206 bp, which was consistent with the size of the 
mRNA and the endogenous protein. The clone was subcloned into a mammalian expression 
vector and resulted in the synthesis of a protein of the expected size for 401 amino acids (MW 
44 kDa).  
 
Cell culture and viral transduction  
The human melanoma cell line Mel JuSo, Mel JuSo stably transfected with DR-βGFP 
[S7], and HeLa cells were used. Mel JuSo cells were stably transfected with the GFP-Rab7 or 
GFP-Rab7Q67L. Transfected cells were FACS sorted for equal and homogenous 
fluorescence. HeLa cells were transiently transfected with expression vectors encoding RILP 
and either myc-tagged Rab7 or vsv-tagged p50dynamitin by electroporation. The transfectants 
were cultured for 30 hr prior to fixation and processing for electron microscopy. To disrupt 
microtubules, cells were treated with nocodazole (10 μg/ml, Biomol, USA) for at least 20 
min. To block translation, cells were incubated in media containing 200 μM cycloheximide 
(Sigma) 10 min prior to injection and continued till 1 hr after injection. The block was 
released by two 2 min washes.  
RILP or ΔN cDNA was cloned into a modified retroviral LZRS-MS-IRES-GFP vector to 
enable retroviral transduction [S8, S9]. Mel JuSo cells were superinfected with retroviruses 
encoding RILP or ΔN for 16 hr and harvested after 36 hr.  
 
Cell fractionation and immunoblot analysis  
Mel JuSo cells superinfected with virus expressing RILP or ΔN and untransfected cells 
were grown to confluency and homogenized by approximately 15 strokes through an 8.020 
mm cell cracker (EMBL) with an 8.006 mm ball. The postnuclear supernatant was centrifuged 
at 15.300 rpm for 30 min at 4°C. Equal amounts of protein of both pellet and supernatant 
fractions were separated by 10% SDS-PAGE and electrophoretically transferred to 
nitrocellulose (Schleicher & Schuel). The nitrocellulose filters were incubated with the 
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Antibodies and markers  
The following antibodies were used: mouse monoclonal anti-CD63 [10], rabbit polyclonal 
anti-Rab7 (kindly provided by P. van der Sluijs), mouse monoclonal anti-tyrosinated tubulin 
(1A2, Sigma), mouse monoclonal anti-p50 (Transduction Laboratories), mouse monoclonal 
anti-p150
glued 
(Transduction Laboratories), mouse monoclonal anti-dynein intermediate chain 
(Sigma), rabbit polyclonal anti-dynein heavy chain (Santa Cruz), rabbit polyclonal anti-
kinesin heavy chain (kind gift of R. Vallee), monoclonal mouse anti-vsv (P5D4F7), and 
monoclonal mouse anti-myc (9E10). Polyclonal rabbit anti-RILP was raised against GST-ΔN 
fusion proteins. For immunostaining, antibodies were diluted in PBS with 0.5% BSA. FITC-
(DAKO), Texas red-(Molecular Probes) and Cy5-(Jackson Labs) conjugated mouse and rabbit 
secondary antibodies were used.  
 
Electron microscopy  
Mel JuSo cells were fixed in a mixture of 4% formaldehyde (w/v) and 0.1% (v/v) 
gluteraldehyde in 0.1 M phosphate buffer (pH 7.2). Ultrathin cryosections were incubated 
with the anti-RILP and either anti-tyrosin-ated tubulin (1A2) or anti-vsv or anti-myc. 
Secondary antibodies were coupled to gold. Images were made with a Philips CM 10 electron 
microscope.  
 
Microinjection and confocal analyses  
For living cell analyses, cells were seeded on coverslips at least 48 hr before the 
experiment to achieve 40%–60% confluency at the time of nuclear microinjection [S6]. Cells 
were injected on a heated xy stage of an Olympus XL70 microscope equipped with an 
Eppendorf manipulator 5171/transjector 5246 system. Usually, 50–100 cells were injected 
intranuclearly with a mix of cDNAs at a final concentration of 100–200 ng/μl in 
microinjection buffer containing 120 mM KGlutamate, 40 mM KCl, 1 mM MgCl2, 1 mM 
EGTA, 200 mM CaCl2, 10 mM Hepes, and 40 mM Mannitol (pH 7.2). Texas Red Dextran-70 
(25 μgml-
1
, Molecular Probes, Leiden) was used as an injection marker. Cells were 
subsequently cultured at 37°C, and after 3–7 hr, cells were analyzed or fixed and 
immunostained before analysis by CSLM. Fixation was either in 3.7% formaldehyde for 10 
min at room temperature and permeabilization in 0.1% Triton-X100 or in methanol (-20°C) 
for 2 min. All experiments presented were repeated several times on different days and results 
were fully consistent and reproducible. Confocal analyses were performed using a Leica TCS 
SP confocal laser-scanning microscope equipped with an Argon/Krypton laser (Leica 
Microsystems, Heidelberg, Germany). Green fluorescence was detected at λ 515 nm and was 
excited at λ 488 nm. For dual analyses, green fluorescence was detected at λ 520–560 nm. 
Red fluorochromes were excited at λ 568 nm and were detected at λ 585 nm. Triple analysis 
was performed using TxR excited at  λ 568 nm and detected at λ 600–620 nm and Cy5 
excited at λ 633 and detected at λ 660 nm.  
 
Movement analysis by time-lapse microscopy/ fluorescence recovery after photobleaching 
(FRAP)  
Vesicular movement was visualized by collecting 60 images at 2 s intervals and processed 
as described [S6]. The resulting image shows the movement and was color-coded and merged 
with the first image, which includes the marked injected nucleus. Vesicular movement during 
image acquisition resulted in trails.  
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FRAP experiments were performed as described [S11]. In brief, Mel JuSo cells expressing 
GFP-Rab7 or GFP-Rab7Q67L were seeded on coverslips. Expression vectors encoding RILP 
or ΔN mixed with TxRdextran 70 kDa were introduced by nuclear microinjection. The cells 
S42 were analyzed in culture chamber at 37°C by CLSM (Leica TCS). A small set of vesicles 
was bleached for 1 s by a high-intensity laser beam, and the fluorescence recovery in the 
bleached spot was quantified. To identify the bleached vesicles, cells were incubated with 
LysoTracker Red. When RILP or ΔN was introduced, FRAP analysis was performed 1–4 hr 
after microinjection in cells in which, respectively, clustering and dispersion of the Rab7-
positive vesicles was clearly apparent. The experiments were performed on many cells (n = 9) 
at various days and on positions at the edge and in the middle of a cluster as well as on 
peripheral vesicles. The recovery curves were corrected for loss of total fluorescence due to 






Figure S1. Isolation of the Rab7 effector protein RILP. (a) Interaction of ΔN with various forms of Rab5 and 
Rab7 in yeast two-hybrid analysis. As bait, active Rab7Q67L, wild-type Rab7, dominant-negative Rab7T22N, 
wild-type Rab5, active Rab5Q79L, dominant-negative Rab5S43N, and empty vector were used. β-galactosidase 
is expressed when ΔN interacts with one of the baits. A positive interaction (blue colonies) between the ΔN and 
the different baits is indicated by +; no β-gal activity detected is indicated by -. (b) Tissue expression of RILP. A 
Northern blot with RNA from the indicated human tissues was probed with RILP DNA. The 1.6 kb band 

















Figure S2. RILP and Rab7 determine the intracellular distribution of lysosomes. (a) RILP-induced lysosomal 
collapse depends on active Rab7. Mel JuSo class II-GFP cells were microinjected with cDNA encoding RILP or 
a mixture of cDNAs encoding for RILP and active Rab7Q67L or dominant-negative Rab7T22N. Note that upon 
coexpression with dominant-negative Rab7 (lower panels), RILP no longer induces a lysosomal collapse (upper 
panels). Left panels show class II-GFP, middle panels show RILP, and right panels show the myc-tagged Rab7 
mutants. The bars equal 10 μm. (b) ΔN binds to lysosomes and causes their redistribution into the cell periphery. 
Mel JuSo class II-GFP cells were microinjected with cDNA encoding the C terminus of RILP (ΔN). Left panel 
shows the distribution of class II-GFP; right panel shows ΔN. ΔN expression resulted in a phenotype opposite to 
that observed with RILP: redistribution of the lysosomes into the cell periphery. The bar equals 10 μm. (c) ΔN 
acts dominant-negative over full-length RILP. Mel JuSo class II-GFP cells were microinjected with a mixture of 
cDNA encoding myc-tagged RILP and a 3-fold excess of cDNA encoding ΔN. RILP expression was shown by the 
myc antibody (right panel). Note that the characteristic effect of RILP expression on class II-containing 
lysosomes was not observed (left panel), and that RILP no longer binds to vesicles. The bar equals 10 μm.  




Figure S3. RILP-induced lysosomal cluster is gradually formed. RILP-induced collapse of class II-GFP-
containing lysosomes. Living Mel JuSo class II-GFP cells were microinjected with RILP in the presence of 200 
μM cycloheximide. One hour after injection, the cycloheximide was washed out, and cells were followed for 60 
min at 37°C using time series (60 images at a 1 min interval) by confocal laser-scanning microscope (CLSM). 








Figure S4. RILP selectively affects transport of 
late endosomes and lysosomes. Mel JuSo MHC 
class II-GFP cells injected with cDNA encoding 
RILP were fixed, and RILP was detected with 
anti-RILP antibodies (in green). Markers for 
various compartments were analyzed to verify the 
selectivity of the effect of RILP. Shown are 
markers for early endosomes (EEA1) recycling 
endosomes (Transferrin-TxR) and lysosomes 
(Lamp-1). The markers are shown in red and 
merged onto the RILP labeling in green. Middle-
Golgi was visualized by using Mel JuSo cells 
stably expressing M2-GFP. M2-GFP was color-
coded red. Late endosomes (M6PR) were 
immunolocalized and shown in red. Cells were 
stained for the lysosomal marker CD63 (in 
green), and cells overexpressing RILP were 
indicated by an asterisk. Effects on the endosomal 
pathway were studied by internalization of SR101 
in living Mel JuSo class II-GFP for 15 min 
followed by a 2hr chase. The endosomal pathway 
labeled in red is merged onto the class II-GFP 
signal in green. An asterisk is placed in the 
nucleus of two cells microinjected with cDNA 
encoding RILP. These cells also show the 
characteristic clustering of MHC class II-
containing lysosomes. The bars equal 10 μm.  
 




Figure S5. RILP increase the GTP bound state of Rab7. Cos7 cells were transfected with GFP-Rab7 in the 
presence or absence of RILP. After 48 hr, about 70% of the cells were GFP-Rab7 positive as judged by 
immunofluorescence. Nontransfected and transfected cells were labeled o/n with 200 μCi [
35
P]orthophosphate. 
Cells were washed twice in PBS and lysed in NP40 (10 min), and GFP-Rab7 was isolated with anti-GFP coated 
beads followed by five washes. The immunoprecipitation was completed within 60 min. The immunoprecipitates 
were subsequently incubated 1:1 in phenol-water to release GTP and GDP into the water phase and to terminate 
further GTP hydrolysis. Samples from the water phase were loaded onto PEI cellulose plates and run in a 1M 
orthophosphoric acid ([pH 3.8]; KOH) solution. The position of GTP and GDP (by radioactive 
32
P]GTP) are 
indicated. Control cells are shown in lane -; cells transfected with GFP-Rab7 are shown in lane Rab7; and cells 
transfected with GFP-Rab7 and RILP are shown in lane Rab7 + RILP. It is unclear to what extent GTP 
hydrolysis proceeds during the isolation procedure. However, it is probably considerable since it is mainly GDP 
that is isolated in the GFP-Rab7 transfectants. Still, expression of RILP clearly increased the amount of GTP-





Figure S6. ΔN does not induce recruitment of 
kinesin. Mel JuSo cells were microinjected with 
cDNA encoding ΔN, fixed, and stained for ΔN (left 
panel) and endogenous kinesin heavy chain (KHC; 
right panel). Kinesin did not accumulate on the ΔN-
positive compartments. ΔN-expressing cells are 
indicated by an asterisk. The bar equals 10 μm.  
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Figure S7. Colocalization of Rab7 but not of p50dynamitin with RILP. HeLa cells were transfected with cDNA 
encoding RILP and either myc-tagged Rab7 or vsv-tagged p50dynamitin. Transfectants were fixed, and sections 
were labeled with anti-myc or anti-vsv (10 nm gold) and anti-RILP (15 nm gold) antibodies and analyzed by 
electron microscopy. Two representative examples of a lysosomal multivesicular body with RILP/Rab7 or 
RILP/p50dynamitin are shown. Colocalization was considered when the gold particles were within 10 nm (indicated 
by arrows). RILP and Rab7 colocalized in 54% (n = 50) and RILP and p50dynamitin in 7% (n = 23) of the cases. 
The bar equals 100 nm.  
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The small GTPase Rab7 controls fusion and transport of late endocytic compartments. A 
critical mediator is the Rab7 effector RILP that recruits the minus-end dynein-dynactin motor 
complex to these compartments. We now identify a natural occurring splice variant of RILP 
(RILPsv) lacking only 27 amino acids encoded by exon VII. Both variants bind Rab7, prolong 
its GTP-bound state and induce clustering of late endocytic compartments. However, RILPsv 
does not recruit the dynein-dynactin complex, implicating the 27 amino acids (exon VII) in 
motor recruitment. Clustering can still occur via dimerization, since both RILP and RILPsv 
are able to form hetero- and homo-dimers. Moreover both effectors compete for Rab7 binding 
but with different outcome for dynein-dynactin recruitment and transport. Thus effector splice 




Compartments of the biosynthetic and endocytic pathways continuously undergo fusion 
and fission events to maintain their integrity. These processes are regulated by the family of 
Rab GTPases. Besides regulating membrane fusion, Rab GTPases also regulate membrane 
transport (Jordens et al., 2001; Nielsen et al., 1999; Short et al., 2002). In principle, one single 
Rab can regulate distinct steps in these processes by binding to one or more effector proteins. 
Moreover, each Rab member localizes to a specific compartment and cycles between an 
active GTP-bound state and an inactive GDP-bound state, thereby providing a temporal and 
spatial resolution in the regulation of membrane transport and fusion, for review see (Hammer 
and Wu, 2002; Seabra and Wasmeier, 2004; Stenmark and Olkkonen, 2001; Zerial and 
McBride, 2001).  
Rab7 is a key regulator in transport and fusion of late endosomes and lysosomes (Bucci et 
al., 2000; Feng et al., 1995; Meresse et al., 1995; Press et al., 1998; Schimmoller and 
Riezman, 1993; Wichmann et al., 1992). Two Rab7 effectors have been described, Rab7-
interacting lysosomal protein (RILP) and Rabring7 (Cantalupo et al., 2001; Jordens et al., 
2001; Mizuno et al., 2003). Rabring7 has a zinc finger domain and specifically interacts with 
Rab7-GTP. Expression of Rabring7 results in clustering of late endosomes and lysosomes in 
the perinuclear area (Mizuno et al., 2003). RILP, which is unrelated to Rabring7, interacts 
with Rab7-GTP as well. Overexpression also induces clustering of late endosomes and 
lysosomes (Cantalupo et al., 2001; Jordens et al., 2001). In addition, RILP induces 
recruitment of the motor complex dynein-dynactin onto late endosomes and lysosomes, which 
facilitates their transport toward the minus-end of the microtubules (Jordens et al., 2001). 
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Recently the Golgi-restricted Rab34 has been implicated in lysosomal positioning as well 
(Wang and Hong, 2002). Overexpression of the wild type or active mutant of Rab34 resulted 
in clustering of late endosomal and lysosomal compartments in the perinuclear area. Although 
the precise mechanism has not been revealed, it could be due to the fact that Rab34 also 
interacts with RILP (Wang and Hong, 2002).  
Next to RILP, two RILP like proteins have been identified, RLP1 and RLP2 (Wang et al., 
2004). The RLPs share two highly conserved RILP homology domains, RH1 and RH2. 
Interestingly, both RLP1 and RLP2 are unable to bind to Rab7 and do not induce lysosomal 
clustering. Yet, insertion of a domain of RILP (aa 274-333), containing the recently identified 
Rab7-binding domain, causes RLP1 to interact with Rab7 and to induce clustering of late 
endosomes and lysosomes (Wu et al., 2005).  
Here we describe a splice variant of RILP lacking exon VII (aa 315-342). This exon is 
proline rich and shows no homology to other sequences in the database. Both RILP and 
RILPsv are present in a variety of tissues. RILPsv still interacts with Rab7-GTP, but it lacks 
the ability to induce recruitment of the dynein-dynactin complex. However, like RILP, 
RILPsv can dimerize and is able to induce clustering of Rab7-positive compartments. Co-
expression of full-length RILP can restore motor recruitment in RILPsv-expressing cells 
indicating that the RILP can compete with RILPsv for Rab7 binding in vivo. Hence, splice 
variants of the effector protein RILP provide an additional layer of complexity to the control 
of vesicle fusion and transport by the small GTPase Rab7.  
 
Materials and Methods 
 
Plasmids 
Wild type Rab7 (Meresse et al., 1995; Meresse et al., 1999) and wt Rab5 cDNAs (Gorvel 
et al., 1991; Stenmark et al., 1994) were subcloned into the bacterial expression vectors 
pRP261 to generate glutathion-S-transferase (GST) fusion proteins. For myc-tagging Rab7 
was cloned into pcDNA3. For yeast two hybrid assay, the Rab7 binding half of RILP and 
RILPsv were both cloned into pACT. Rab7wt, Rab7Q67L, Rab7T22N and Rab7I125N were 
after deletion of the CAAX box cloned into the pGBT9 (Stratagene). GFP-Rab7wt, GFP-
RILPdeltaN (aa 199-401) and RILP-myc were described before (Jordens et al., 2001). 
RILPsv was constructed by introduction of a KpnI site at 1041 bp. RILPsv was subcloned 
into eukaryotic expression vector pcDNA3 (Invitrogen) with or without myc-tag introduced 
by PCR. All PCR products were sequence verified. For GFP-tagging both RILP and RILPsv 
were subcloned into the eukaryotic EGFP-C1 vector (Clontech).  
 
Yeast 2-hybrid screening  
The C-terminal portion of both RILP (199-401 aa) and RILPsv (199-314 and 343-401 aa) 
fused with the GAL4-BD were co-transformed into the host strain Y190 via the standard 
Lithium Acetate method together with either wild type Rab7, Rab7Q67L or Rab7T22N fused 
to the GAL4-AD. For selection transformed yeasts were grown on SC without leucine and 




Human tissue RNAs were obtained from D. Atsma (Pathology department of the 
Netherlands Cancer Institute) isolated from respectively lung, lymph node, intestine and liver. 
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RNAs were isolated from the cell lines T47D (breast carcinoma), 603D (melanoma), WiDR 
and Colo205 (colon carcinoma) by TriZol following manufactures protocol. mRNAs were 
reverse transcribed using SuperScriptTM II reverse transcriptase (Invitrogen) by oligo-dT. The 
First strand cDNA synthesis was performed using oligo’s QS (654-673 bp) and QAS3 (1218 - 
1238 bp). Thirty-five cycles of amplification were employed. This product was used in a 
second nested PCR using WTS (751-768 bp) and QAS3.  
 
Antibodies and Markers 
The following antibodies were used; rabbit polyclonal anti-CD63 (Vennegoor et al., 1985) 
and mouse monoclonal anti-CD63 (Cymbus Biotechnology), mouse monoclonal anti-EEA-1 
(BD Transduction laboratories), mouse monoclonal anti-Golgin-97 (Molecular Probes), 
mouse monoclonal anti-dynactin p50 and mouse monoclonal anti-p150Glued (BD Transduction 
laboratories), mouse monoclonal anti-vsv (P5D4F7) and mouse monoclonal anti-myc (9E10),  
rabbit polyclonal anti-RILP (Jordens et al., 2001). For immuno-staining antibodies were 
diluted in PBS with 0.5% BSA. Alexa 488- or Texas Red/Alexa 568-conjugated mouse or 
rabbit secondary antibodies were used (Molecular Probes, Leiden, The Netherlands). 
For living cell analyses, lysosomal compartments were labeled by LysoTracker Red 
(Molecular Probes, Leiden) added 5 minutes prior to analysis.   
 
Tissue Culture 
The human melanoma cell line Mel JuSo was maintained in Iscoves medium (GIBCO-
BRL) supplemented with 7.5% FCS, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml 
streptomycin. Mel JuSo stably transfected with GFP-Rab7 (Jordens et al., 2001) were 
maintained in the same medium supplemented with 500 μg/l G418 (GIBCO-BRL). The cells 
were grown at 37°C under 5% CO2. HeLa cells were maintained in Iscoves medium (GIBCO-
BRL) supplemented with 7.5% FCS, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml 
streptomycin. Cells were transiently transfected by Polyethylenimine 25 kDa (PEI) 
transfection (Polysiences). Briefly, 1 μg DNA and 3 μg PEI reagent were used to transfect 1 x 
106 cells. Fresh medium was added after 24 hours. The transfectants were cultured for 24-48 
hrs prior to fixation or further processing.   
 
Micro-injection and Confocal Analyses 
For micro-injection, cells were seeded on coverslips in Iscoves medium lacking G418 at 
least 24 hrs before the experiment, to achieve 40-60 % confluency at the time of injection. 
Cells were injected on a heated xy stage of an Olympus XL70 microscope equipped with an 
Eppendorf manipulator 5171/transjector 5246 system. Usually, 50-100 cells were injected 
intranuclearly with a mix of cDNAs at a final concentration of 100 - 200 ng/μl (unless 
indicated otherwise). Texas Red Dextran-70 (Molecular Probes, Leiden) was used as injection 
marker. Cells were subsequently cultured at 37°C and, 3-7 hr after microinjection, living cells 
were analyzed or cells were fixed and immuno-stained before analysis by CSLM. Fixation 
was either in 3.7% formaldehyde for 15 minutes at room temperature followed by 
permeabilization in 0.1% Triton-X100 or in methanol (-20ºC) for 2 minutes. All experiments 
presented were repeated several times on different days and results were consistent and 
reproducible. 
Confocal analyses were performed using a Leica TCS SP confocal laser-scanning 
microscope equipped with an Argon/ Krypton laser (Leica Microsystems, Heidelberg, 
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Germany). Green fluorescence was detected at λ > 515 nm after excitation at λ = 488 nm. For 
dual analyses, green fluorescence was detected at λ = 520-560 nm. Red fluorochromes, were 
excited at λ = 568 nm and were detected at λ > 585 nm.  
 
Fluorescence Recovery after Photobleaching (FRAP) 
FRAP experiments were performed as described (Jordens et al., 2001; Reits et al., 2000). 
In brief, Mel JuSo cells expressing GFP-Rab7 were seeded on coverslips in Iscoves medium 
lacking G418 at least 48 h before the experiment. Coverslips were mounted in a tissue-culture 
device. Expression vectors encoding RILP or RILPsv mixed with 70 kDa TxR-dextran were 
introduced by nuclear microinjection. The cells were analyzed in culture chamber at 37oC by 
CLSM. A small set of fluorescent vesicles was bleached for one second by a high intensity 
laser beam and the fluorescence recovery in the bleached spot was quantified. To identify the 
bleached vesicles, cells were incubated with LysoTracker Red. When RILP or RILPsv was 
introduced, FRAP analysis was performed 1-4 hr after microinjection in cells where clustering 
of the Rab7-positive vesicles was apparent. The experiments were performed on multiple cells 
and at various days. Because the bleached vesicles were not completely stationary their 
positions were tracked by LysoTracker Red and corrected with a program written in Matlab 
(Mathworks) 
 
Expression and Purification of Recombinant Proteins 
RILP and RILPsv were expressed in Escherichia coli strain Rosetta(DE3)pLysS 
(Novagen) at 20oC overnight as amino-teminal hexahistidine-tagged (His6-tagged) fusions 
using the pETM-11 expression vector (kind gift of Gunther Stier, EMBL, Heidelberg, 
Germany). After collection, cells were resuspended in buffer A (25 mM HEPES, pH 7.5, 300 
mM NaCl, Complete EDTA-free protease inhibitor cocktail (Roche), 1 mM PMSF, 5 mM β-
mercaptoethanol, 10 mM imidazole, and 0.05% (v/v) Triton X-100) and lyzed by sonication 
on ice. All subsequent steps were performed at 4oC. Lysates were loaded onto pre-equilibrated 
BD Talon Metal Affinity (Clontech) resin, and washed with buffer A containing 20 mM 
imidazole. The resin was then packed into a column and bound proteins were eluted with 
buffer A containing 400 mM imidazole. Eluted proteins were concentrated in storage buffer 
(25 mM HEPES, pH7.5, 300 mM NaCl, 10% (v/v) glycerol) using a Vivaspin-2 concentrator 
(Vivascience), shock-frozen and stored at –80oC.  
Rab7 was cloned into pET-28a (Novagen) and expressed as His6-tag fusion in Escherichia 
coli strain BL21(DE3)pLysS. Recombinant His-Rab7 protein was purified under native 
conditions by affinity-chromatography using Ni2+ according to the manufacturers (Qiagen). 
Rab7 and Rab5 were expressed in Rosetta(DE3)pLysS (Novagen) as glutathione-S-transferase 
(GST) fusions using the expression vector pRP261, a derivative of pGEX-3X (Amersham 
Biosciences). GST-fusions were affinity-purified using the glutathione-Sepharose 4B resin 
(Amersham Biosciences) as described by the manufacturer. Protein concentration was 
determined using the Bradford protein concentration assay (Biorad) calibrated with bovine 
serum albumin standards. 
 
Pull-down assays and Immunoblot analysis 
For the GST-mediated pull-down assay, 100 μg of GTPγS preloaded GST-Rab7 or GST-
Rab5 immobilized on 20 μl of packed glutathione-Sepharose 4B (Amersham Biosciences) 
resin were used per 5 x 106 Mel JuSo cells. For the His-tag-mediated pull-down assay, 20 μg 
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of either His6-RILP or His6-RILPsv were immobilized on 10 μl of packed BD Talon Metal 
Affinity (Clontech) resin. 
Mel Juso cells were electroporated with either GFP-RILP or GFP-RILPsv. At 24-30 hrs 
after electroporation, cells were washed twice with PBS and lyzed for 20 min on ice in 
binding buffer (20 mM HEPES pH 7.5, 100 mM NaCl, 0.1% (v/v) Nonidet P-40, 5 mM 
EDTA, 10 mM MgCl2, 1 mM DTT, Complete EDTA-free protease inhibitor cocktail (Roche). 
Total lysates were cleared by centrifugation at 12000 g for 10 min at 4°C. Subsequently, 
supernatants were incubated with immobilized GST-fusions or His6-fusions for 2 hours at 
4°C, in binding buffer. Resin fractions were washed 5 times with 20 mM HEPES pH 7.5, 150 
mM NaCl, 0.1% (v/v) Nonidet P-40, 10 mM MgCl2, 1 mM DTT and resuspended and boiled 
in reducing Laemmli sample buffer. Protein samples were separated by SDS-PAGE, 
transferred onto PVDF membranes and probed with polyclonal anti-GFP before detection by 
ECL (Amersham) 
 
In Vitro GTPase assay 
GTPase activity in solution was assayed by release of [32P]Pi using a modified charcoal 
binding assay (Brandt et al., 1983; Higashijima et al., 1987). His6-Rab7 (50 pmol) was 
preloaded with 4 μl of [γ-32P]GTP (5000 Ci/mmol; Amersham Biosciences) in preload buffer 
(50 mM Tris/HCl pH 7.5, 250 mM NaCl, 1mM DTT, 5 % (v/v) glycerol, 0.5 mg/ml BSA) 
supplemented with 10 mM EDTA on ice for 2 hours in 10 μl total volume. Preload reactions 
were diluted with 20 μl of preload buffer supplemented with 20 mM MgCl2 prior to passage 
at 4oC through a P-6 polyacrylamide Micro Bio-Spin column (BioRad) pre-equilibrated with 
preload buffer supplemented with 10 mM MgCl2.  
The effect of RILP or RILPsv on the intrinsic GTP hydrolysis of Rab7 was analyzed by 
incubating preloaded His6-Rab7 in reaction buffer (40 mM Tris/HCl (pH 8.0), 8 mM MgCl2, 
1 mM DTT, 2 mM GTP) alone (intrinsic hydrolysis) or with 3 μM of His6-RILP, His6-
RILPsv, or BSA. Reactions were performed for 5 hours at 25oC. Triplicate timed 50 μl 
aliquots were mixed with 1 ml of 7% activated charcoal (w/v) in 10 mM KH2PO4 on ice. The 
mixture was vortexted, and centrifuged at 3000 x g for 5 min at 4oC, and the [32P]Pi release in 




RILPsv, a natural occurring splice variant of the Rab7 effector RILP 
Late endosomal and lysosomal transport is regulated by the small GTPase Rab7 and its 
effector RILP (Rab7-interacting lysosomal protein). Upon activation, Rab7 interacts with 
RILP, thereby recruiting the minus-end motor complex dynein-dynactin, which results in the 
accumulation of late endosomal/lysosomal compartments at the microtubule organizing center 
(Jordens et al., 2001). 
Besides RILP, an alternatively spliced variant of RILP (RILPsv) was identified in the 
original yeast two-hybrid screen with Rab7. This variant lacks amino acids 315-342, encoded 
by exon VII which represents a proline-rich region (spliced region indicated with the grey box 
in figure 1a). RILPsv still contains the two coiled-coil regions and the spliced region partially 
overlaps with the area interacting with Rab7 and regulating clustering of late endosomes and 
lysosomes (Wang et al., 2004; Wu et al., 2005). In the two-hybrid screen, the splice variant 
still interacted with Rab7, yet the preference for the GTP-bound form seemed less pronounced 
(Table 1). 
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Figure 1. A natural occurring splice variant of the Rab7 effector RILP 
(a) Schematic representation of RILP (CC: represents the predicted coiled-coil region) and the amino acid 
sequence corresponding to exon VII, aa 315-342, absent in RILPsv is depicted by the gray box. (b) RNA isolated 
from indicated tissues and cell lines were analyzed by RT-PCR. PCR was performed with oligo’s flanking exon 
VII and product sizes of both RILP and RILPsv are indicated. 
 
 
Several human est sequences for RILP were found in the database that specifically lack exon 
VII (data not shown). Moreover, RILPsv appeared to be present in different cell types and 
tissues, which is shown by RT-PCR (figure 1b). In several cell lines and tissues two products 
corresponding to the expected sizes for respectively RILP and RILPsv appeared in a nested 
PCR when oligo’s were used located in exon VI and VIII (figure 1b). As a positive control 
cDNA encoding RILP was used. The intestine did not show either of the two bands, which is 
consistent with previous observations showing that RILP is poorly expressed in the intestine 




Table 1. Yeast two hybrid assay showing an interaction of both RILP and RILPsv with Rab7. S. cerevisiae strain 
Y190 was co-transfected with GAL4-AD-RILP or GAL4-AD RILPsv with GAL-BD-Rab7wt, Q67L or T22N. Both 
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Figure 2. RILPsv causes clustering of late endocytic compartments 
(a) Confocal fluorescence analyses of Mel Juso cells expressing either RILP or (b) RILPsv, immunolabeled with 
anti-CD63 (upper panel), anti-Golgin (middle panel) or anti-EEA-1 (lower panel). Both RILP and RILPsv only 
affect the localization of late endosomes and lysosomes as observed by clustering of CD63-positive 
compartments. Both EEA-1 and Golgi distribution are not affected. Although Golgi is partially repositioned 
when late endosomes and lysosomes occupy the space around the MTOC. (c) Confocal fluorescence analysis of 
HeLa cells expressing RILP or RILPsv stained for CD63 or (d) Golgin. Zoom in boxes are indicated in the upper 
right corner of the panels. Bars: 10 μm  
 
 
Ectopic expression of RILPsv causes clustering of late endocytic compartments 
RILP induces clustering of late endosomal and lysosomal compartments tightly around the 
microtubule organizing center (MTOC) (Cantalupo et al., 2001; Jordens et al., 2001). In order 
to compare the phenotype of RILPsv with that of RILP, both proteins were expressed in Mel 
JuSo cells. Twenty-four to forty-eight hours after transfection, cells were fixed and stained for 
RILP (figure 2a, middle panels) and RILPsv (figure 2b, middle panels). The early endosomes 
and Golgi apparatus were identified by co-staining for the markers EEA-1 (figure 2a-b, lower-
left panel) and Golgin (2a-b, middle-left panel). As shown in figure 2a and 2b, RILPsv as well 
as RILP only affect the distribution of late endosomal and lysosomal compartments marked 
by CD63 (figure 2a-b, upper-left panel). The early endosomes are unaffected. It should be 
noted that the Golgi is still located perinuclearly; only the localization of the late endosomes 
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and lysosomes relative to the Golgi was affected. Whereas in RILP-expressing cells late 
endosomes and lysosomes have moved inside the Golgi area, they remain clustered around or 
in-between the Golgi in RILPsv-expressing cells.  
When the clusters were analyzed in more detail, we observed that the effect of RILP and 
RILPsv on late endosomal positioning was different. Whereas RILP induced a tight cluster of 
late endosomal/lysosomal compartments (figure 2a), RILPsv induced a less condensed, more 
dispersed cluster and often smaller separated clusters are observed (figure 2b). In HeLa cells, 
where late endosomes and lysosomes are more dispersed, the difference between RILP and 
RILPsv is even more apparent (figure 2c and d). These results indicate that exon VII affects 
clustering of late endosomes and lysosomes. 
 
Functional Rab7 is necessary for late endosomal/lysosomal clustering induced by 
RILPsv 
Both RILPsv and RILP interact with Rab7 in Y2H. However, RILP induced a stronger 
transactivation suggesting that it associates with Rab7 with a higher affinity (Table 1). To 
biochemically confirm that Rab7 interacts with both RILP and RILPsv, Mel JuSo cells were 
transfected with cDNA encoding either EGFP-tagged RILP or RILPsv. Twenty-four hours 
after transfection, when clustering of the late endosomes and lysosomes was clearly visible, 
cells were lyzed. Lysates were subsequently incubated with GST-Rab5wt or GST-Rab7wt 
immobilized on glutathione beads. EGFP-tagged proteins were detected by Western Blotting 
with anti-GFP. Both EGFP-RILP and EGFP-RILPsv were pulled down only with GST-Rab7 
and not with GST-Rab5 (figure 3a). This indicates that both RILP and RILPsv interact with 
Rab7. 
The involvement of Rab7 in the formation of the lysosomal clustering induced by RILPsv 
was studied in more detail by co-expression of a dominant-negative mutant of Rab7, 
Rab7T22N. Seven hours after co-injection of cDNAs encoding respectively RILP-myc or 
RILPsv-myc and myc-Rab7T22N, cells were fixed and stained for CD63 (figure 3b, left 
panels), RILP and RILPsv (figure 3b, middle panels). Whereas clustering is only reversed in a 
low percentage of the RILP-expressing cells, almost all RILPsv-expressing cells now show a 
more dispersed phenotype (figure 3b). Note the difference in distribution between RILP and 
RILPsv; upon co-expression of Rab7T22N, RILPsv dissociates from the membrane, whereas 
RILP remains associated to the membrane in most cells. This suggests that RILP is more 
intensively interacting with endogenous Rab7 than RILPsv.  
 
Binding of RILPsv to Rab7 prolongs its GTP-bound active state 
Fluorescent recovery after photobleaching (FRAP) was successfully used to study the 
GTPase activation cycle of EGFP-tagged Rab7 (Jordens et al., 2001; Marsman et al., 2004). 
After bleaching of a portion of membrane-bound EGFP-Rab7, the recovery of fluorescence in 
the bleached spot was measured by time-lapse confocal laser scanning microscopy (CLSM). 
The recovery represents GTP hydrolysis and replacement of membrane-bound bleached Rab7 
with fluorescent Rab7 from the cytosol, and thus represents the Rab7 activation cycle. Using 
this approach we could show that RILP locks Rab7 in the active, membrane-bound form 
(Jordens et al., 2001).  
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To study whether RILPsv has a similar effect on the Rab7 cycle, RILP or RILPsv were 
expressed in a Mel Juso cell line stably expressing EGFP-Rab7. As shown before in wild type 
EGFP-Rab7 expressing cells the mobile fraction, which is the percentage of maximal 
recovered EGFP-Rab7, is 64 % (figure 4a and b) (Jordens et al., 2001; Marsman et al., 2004). 
As shown previously, RILP expression resulted in a rapid clustering of the EGFP-Rab7 
containing vesicles and a concomitant drop in the mobile fraction of EGFP-Rab7 to 
approximately 10% (figure 4a and b). Interestingly, expression of RILPsv had a similar effect 
on recovery; after bleaching, only 20% of the EGFP-Rab7 was recovered (figure 4a and b). In 
both cases an accurate recovery time (t½) could not be determined. 
Beside the in vivo approach using FRAP, an in vitro approach using [γ 32P]GTP has been 
used to study the effect of His6-RILP and His6-RILPsv on the intrinsic GTPase activity of 
Rab7 (Brandt et al., 1983; Higashijima et al., 1987). By loading wild type Rab7 with [γ 
32P]GTP, the hydrolysis of GTP could be followed in time by measuring the release of  
[32P]Pi. Quantification of  [32P]Pi released from GTP-bound Rab7, showed that even after 5 
hours of hydrolysis saturation was not reached. This is consistent with the rather slow 
intrinsic GTPase activity of Rab7 (Shapiro et al., 1993) (figure 4c).  
In order to test the effect of RILP and RILPsv on the hydrolysis rate of Rab7, His6-RILP or 
His6-RILPsv proteins were incubated with [γ32P]GTP loaded Rab7. Consistent with the FRAP 
data, addition of either His6-RILP or His6-RILPsv resulted in a significant decrease in GTP 





Figure 3. Functional Rab7 is 
required for late endocytic 
clustering induced by RILPsv 
(a) GST-Rab7 or GST-Rab5 
coupled to gluthation sepharose 
beads were incubated with cell 
lysates from Mel Juso cells 
expressing GFP-RILP or GFP-
RILPsv. Proteins were transferred 
to PVDF and visualized by anti-
GFP antibodies. (lanes 1 and 2). 
RILP and RILPsv bind to GST-
Rab7 (lanes 3 and 4), but not to 
GST-Rab5 (lanes 5 and 6).(b) 
Dominant-negative Rab7T22N 
was co-expressed in molar excess 
with RILP (upper panels) or 
RILPsv (lower panels) via micro-
injection and immunolabeled for 
CD63 (left panel) and 
RILP/RILPsv (right panels). 
Rab7T22N could reverse the 
phenotypes of RILP and RILPsv 
(lower panels), shown by 
dispersed instead of clustered 
lysosomes (lower left panel). 
Micro-injected cells indicated by 
an asterisk. Bars: 10 μm. 
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hydrolysis rate of Rab7 (figure 4c). As a control, [γ32P]GTP loaded Rab5 was used. There was 
no effect of either RILP or RILPsv on the hydrolysis rate of Rab5 (data not shown). Taken 
together, the in vivo data using FRAP and the in vitro data using [γ32P]GTP show that both 
RILP and RILPsv can strongly reduce Rab7 hydrolysis thereby keeping Rab7 in the active 
GTP-bound state. 
                                                                                    




Figure 4. RILPsv arrests Rab7 
in the active state 
(a) The Rab7 GTPase cycle was 
studied using FRAP. A portion 
of GFP-Rab7 compartments in 
control cells and cells 
expressing RILP or RILPsv 
were bleached and the recovery 
of fluorescence in the bleached 
spot was plotted in a recovery 
curve. The fluorescence was 
related to the initial 
fluorescence set at 100%, t=0 is 
the first measurement after the 
bleach. (b) Quantifications of 
the mobile fractions deduced 
from the recovery curves 
including SE are depicted (n=5-
10). (c) An in vitro assay was 
used to measure the GTPase 
cycle using [γ32P]GTP, in 
which, the hydrolysis of GTP 
can be followed in time by 
monitoring the release of 
[32P]Pi. [32P]Pi is slowly 
released from GTP-Rab7 (filled 
squares). Addition of His-RILP 
and His-RILPsv significantly 
reduced the GTP hydrolysis 
rate of Rab7 (c, circles). BSA 
had no effect on the hydrolysis 
of Rab7 (open squares) and 
hydrolysis of Rab5 was not 
affected by the addition of His-
RILP or His-RILPsv (data not 
shown). 
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Figure 5. RILPsv fails to recruit dynein motors to late endocytic compartments 
(a) Confocal fluorescence analysis of Mel Juso cells ectopically expressing either RILP (upper panel) or RILPsv 
(middle and lower panel). RILP and RILPsv were labeled with anti-RILP (middle panels) and dynein-dynactin 
motors were visualized by anti-p150Glued (left panels). (b) Motor recruitment in RILP and RILPsv expressing 
cells was quantified. Values are given as mean percentage of p150Glued recruitment +/- error bars indicating the 
standard deviation (n>100 injected cells in two independent experiments). RILPsv shows a major reduction in 
dynein-dynactin motor recruitment. (c) Co-expression of RILP in RILPsv-expressing cells could restore the 
motor recruitment. RILP and RILPsv were expressed via micro-injection and labeled with anti-RILP (right 
panels) and dynein-dynactin motors were labeled by anti-p150Glued (middle panels). Bars: 10 μm. 
 
Exon VII is critical for recruiting the minus-end motor dynein to late endocytic 
compartments 
Although RILPsv interacts with Rab7, it induces a different phenotype upon ectopic 
expression. RILP has been shown to induce recruitment of the dynein-dynactin complex to 
late endosomal and lysosomal compartments (Jordens et al., 2001). To investigate whether 
RILPsv shares this ability with RILP, we injected cDNA encoding RILP or RILPsv in Mel 
Juso cells. After fixation, the p150Glued subunit of the dynein-dynactin complex was detected. 
In RILP expressing cells, tight RILP-positive clusters were formed labeling for the p150Glued 
 
B 
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subunit (figure 5a, upper panels). However, co-staining with p150Glued was usually not 
observed in cells expressing RILPsv (figure 5a, middle and lower panels). Quantification 
shows a significant decrease of approximately 70% in the recruitment of p150Glued to the 
RILPsv-positive compartments (figure 5b). These findings indicate that exon VII is involved 
in the recruitment of the dynein-dynactin complex. 
Co-expression of RILP in RILPsv expressing cells could restore motor recruitment as 
shown in figure 5c. Thus full-length RILP can compete with RILPsv for dynein recruitment to 
Rab7-positive compartments 
 
RILP and RILPsv both form hetero- and homo-dimers 
Although RILPsv does not recruit the dynein/dynactin motor, it still induces clustering of 
late endocytic compartments. Other proteins have been described that cause clustering of late 
endosomal/lysosomal compartments independent of dynein-dynactin, like VPS18 and Vam6p 
(Caplan et al., 2001; Poupon et al., 2003). These proteins are able to form homo-oligomers 
and it has been shown that this homo-oligomerization is critically involved in their clustering 
ability. In addition the recent crystal structure of Rab7 with a fragment of RILP reveals that 
RILP acts as a dimer interacting with two Rab7 molecules (Wu et al., 2005). In order to test 
the ability of both RILP and RILPsv to form heterodimers, Mel Juso cells were electroporated 
with either EGFP-RILP or EGFP-RILPsv. Twenty-four hours after electroporation, when both 
proteins were expressed and showed their related phenotypes, cells were lyzed. Lysates were 
incubated with either His6-RILP or His6-RILPsv. Subsequently, lysates were run over a Ni+ 
column to isolate the His-tagged proteins. Bound proteins were detected by Western Blotting 
probed with anti-GFP (figure 6). His6-RILP recruited both EGFP-RILP and EGFP-RILPsv. 
Moreover, His6-RILPsv also interacted with EGFP-RILPsv. This indicates that both RILP and 
RILPsv can form hetero- and homo-dimers, which might be involved in the clustering of late 




Figure 6. RILP and RILPsv form hetero- and homo-dimers 
Mel Juso cells expressing GFP-RILP or GFP-RILPsv were lyzed and incubated with either His-RILP or His-
RILPsv coupled to Talon beads. Bound proteins were analyzed by immunoblotting probed with anti-GFP 
antibodies. His-RILP and His-RILPsv can form both hetero- and homo-dimers with GFP-RILP and GFP-
RILPsv. Non-transfected cells were used as a control.  
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Late endosomal and lysosomal biogenesis is regulated by heterotypic and homotypic 
fusion, and bidirectional transport along microtubules to bring vesicles in close contact, for 
review see (Novick and Zerial, 1997; Seabra and Wasmeier, 2004; Somsel Rodman and 
Wandinger-Ness, 2000; Stenmark and Olkkonen, 2001; Zerial and McBride, 2001). A key 
regulator in these processes is the small GTPase Rab7 (Bucci et al., 2000; Feng et al., 1995; 
Meresse et al., 1995; Press et al., 1998; Schimmoller and Riezman, 1993; Wichmann et al., 
1992). Thus far, two effector proteins have been described for Rab7, Rabring7 and RILP 
(Cantalupo et al., 2001; Jordens et al., 2001; Mizuno et al., 2003). Both effectors induce 
lysosomal clustering. Additionally, RILP sequesters dynein-dynactin motors onto lysosomal 
compartments resulting in a tight accumulation around the microtubule-organizing center 
(MTOC) (Jordens et al., 2001). Here, we describe a natural occurring splice variant of RILP 
lacking exon VII. Exon VII, absent in RILPsv, contains a proline-rich domain which is 
commonly known for its involvement in protein-protein interactions. Like RILP, RILPsv also 
induces lysosomal clustering (albeit not as tight as RILP), but does not induce the recruitment 
of the dynein motor complex. This defines a proline rich region of 27 amino acids, 
representing exon VII, involved in transferring a signal from Rab7 to the dynein motor 
complex. 
Recently, Wang et al described two RILP-like proteins containing two highly conserved 
RILP homology domains, RLP1 and RLP2 (Wang et al., 2004). These proteins do not 
associate with Rab7-positive compartments and do not affect the position of late endosomes 
and lysosomes. Introduction of a 62 amino acid domain of RILP (274-333) could restore the 
ability of RLP1 to bind to Rab7 and to induce clustering of late endosomes and lysosomes.  
We describe a splice variant of RILP that lacks amino acid 315-342, which partially 
overlaps with the domain of RILP required for interaction with Rab7 (Wang et al., 2004; Wu 
et al., 2005). However, RILPsv can still interact with Rab7. This is in accordance with more 
recent observations by Wu et al that amino acids 241-320 of RILP are necessary for Rab7 
binding. These essential amino acids are contained within RILPsv (Wu et al., 2005). 
Moreover, like RILP, RILPsv can lock Rab7 in the active, membrane-bound state as is shown 
by both the FRAP analyses in living cells and the in vitro GTPase assay. This is supported by 
the recently published crystal structure of Rab7 and RILP showing that RILP is a dimer 
surrounded by two GTP-loaded Rab7 proteins. The regions in RILP that contact the switch 
and interswitch regions of Rab7 are still present in RILPsv (Wu et al., 2005). Exon VII 
lacking in RILPsv immediately follows the crystallized part of RILP with Rab7.  
Interestingly, expression of RILPsv results in a different phenotype compared to that 
induced by RILP. This difference is more evident in HeLa cells, which have a less 
pronounced perinuclear localization of late endosomes and lysosomes than the melanoma cell 
line Mel JuSo. We show that the ability of RILPsv to induce recruitment of the minus-end 
dynein-dynactin motor complex is largely reduced. This implicates the 27 amino acids 
encoded in exon VII in motor recruitment.  Previously we have shown that a deletion mutant 
of RILP lacking the N-terminal half (RILP-ΔN), still containing exon VII, fails to recruit the 
dynein motor as well (Jordens et al., 2001). Thus information in both the N-terminus and exon 
VII of RILP is required for dynein motor recruitment. Moreover, we show that RILP can 
compete with RILPsv for Rab7 binding, thereby inducing dynein motor recruitment. Thus two 
products from the same gene can induce different effects in terms of motor protein 
recruitment, but compete for the same binding site: Rab7-GTP. 
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Although RILPsv cannot efficiently recruit the minus-end dynein motor, it induces late 
endosomal clustering. Two other late endosomal/lysosomal-associated proteins cause similar 
clustering without inducing dynein motor recruitment. These proteins are mVps18 and 
hVam6p (Caplan et al., 2001; Poupon et al., 2003). These proteins are mammalian 
homologues of subunits of the yeast homotypic fusion complex, HOPS, which is involved in 
vacuolar fusion (Huizing et al., 2001; Kim et al., 2001; Nakamura et al., 1997; Price et al., 
2000; Richardson et al., 2004; Rieder and Emr, 1997; Sato et al., 2000; Seals et al., 2000; 
Wurmser et al., 2000). A common feature of mVPS18 and hVam6p is their CLH (clathrin 
homology) domain, which is found to be essential for clustering of late endosomes and 
lysosomes. In addition, this domain appeared to be involved in homo-oligomerization and 
interaction with other components of the HOPS complex (Caplan et al., 2001; Darsow et al., 
2001; Poupon et al., 2003; Ybe et al., 1999). 
 RILP has no CLH domain, but both RILP and RILPsv are able to hetero- and homo-
dimerize. This might explain the observed phenotype for RILPsv. No dynein motor is 
recruited, but the hetero- or homo-dimerization of RILPsv with itself or endogenous RILP 
still results in clustering of lysosomal compartments, comparable to mVps18 and hvam6p. 
Yet, only full-length RILP induces dynein-dynactin motor recruitment resulting in a compact 
lysosomal cluster. 
Our data describe a natural occurring splice variant of the Rab7 effector RILP lacking only 
27 amino acids encoded in exon VII. This 27 amino acid, proline-rich stretch is critical for 
dynein-motor recruitment to Rab7 compartments and transport of these compartments to the 
microtubule minus-end. We show an example of a splice variant of an effector protein that 
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Dynein-mediated Vesicle Transport Controls Intracellular 
Salmonella Replication 
 





Salmonella typhimurium survives and replicates intracellular in a membrane-bound 
compartment, the Salmonella-containing vacuole (SCV). In HeLa cells, the SCV matures 
through interactions with the endocytic pathway, but Salmonella avoids fusion with mature 
lysosomes. The exact mechanism of the inhibition of phagolysosomal fusion is not 
understood. Rab GTPases control several proteins involved in membrane fusion and vesicular 
transport. The small GTPase Rab7 regulates the transport of and fusion between late 
endosomes and lysosomes and associates with the SCV. We show that the Rab7 GTPase 
cycle is not affected on the SCV. We then manipulated a pathway downstream of the small 
GTPase Rab7 in HeLa cells infected with Salmonella. Expression of the Rab7 effector RILP 
induces recruitment of the dynein/dynactin motor complex to the SCV. Subsequently, SCV 
fuse with lysosomes. As a result, the intracellular replication of Salmonella is inhibited. 





Salmonella typhimurium species are gram-negative facultative intracellular pathogens. 
Salmonella causes diseases ranging from gastroenteritis to typhoid fever, depending on the 
serotype and the host. In epithelial cells, Salmonella survives and replicates in a membrane-
bound compartment, the Salmonella-containing vacuole (SCV) (Meresse et al., 1999b). 
Intracellular replication starts after a lag phase of ± 4h (Garcia-del Portillo et al., 1993). The 
SCV acquires the vacuolar ATPase pump and lysosomal glycoproteins, such as LAMP-1 
(Meresse et al., 1999a; Steele-Mortimer et al., 1999). In contrast to phagosomes containing 
latex beads (Desjardins et al., 1994; Garcia-del Portillo and Finlay, 1995), the SCV segregates 
from the normal endocytic pathway and does not acquire the mannose-6-phosphate receptor 
and lysosomal hydrolases such as cathepsin D and L (Garcia-del Portillo and Finlay, 1995; 
Meresse et al., 1999a). By avoiding fusion with mature cathepsin D-and L-containing lyso-
somes, Salmonella is probably protected from degradation (Meresse et al., 1999b). Prevention 
of fusion with mature lysosomes depends on the ability of the pathogen to modulate the 
interaction of the phagosome with elements of the host’s endocytic pathway (Holden, 2002).  
Members of the Rab family of small GTPases are regulators of the host endocytic pathway. 
Numerous Rab proteins have been described, and each Rab member localizes to a specific 
compartment (Stenmark and Olkkonen, 2001). By interacting with one or more effector 
proteins, Rab proteins regulate specific downstream functions such as membrane transport 
and fusion (Novick and Zerial, 1997; Somsel Rodman and Wandinger-Ness, 2000). For 
example, Rab5 regulates fusion between early endosomes and motility of these compartments 




the endocytic pathway, regulating transport to late endosomes (Feng et al., 1995; Press et al., 
1998) and regulating transport of and fusion between late endosomes and lysosomes (Meresse 
et al., 1995; Vitelli et al., 1997; Bucci et al., 2000). In HeLa cells, Rab7 interacts with the 
SCV and is involved in its maturation (Meresse et al., 1999a).  
We show that the Rab7 GTPase cycle is identical on late endocytic structures and the SCV 
by using fluorescent recovery after photobleaching (FRAP) experiments. Apparently, the 
mere presence of Rab7 is not sufficient to regulate fusion between mature lysosomes and the 
SCV in HeLa cells. We have shown previously that the Rab7 effector RILP (Cantalupo et al., 
2001; Jordens et al., 2001) recruits the minus-end–directed motor complex dynein-dynactin to 
late endosomal/lysosomal compartments, thereby facilitating their transport toward the 
microtubule-organizing center (Jordens et al., 2001). RILP and the dynein motor also have 
been implicated in the regulation of fusion between latex-beads containing phagosomes and 
lysosomes (Harrison et al., 2003). Moreover, the dynein motor transports Chlamydiae 
inclusions, although it is unclear how this is regulated (Grieshaber et al., 2003).  
Here, we studied whether manipulation of motor-mediated transport of the SCV to 
lysosomes during the early phase of infection can modulate intracellular replication. 
Therefore, the Rab7 effector RILP was expressed during the lag phase of Salmonella 
infection. Expression of RILP induced the recruitment of the minus-end motor dynein to the 
SCV. Subsequently, SCV were rapidly transported toward the minus-end of microtubules 
where they fused with lysosomes. As a result, the intracellular replication of Salmonella in 
HeLa cells was impaired. For the first time, a motor protein (dynein) is implemented in the 





DNA Constructs  
Wild-type and mutant Rab7 cDNA, a kind gift from P. Chavier (Meresse et al., 1995; 
Meresse et al., 1999a), were subcloned into pcDNA3 (Invitrogen, Carlsbad, CA) with an N-
terminal myc-tag for immunodetection. To generate the green fluorescent protein (GFP)-
tagged constructs, the ATG start codon of RILP, RILP-ΔN, and Rab7 were eliminated by 
polymerase chain reaction, and the fragments were cloned into pEGFP-C1 (BD Biosciences 
Clontech, Palo Alto, CA). cDNA encoding p50
dynamitin 
(Echeverri et al., 1996) and RILP-ΔN 
were subcloned in the eukaryotic expression vector pCMVβ with an N-terminal vsv-tag as 
described previously (Wubbolts et al., 1999). cDNA encoding GFP-p50
dynamitin 
was a kind gift 
from C. Hoogenraad (Hoogenraad et al., 2001; Matanis et al., 2002). RILP was subcloned 
into the eukaryotic expression vector pcDNA3 (Invitrogen) with a C-terminal myc-tag. All 
constructs were sequence verified.  
 
Cell Culture  
HeLa cells were maintained in Iscoves medium (Invitrogen) supplemented with 10% fetal 
bovine serum, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. Cells were 
transiently transfected with GFP-Rab7 by using Genejammer transfection reagent according 
to the manufacturer’s protocol (Stratagene, La Jolla, CA). Briefly, 4 μg of DNA and 24 μl of 
Genejammer reagent were used to transfect 3 x 106 cells. Fresh medium was added after 24 h 
and the cells were further incubated for at least 24 h before infection.  
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Bacterial Strains, Growth Conditions, and Infections  
The mouse virulent strains S. typhimurium SL1344, GFP-S. typhimurium SL1344, and 
GFP-S. typhimurium 12023 (a kind gift from S. Meresse; Meresse et al., 1999a) were used. 
Bacteria were grown in Luria-Bertani (LB) media at 37°C in 5% CO2. HeLa cells were seeded 
on glass coverslips at a density of 6 x 106 cells/10 cm dish or 3 x 106 cells/6 cm dish. Cells 
were cultured at 37°C in 5% CO2 for 48 h in Iscoves media without penicillin/streptomycin. 
Bacteria were grown overnight at 37°C while shaking, subcultured at a dilution of 1:33 in 
fresh LB media, and incubated at 37°C while shaking for 3.5 h. Cells were infected with 100 
bacteria/cell (unless otherwise indicated) in Iscoves media without antibiotics for 30 min at 
37°C in 5% CO2. Infected cells were washed four to six times and incubated for 1h in media 
containing 50 μg/ml gentamicin (Invitrogen). Infected cells were subsequently incubated for 
the indicated time points in media containing 10 μg/ml gentamicin.  
 
Microinjection  
Infected cells seeded on glass coverslips at a confluence of 30–60% were used. Cells were 
injected on a heated xy stage of an Olympus XL70 microscope equipped with an Eppendorf 
manipulator 5171/transjector 5246 system. Approximately 100–200 cells were injected with 
cDNA at a final concentration of 100–200 ng/μl (unless indicated otherwise) in microinjection 
buffer containing 120 mM K-glutamate, 40 mM KCl, 1 mM MgCl2, 1 mM EGTA, 200 μM 
CaCl2, 10 mM HEPES, 40 mM mannitol, pH 7.2. Fluorescein isothiocyanate (FITC)-Dextran 
3000 mW 1 mg/ml (Molecular Probes, Eugene, OR) was used as a microinjection marker for 
live imaging. When indicated, H2B-GFP cDNA (100 ng/μl) was used as an injection marker. 
Cells were subsequently cultured at 37°C in 5% CO2 and analyzed at the indicated time 
points. Fixation was either in 3.7% formaldehyde for 15 min followed by permeabilization 
with 0.1% Triton X-100 or in methanol (-20°C) for 2 min. Fixed cells were immunostained 
with the indicated antibodies in phosphate-buffered saline + 0.5% bovine serum albumin 
(BSA) and analyzed by confocal laser scanning microscopy (CLSM).  
 
Confocal Laser Scanning Microscopy  
Confocal analysis was performed using a Leica TCS SP confocal laser scanning 
microscope equipped with an Argon/Krypton laser (Leica Microsystems, Heidelberg, 
Germany). Green fluorescence was detected at λ 515 nm after excitation at λ 488 nm. For 
dual analyses, green fluorescence was detected at λ 520–560 nm. Red fluorochromes were 
excited at λ 568 nm and detected at λ 585 nm. Triple analysis was performed using Texas-
Red excited at λ 568 nm and detected at λ 600–620 nm, and Cy5 was excited at λ 633 and 
detected at λ 660 nm. All experiments presented were repeated several times on different 
days, and results were consistent and reproducible. The results from different experiments 
were calculated and presented as mean percentage ± SE. 
 
SCV Fusion with SR101 or DQ Red BSA-labeled Lysosomes  
HeLa cells seeded on glass coverslips were labeled with sulforhodamine 101 (SR101: 50 
μg/ml) (Molecular Probes) by a 30-min pulse at 37°C in 5% CO2. The labeling media were 
removed, and the cells were washed extensively and incubated for at least 2 h before 
infections were started, according to the protocol described using GFP-S. typhimurium 
SL1344. After incubation with 50 μg/ml gentamicin for 1 h, cells were cultured in media 




for RILP, and FITC-dextran was used as an injection marker. One hour after injection, fusion 
between SCV- and SR101-loaded lysosomes was studied using living cell analysis with time-
lapse confocal microscopy. Fusion between SCV-and SR101-loaded lysosomes was followed 
in cells injected with RILP cDNA and control cells for 4 h. The protocol described above was 
also followed to study the interaction of the SCV with DQ Red BSA-positive vesicles. Except 
that DQ Red BSA was added to the cells before the imaging, 1 h after microinjection. DQ 
Red BSA is dequenched after proteolysis in lysosomes (DQ Red BSA 10 μg/ml) (Molecular 
Probes).  
 
Fluorescent Recovery After Photobleaching  
FRAP experiments were performed as described previously (Reits et al., 2000; Jordens et 
al., 2001). Briefly, HeLa cells transiently expressing GFP-Rab7 were seeded on coverslips 
and infected. Approximately 24 h after infection, SCV containing elongated bacteria were 
bleached for 1s by a high-intensity laser beam. Subsequently, the recovery of fluorescence in 
the bleached spot was quantified. As a control Rab7-positive late endosomes and lysosomes 
were simultaneously bleached in the same cell or in noninfected control cells. SCV and 
control vesicles were visualized by LysoTracker Red (Molecular Probes). SCV and control 
late endosomes and lysosomes with little lateral movement were selected. Because they were 
not completely stationary their position was tracked and corrected by a program written in 
Matlab (Mathworks, Natick, MA) and the half-time of fluorescence recovery (t1/2) was 
determined. The experiments were repeated several times on different days. 
  
Isolation of the SCV  
HeLa cells (2–3 x 107) cells infected with GFP-S. typhimurium SL1344 for 3 h or non-
infected HeLa cells were washed four times with phosphate-buffered saline. Cells were 
harvested by scraping and diluted in 1 ml of homogenization buffer HB (20 mM 250 mM 
sucrose, Tris, pH 7.5, and a cocktail of protease inhibitors (Complete; Roche Diagnostics, 
Indianapolis, IN) and homogenized with a ball-bearing homogenizer (ball size 8.008). Nuclei 
and debris were removed by low-speed centrifugation (100 x g, 3 min). The resulting post-
nuclear supernatant was layered on top of a stepwise sucrose gradient containing layers of 
0.4/0.6/1.0/1.2/1.6/2.0M sucrose prepared in HB. The samples were centrifuged in a Beckman 
SW40 Ti for 2 h at 28,000 rpm at 4°C. Fractions of 0.5 ml were taken from the top, and 
proteins were recovered by trichloroacetic acid precipitation before analysis by 12% SDS-
PAGE and Western blotting. The sucrose concentration of the fractions was measured after 
the run with a refractomer (PmT Tamson) and is indicated in the figure. Lysosomal fractions 
were determined by assaying for β-hexosaminidase activity in all sucrose gradient fractions. 
The position of LAMP-1, cathepsin D, RILP, and Rab7 were detected using specific 
antibodies. The position of the SCV was determined using anti-GFP antibodies.  
 
Antibodies and Reagents  
The following antibodies were used: rabbit polyclonal anti-CD63 (Vennegoor et al., 1985), 
mouse monoclonal anti-p150
glued 
(BD Transduction Laboratories, Lexington, KY), mouse 
monoclonal p50
dynamitin 
(BD Transduction Laboratories), rabbit polyclonal anti-Rab7 (Santa 
Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal anti-kinesin heavy chain (kind gift 
from R. Vallee, Columbia University, New York, NY), rabbit polyclonal anti-RILP (Jordens 
et al., 2001), rabbit polyclonal anti-GFP (van Ham et al., 1997). Mouse anti-LAMP-1 (BD 
Transduction Laboratories), goat polyclonal anti-cathepsin D (Santa Cruz Biotechnology), 
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mouse anti-EEA1 (BD Transduction Laboratories), and mouse monoclonal anti-myc (9E10). 
Rabbit polyclonal anti-S. typhimurium lipopolysaccharide (LPS) (Difco, Detroit, MI) and 
mouse monoclonal 1E6 anti-S. typhimurium LPS (Biodesign International, Kennebunk, ME). 
FITC-and Texas Red (Molecular Probes)-conjugated mouse and rabbit secondary antibodies 




SCV Recruits Functional Rab7 in HeLa Cells  
  
S. typhimurium strains 12023 and SL1344 were used to study the intracellular fate of 
Salmonella. The S. typhimurium SL1344 strain forms elongated bacteria when replicating, 
due to a lack of septation in some cell types (Martinez-Lorenzo et al., 2001). These elongated 
bacteria reside in a membrane-bound vacuole, called the SCV, with the same characteristics 
as for other Salmonella strains. Although they acquire late endosomal/lysosomal markers such 
as LAMP-1 and CD63, they exclude hydrolases that reside in mature lysosomes, protecting 
them from degradation (Martinez-Lorenzo et al., 2001). The intracellular formation of 
elongated bacteria was used to visualize intracellular bacterial replication.  
To study the interaction of Rab7 with the SCV, HeLa cells were transiently transfected 
with GFP-Rab7. At various timepoints after infection, the interaction between Rab7 and the 
SCV was visualized by CLSM and subsequently quantified. Colocalization of GFP-Rab7 with 
the SCV was already observed 30 min after infection. Figure 1a shows a representative image 
3 h after infection. Approximately 80% of the SCV recruited detectable amounts of GFP-
Rab7 at all indicated time points (Figure 1b) with ±70% at time point 7 h. The elongated 
bacteria were detected after overnight culture and accumulated GFP-Rab7 in 70–90% of SCV 
(Figure 1a; our unpublished data). This indicates that Rab7 is present at the membrane of 
SCV. This was further confirmed using the active GTPase-deficient mutant of Rab7, 
Rab7Q67L. Rab7Q67L was recruited to the membrane of the SCV containing elongated 
bacteria. Expression of this mutant did not interfere with intracellular replication of the 
bacteria because elongated bacteria were still formed after o/n culture (our unpublished data).  
Small GTPases such as Rab7 cycle between an active membrane-bound and an inactive 
mainly cytosolic state. We previously used FRAP to visualize the Rab7 cycle in GFP-Rab7–
expressing cells. After bleaching the fluorescence of a small portion of vesicles, the recovery 
of fluorescence in this bleached spot was followed by time-lapse CLSM. Recovery of 
fluorescence can only occur when membrane-bound bleached GFP-Rab7 dissociates from the 
membrane and is replaced by fluorescent GFP-Rab7 from the cytosol. Therefore, the 
fluorescence recovery in the bleached spot represents the Rab7 activation cycle (Jordens et 
al., 2001).  
FRAP was used to study the Rab7 cycle on the SCV and to determine whether Salmonella 
alters the Rab7 activation cycle on the SCV. HeLa cells were transiently transfected with 
GFP-Rab7, and ±24 h after infection the SCV containing elongated bacteria were bleached. 
Representative images before and after the bleach are shown in Figure 1c. Recovery of 
fluorescence was plotted in a recovery curve (Figure 1d). From the recovery curve, the 
recovery time (t1/2, the time in which 50% of the fluorescence was recovered in the bleached 
spot) of the SCV was determined. Vesicles and elongated structures were always completely 
bleached to prevent recovery of fluorescence by lateral diffusion of GFP-Rab7 on the 




considerably faster than the normal Rab7 cycle, partial bleaching could be easily 
distinguished from complete bleaching of the structures (our unpublished data). 
No difference was observed in the cycle time between late endocytic structures in infected 
cells and in noninfected cells (Figure 1e, control). The cycle time of GFP-Rab7 on late 
endocytic structures was 58.5 ± 6.9 s; the SCV showed a recovery time of 58.6 ± 7.7 s (Figure 
1e). These data indicate that the Rab7 cycle is comparable between SCV and late endocytic 
compartments, even within the same cell. Thus, Salmonella does not alter the Rab7 GTPase 
cycle on the SCV.  
 
 




Figure 1. SCV recruits functional Rab7. (A) Confocal fluorescence analysis of HeLa cells transiently transfected 
with GFP-Rab7 and infected with S. typhimurium SL1344. The SCV recruited GFP-Rab7 after 30 min of 
infection. Representative confocal images at 3 h and after o/n culture are shown. The insets in the top panels 
show a coat of GFP-Rab7 on the SCV that is representative for the accumulation of Rab7 observed at all time 
points. The majority of the SCV contained elongated bacteria after o/n culture, still colocalizing with GFP-Rab7 
(bottom). Left, GFP-Rab7; right, anti-Salmonella LPS; Bar, 10 μm. (B) Quantification of three experiments for 
colocalization of the SCV with GFP-Rab7. Values are given as mean percentage of colocalization ± SE. t = 0.5 h 
is the time point immediately after the 30 min infection (for each time point 100 cells were counted). (C) To 
determine whether the Rab7 recruited to the SCV is functional, the GTPase cycle of Rab7 was studied using 
FRAP. Representative examples of GFP-Rab7 cells are shown. Images are shown before bleach (prebleach), 
immediately after bleach and at three time points after bleach. The bleached area and the nucleus (N) are 
indicated. Top, SCV indicated with a rectangle and control late endocytic structures in the circle were bleached. 
Bottom, noninfected control cell was bleached in the circle. Bar, 10 μm. (D) Representative curves of fluorescent 
recovery in the bleached spot/area. The fluorescence (percentage) was related to the initial fluorescence set at 
100%. t = 0s is the first image after the bleach. (E) Quantification of the recovery time (t1/2) deduced from the 
curves including the SE. There is no difference between the t1/2 of SCV and late endocytic structures (control) 
even within the same cell. (F) Sucrose gradient fractionation profile of vesicles from cells infected with GFP-S. 
typhimurium SL1344. Lysosomes were detected by β-hexosaminidase activity and mature cathepsin D staining. 
The density (molar concentration sucrose) of the corresponding fractions measured with a refractomer is 
indicated (top). The localization of the SCV was determined with anti-GFP antibodies. LAMP-1, Rab7, and 
RILP localization were analyzed with specific antibodies. Bottom, corresponding Western blots for LAMP-1, 




To test whether the Rab7 effector RILP could be recruited to SCV in HeLa cells, 
subcellular fractions were analyzed (Figure 1f). HeLa cells infected with GFP-S. typhimurium 
SL1344 or noninfected were homogenized, and the postnuclear supernatant was separated by 
sucrose density centrifugation. Fractions were subsequently taken from top and analyzed by 
SDS-PAGE and Western blotting. The position of the early endosomes was determined by 
immunostaining for EEA1. EEA1 migrated in fraction 1–5 (our unpublished data). The 
position of the lysosomes was determined by β-hexosaminidase activity. Lysosomes were 
detected around fraction 8–11 in both control (our unpublished data) and infected cells 
(Figure 1f); mature cathepsin D also comigrated in these fractions. The position of the SCV 
was determined by immunostaining with anti-GFP. SCV run at a higher density than late 
endocytic structures around fraction 17–19. Mostly immature cathepsin D (precath D) 
comigrated with the SCV. Rab7 comigrated with cathepsin D and LAMP-1 in the late 
endocytic fraction (fraction 11), but also comigrated at a higher density with the SCV. A 
major portion of RILP was present in the soluble fraction (top fractions 1–5) and a small 
portion comigrated with Rab7 in the late endocytic fractions and with Rab7 in the SCV-
containing GFP fractions. These data suggest that the SCV, like late endocytic structures, 
sequester both Rab7 and RILP but mainly contain the immature form of cathepsin D. 
  
The Rab7 Effector RILP Blocks Replication of Salmonella in HeLa Cells  
Although Rab7 and RILP are both present on late endocytic structures, overexpression of 
RILP is required for efficient dynein motor recruitment to these compartments (Jordens et al., 
2001). To test whether this is also occurring for the SCV and whether this may change the 
fate of intracellular Salmonella, we overexpressed RILP at several time points after infection 
by microinjection of RILP cDNA. Intracellular Salmonella replication was followed by the 
formation of elongated structures for the SL1344 strain. Ectopically expressed RILP was 
sequestered to the SCV where it colocalized with Rab7 (Figure 2a). When RILP was 
expressed 2–4 h after Salmonella uptake, before bacterial replication had started, a marked 
reduction in Salmonella replication was observed after o/n culture. RILP expression resulted 
in less elongated bacteria and more single bacteria per cell (Figure 2b).  
Quantification of the confocal images of five individual experiments showed that 75% of the 
SCV contained elongated bacteria, which was reduced to 23% when RILP was expressed 
(Figure 2c). Seventy-seven percent of the RILP-expressing cells contained a small number of 
single bacteria per cell (10–0 bacteria/cell), compared with 25% in control cells not 
ectopically expressing RILP (Figure 2c). Timing of RILP expression was critical because 
expression of RILP 6–8 h or longer after infection resulted in SCV containing elongated 
bacteria, as observed for control cells (our unpublished data). This suggests that RILP should 
be expressed before Salmonella starts replicating and segregates from the endocytic pathway. 
As a control, microinjection of H2B-GFP cDNA did not effect the intracellular replication 















Figure 2. Expression of RILP results in a replication block of Salmonella. (A) Confocal analysis of infected 
cells expressing GFP-Rab7 microinjected with RILP and H2B-GFP. From left to right, GFP-Rab7 and H2B-
GFP, Salmonella SL1344 labeled with anti-LPS-Texas Red and RILP. Bar, 10 μm. (B) Confocal analysis of cells 
infected with either SL1344 (top) or the 12023 Salmonella strain (bottom) and microinjected with RILP. Cells 
microinjected with RILP cDNA (and H2B-GFP cDNA as injection marker) show clustering of late endosomes 
and lysosomes. In these cells, the elongated bacteria are not formed after o/n incubation (top). Note that 
elongated bacteria occurred in control cells. Microinjected cells are indicated with an asterisk. Left, Salmonella 
(stained with anti-LPS) is shown; Right, CD63 staining. Bar, 10 μm. Bottom, cells infected with the Salmonella 
12023 strain. Microinjected cells are indicated with an asterisk. Left, Salmonella 12023 strain. Right RILP. Bar, 
10 μm. (C) Quantification of five individual experiments (n = 30–40 microinjected cells and n = 100 control 
cells). Left, mean percentage of SCV-containing elongated bacteria or 10–0 single bacteria are indicated ± SE 
for both RILP and control cells infected with the Salmonella SL1344 strain. Right, SCV containing >30 
bacteria/cell or 10–0 single bacteria/cell are indicated ± SE for both RILP and control cells infected with the 
Salmonella 12023 strain.  
 
A significant reduction also could be observed when the S. typhimurium 12023 strain was 
used. This strain can replicate normally inside HeLa cells, although the high load of 
intracellular bacteria can lead to apoptosis in a subset of the cells. Reducing the mode of 
infection to >50 bacteria per cell results in a heterogenic population after overnight 
incubation, with the majority of the cells containing replicating bacteria (Figure 2c). When 
RILP was expressed the number of cells containing >30 bacteria per cell decreased by one-
half. The number of cells containing ±10 bugs per cell increased as a result of RILP 




typhimurium 12023 strain and expressing RILP (Figure 2, b and c). It should be noted that our 
experimental protocol does not allow quantification of the RILP effect by plating assays, 
because RILP had to be expressed in a rather narrow window of time (2–4 h after infection), 
which could only be achieved by microinjection of cDNA.  
 
 
Figure 3. The SCV recruits the minus end motor dynein. (A) Confocal analysis of cells immunolabeled for the 
dynein-dynactin subunit p150
glued
. The images presented are representative for the colocalization of p150
glued 
and 
the SCV at time points 1, 3, and 7 h and o/n after infection. At all time points a significant colocalization was 
observed in the cells microinjected with cDNA encoding RILP (and H2B-GFP cDNA as injection marker), 
whereas no colocalization was observed in control cells. Insets (top) show the area of the microinjected cell 
depicted in the box. After o/n incubation after infection, the control cells showed formation of the elongated 
bacteria. RILP-expressing cells contained a small number of single bacteria, which colocalized with p150
glued 
(bottom). Insets of the microinjected cell are shown in the bottom panels. Injected cells are indicated with an 
asterisk. Left, p150
glued
and H2B-GFP; Right, Salmonella; Bar, 10 μm. (B) Quantification of colocalization 
between the SCV and p150
glued 
of six individual experiments 3 h after infection. These data represent 50 
microinjected cells and 100 control cells. Mean ± SEs are indicated. (C) Confocal analysis of control cells 
immunolabeled with p150
glued 
3 h after infection. Left, p150 
glued
; Right, Salmonella. Bar, 10 μm. 
SCV Recruits the Minus-End directed Dynein Motor after RILP Expression  
To examine whether the dynein motor also could be recruited to the SCV following RILP 
expression, the interaction between the endogenous minus-end directed motor dynein and the 
SCV was analyzed. Dynein recruitment was visualized by immunolabeling cells with 
antibodies recognizing p150
glued
, a subunit of the dynein-dynactin complex. Figure 3a shows 
that p150
glued 
was recruited to the SCV upon RILP expression. Note that in some cases the 
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SCV was more intensively labeled with p150
glued 
than late endocytic structures in the same 
cell. No significant difference in motor recruitment was observed between cells expressing 
RILP for 1, 3, and 7h or o/n. In all cases, the p150
glued 
motor subunit could be detected on 
±40% of the SCV (Figure 3b). Importantly, p150
glued 
was never observed on the SCV in 
control cells (Figure 3c; representative image 3 h after infection).  
Similar results were obtained with p50
dynamitin
, another subunit of the dynein-dynactin 
complex and with the Salmonella 12023 strain (our unpublished data). Recruitment of the 
opposite, plus-end motor kinesin could not be observed at any time point (our unpublished 
data). These data show that RILP specifically recruits the dynein-dynactin motor toward 
Rab7-containing compartments, including the SCV.  
 
Dynein-Dynactin Motor Activity Inhibits Salmonella Replication  
The C-terminal one-half of RILP (RILP-ΔN) binds to active GTP-bound Rab7 but cannot 
recruit the minus-end motor dynein (Jordens et al., 2001). Consequently, late 
endosomal/lysosomal compartments move toward the cell periphery. Thus, in contrast to 
RILP-expressing cells, in cells expressing GFP-RILP-ΔN the late endosomes and lysosomes 
are dispersed instead of clustered (Figure 4a). Importantly, when GFP-RILP-ΔN was 
expressed 2– 4h after infection, no reduction of elongated bacteria was observed after o/n 
incubation (Figure 4a). Instead the GFP-RILP-ΔN–expressing cells showed formation of 
elongated bacteria similar to control cells. These data indicate that the RILP-induced dynein 
motor recruitment inhibits Salmonella replication.  
 
 
Figure 4. Recruitment of functional dynein motor is necessary for the replication block. (A) Microinjection of 
GFP-RILP-ΔN cDNA results in dispersion of late endosomes/lysosomes and formation of elongated bacteria. 
Microinjected cells are indicated by an asterisk. Left, GFP-RILP-ΔN. Right, Salmonella SL1344 stained with 
anti-LPS antibodies. (B) Disruption of the minus-end dynein motor can overcome the RILP-induced replication 
block. A 10-fold molar excess GFP-p50
dynamitin
 cDNA was microinjected together with RILP cDNA, to uncouple 
RILP action from dynein motor recruitment. Confocal images show GFP-p50
dynamitin
-containing vesicles that 
relocated to the cell periphery. These cells contained elongated bacteria. Left, GFP-p50
dynamitin
. Right, 




We further investigated whether the recruited dynein-dynactin motor complexes were 
functionally involved in the inhibition of bacterial replication. Therefore, RILP expression 
was combined with inactivation of the dynein motor by overexpressing GFP-p50
dynamitin 
by 
simultaneous microinjection of cDNA for both proteins. Overexpression of p50
dynamitin 
dissociates the dynactin complex, thereby uncoupling the dynein motor from its cargo 
(Burkhardt et al., 1997). In cells coexpressing p50
dynamitin 
and RILP, the p50
dynamitin 
subunit of 
the dynein-dynactin motor complex is still recruited to late endosomes/lysosomes by RILP 
(Jordens et al., 2001) (Figure 4b).  
Coexpression of RILP with excess GFP-p50
dynamitin 
reversed the late endosomal/lysosomal 
clustering normally induced by RILP (Figure 4b). More importantly, the inhibitory effect of 
RILP on intracellular growth of Salmonella is reversed as well, and elongated structures are 
formed similar to control cells. GFP-p50
dynamitin 
localized to the dispersed late endosomes and 
lysosomes, indicating that RILP was expressed as well. This was confirmed in a reciprocal 
experiment using GFP-RILP with VSV-tagged p50
dynamitin 
(our unpublished data). These data 
imply that both the recruitment and the activity of the minus-end dynein motor are critical for 
the inhibition of bacterial replication.  
 
Expression of RILP induces SCV transport to and subsequent fusion with lysosomes  
Besides regulating vesicle transport (Jordens et al., 2001), Rab7 is a key regulator of fusion 
between late endosomes and lysosomes (Meresse et al., 1995; Bucci et al., 2000). The RILP-
induced motor recruitment might target the bacteria for degradation by increasing transport to 
the microtubule minus-end, where the lysosomes reside, and induce fusion with lysosomes at 
this site. The interaction between lysosomes and the SCV was visualized with an antibody 
recognizing the aspartic proteinase cathepsin D. Cathepsin D is involved in degradation of 
proteins in the lysosomal compartment. In control cells, some of the SCV recruited cathepsin 
D (Figure 5, b and c). This increased significantly when RILP was expressed for 3–4 h 
(Figure 5, a and c), indicating that RILP expression enhanced fusion with lysosomes.  
To further test this RILP-induced fusion with lysosomes, cells were preloaded with the fluid 
phase marker SR101 for 30 min followed by a 2 h incubation to allow the fluorophore to 
accumulate in lysosomes. Cells were then infected with Salmonella SL1344 and RILP was 
expressed 2–4 h after infection. One hour after microinjection of RILP, living cells expressing 
RILP and control cells were followed using time-lapse confocal microscopy. Cells 
microinjected with RILP showed a rapid accumulation of SR101 in 42.5 ± 5.0% of the SCV 
(Figure 5, d and f). In control cells, only 14.0 ± 2.4% of the SCV accumulated SR101 (Figure 
5, e and f). Similar results were obtained for the 12023 strain (our unpublished data). As a 
control, RILP-ΔN was expressed and then the SCV accumulated SR101 similar to control 
cells (our unpublished data). Moreover, similar results were obtained with DQ Red BSA, a 
strong self-quenched fluid phase marker that is dequenched upon proteolytic digestion. In 
control cells, only few of the SCV accumulated dequenched DQ Red BSA (Figure 5, h and i), 
which was significantly increased (2-fold) upon RILP expression (Figure 5, g and i).  
Together, these results indicate that the minus-end motor dynein directs transport of the 
SCV to sites where lysosomes reside. Here, fusion between the two compartments can occur. 










Figure 5. RILP-induced motor recruitment increases fusion with lysosomes. (A) Infected cells microinjected 
with RILP cDNA showing cathepsin D accumulation on the SCV. Left, Salmonella SL1344. Right, cathepsin D. 
Bar, 10 μm. (B) Control cells immunostained for cathepsin D. Left, Salmonella SL1344. Right, cathepsin D. Bar 
10 μm. (C) Quantification of cathepsin D accumulation on the SCV of three individual experiments 3–4 h after 
infection. These data represent 40 microinjected cells and 80 control cells. Mean ± SEs are indicated. (D) 
Confocal analysis of living HeLa cells labeled with SR101, infected with GFP-SL1344 Salmonella and 
microinjected with RILP cDNA. Cells were followed for 4h at 37°C. Microinjected cells were visualized using 
FITC-dextran as an injection marker. Microinjected cells accumulated SR101 in the SCV. Insets are shown of 
these areas. Left, GFP-SL1344 Salmonella and injected cells with FITC-dextran. Right, SR101 labeling of 
lysosomes. Bar, 10 μm. Injected cells are indicated by an asterisk. (E) Zoom in of the area indicated with an 
arrow in Figure 5d, bottom right. In this area, the SCV in the nonmicroinjected cell showed no SR101 
accumulation. Left, GFP-SL1344 Salmonella. Right, SR101 labeling of lysosomes. (F) Quantification of seven 
independent experiments. The mean percentage of colocalization between SCV and SR101 is presented ± SE in 
control (n = 90) and RILP-expressing cells (n = 80). (G) Confocal analysis of living cells microinjected with 
RILP cDNA and labeled with DQ Red BSA which is a fluid phase marker that is dequenched upon proteolytic 
activity. Cells were followed for 4h at 37°C. Microinjected cells were visualized using FITC-dextran as an 
injection marker. Left, GFP-SL1344 Salmonella and injected cells with FITC-dextran. Right, DQ Red BSA 
labeling. Bar, 10 μm. (H) Confocal analysis of control cells labeled with DQ Red BSA. Left, GFP-SL1344 
Salmonella. Right, DQ Red BSA labeling. Bar, 10 μm. (I) Quantification of colocalization between the SCV and 
DQ Red BSA of two individual experiments. The data represent 50 microinjected cells and 100 control cells. 
Mean ± SEs are indicated. Positions of SCV are indicated by arrows. 
 
Discussion  
S. typhimurium resides in a specialized vacuole inside host cells that does not fuse with 
mature lysosomes (Garciadel Portillo and Finlay, 1995; Meresse et al., 1999a). Although 
various Salmonella proteins have been identified that could interfere with lysosomal fusion, it 
is unclear which host cell systems are targeted. Furthermore, it remains unclear how host cells 
can clear Salmonella infections. Our study shows that manipulation of a pathway downstream 
of Rab7, through its effector RILP, induces the recruitment of the dynein motor to the SCV. 
This results in transport of the SCV to lysosomes, where Salmonella growth is inhibited.  
The small GTPases Rab5 and Rab7 are regulators of different transport and fusion steps in 
the endocytic pathway (Novick and Zerial, 1997; Somsel Rodman and Wandinger-Ness, 
2000). Phagosomes containing bacteria or inert particles acquire Rab5 and Rab7 sequentially 
when they mature along the endocytic pathway (Desjardins et al., 1994). At the final stage of 
the endocytic pathway, bacteria are degraded in mature lysosomes that contain hydrolases. 
Therefore, several bacteria interfere with the host’s endosomal pathway to avoid degradation 
in lysosomes (Knodler et al., 2001). For example, retention of Rab5 on the phagosome and 
failure to acquire Rab7 protects M. tuberculosis from degradation (Via et al., 1997; Kelley 
and Schorey, 2003). In murine macrophages, fusion with early endosomes and retention of 
Rab5 on the SCV is important in preventing transport to lysosomes as well (Hashim et al., 
2000; Mukherjee et al., 2001). However, studies in other cells, including HeLa, showed that 
the SCV does acquire Rab7. In HeLa cells, expression of a dominant-negative form of Rab7 
delayed the maturation of the SCV, suggesting that Rab7 is involved in the maturation of the 
SCV (Meresse et al., 1999a).  
Although Rab7 interacts with the SCV in HeLa cells (Martinez-Lorenzo et al., 2001; 
Meresse et al., 1999a), there is no fusion with mature lysosomes. For other intracellular 
bacteria, it has also been shown that targeting of Rab7 to phagosomes is not sufficient for 
phagolysosomal fusion. For instance, targeting of Rab7 to phagosomes containing 
Mycobacterium tuberculosis or Legionella pneumophila could not induce fusion with 
lysosomes (Clemens et al., 2000; Kelley and Schorey, 2003). Moreover, using 
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phosphatidylinositol 3-kinase inhibitors, Vieira et al. (2003) could induce a maturation block 
due to prolonged Rab5 activity on phagosomes containing latex beads. In these cells, 
recruitment to and activation of Rab7 on the phagosomes was not sufficient to overcome the 
maturation block (Vieira et al., 2003).  
We confirmed that Rab7 is targeted to the SCV in HeLa cells. Using transient expression of 
GFP-Rab7, we could show that Rab7 is present on the SCV during all phases of infection, and 
not only during the early phases of infection (Meresse et al., 1999a). By using FRAP, the 
Rab7 activation cycle on the SCV was compared with the cycle on late endocytic structures, 
even within the same cell. This is considerably more complicated, if not impossible, when 
compartments have to be isolated for biochemical analysis. Our experiments showed that the 
Rab7 activation cycle on the SCV was identical to that on late endocytic structures, even 
within the same cell. Thus, Salmonella does not affect the Rab7 activation cycle on the SCV 
or late endocytic structures in our experimental system.  
The role of Rab7 in regulation of late endosomal/lysosomal transport and fusion has been 
widely studied. However, some controversy remains about the exact localization of Rab7. 
Rab7 was reported exclusively located on late endosomes (Feng et al., 1995; Meresse et al., 
1995), whereas others placed Rab7 on late endosomes and lysosomes (Bucci et al., 2000). 
Considering markers that define late endosomes and lysosomes, Rab7 is located on mannose-
6-phosphate receptor-containing structures, a marker for late endosomes (Feng et al., 1995; 
Meresse et al., 1995), as well as on cathepsin D-positive structures, a marker for lysosomes 
(Bucci et al., 2000). However, thus far most reports used ectopic expression of Rab7 
constructs, which might result in a broader distribution. We show that expression of the Rab7 
effector RILP results in clustering of late endosomes as well as lysosomes, because the 
clustered compartments are cathepsin D, SR101, and LysoTracker positive (Figure 5, a–f) 
(Cantalupo et al., 2001; Jordens et al., 2001). Because RILP binds to, and regulates transport 
of, compartments containing (endogenous) Rab7, this implies that endogenous Rab7 should 
be located on both compartments (see also Figure 5, a–f).  
Because Rab7 is crucial in regulating late endosomal/lysosomal fusion, modulating a 
pathway downstream of Rab7 could affect the intracellular fate of Salmonella.We therefore 
tested whether the Rab7 effector RILP could be recruited to the SCV. Because endogenous 
RILP cannot be detected using immunofluorescence, SCV separated by density gradient 
centrifugation were analyzed. RILP comigrated with Rab7 on the SCV and with late 
endocytic fractions. RILP is a limiting factor in controlling dynein motor recruitment to late 
endosomes and lysosomes, because ectopic expression of RILP enhances this motor 
recruitment and activates minus-end transport of late endosomes and lysosomes (Jordens et 
al., 2001). To test whether RILP expression causes similar effects on the SCV or affects 
intracellular survival of Salmonella, cells infected with Salmonella were microinjected with 
RILP. Ectopic expression of RILP inhibited intracellular replication of two Salmonella 
strains. Under normal conditions endogenous RILP is recruited to the SCV (Figure 1f). 
However this level of expression may be insufficient to affect Salmonella infections. Because 
ectopic expression of RILP can affect intracellular Salmonella replication, it might be that 
RILP or RILP activity is a direct target of Salmonella, but this is unclear.  
How does RILP affect intracellular replication of Salmonella? It has been shown that 
phagosomes move along microtubules in a bidirectional manner by using the microtubule 
motors dynein and kinesin. This microtubule-based transport is required for phagosomal 
maturation because it facilitates fusion between phagosomes and endocytic compartments 




containing late endosomes and lysosomes, thereby regulating minus-end transport of these 
compartments (Jordens et al., 2001). Here, we show that expression of RILP induces 
recruitment of the minus-end motor dynein to the SCV and blocks intracellular Salmonella 
replication. This is the result of dynein motor activity because concomitant inactivation of the 
dynein-dynactin motor could overcome the RILP-mediated block in replication of Salmonella. 
Increased movement of the SCV in RILP-expressing cells could not be imaged due to 
phototoxicity. RILP expression only inhibited intracellular Salmonella growth during the 
early intracellular phase (2–4 h after infection). Expression of RILP 8 h or later after infection 
does not inhibit intracellular growth of Salmonella. Later, during the infection, the SCV is 
segregated from the endocytic pathway (Garvis et al., 2001), rendering it not susceptible to 
RILP-induced dynein-mediated transport to lysosomes.  
Our data suggest that transport of the SCV to lysosomes is one of the limiting factors in host 
cells for intracellular survival of Salmonella. Because lysosomes are usually located in the 
perinuclear area, close to the microtubule minus-end, transport of the SCV to this site has to 
precede fusion with lysosomes. Indeed, we show that dynein recruitment resulted in an 
increased fusion of the SCV with lysosomes and inhibition of Salmonella growth. RILP 
induced dynein-mediated transport of the SCV, thus controls intracellular Salmonella 
replication during the early phase of infection. Motor proteins are novel host components 
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Melanosomes are lysosome-derived organelles that synthesise, store and transport 
melanin. In epidermal melanocytes, melanosomes mature and are transferred to surrounding 
keratinocytes, which is essential for skin and coat colour. Mouse coat colour mutants reveal a 
critical role for the small GTPase Rab27a, which recruits Myosin Va through its effector 
protein Melanophilin/Slac2a. Here we have analysed how different Rab GTPases control two 
motor proteins during the transport of melanosomes. We show that the small GTPase Rab7 
mainly associates to early stage melanosomes. Rab7 is able to recruit the microtubule-based 
dynein motor mediated by its effector RILP and thereby controls microtubule-based transport 
of melanosomes. Rab27a is detected in two forms on the melanosomes, a rapidly cycling 
intermediate state and a highly active state on more mature melanosomes. The Rab7-RILP-
dynein pathway controls early and intermediate stage Rab27a-positive melanosomes. Late 
stage melanosomes lack Rab7 and remain associated to the actin network through the Rab27a-
MyoVa link. Thus two Rab proteins regulate two different motor proteins, thereby controlling 
different phases in melanosome biogenesis: Rab7 controls microtubule-mediated transport of 
earlier stage melanosomes and Rab27a the subsequent actin-dependent transport of the more 




Melanin or pigment is responsible for human skin, hair and eye colour. In the skin, 
epidermal melanocytes produce melanin within melanosomes, which are specialised 
organelles related to lysosomes [1]. Melanosomes progress through well-defined sequential 
morphological steps. Stage I are melanin-lacking premelanosomes that resemble late 
endosomal multivesicular bodies, stage II melanosomes are elongated structures with 
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intralumenal fibres (striations), stage III melanosomes show blackened striations and stage IV 
melanosomes are fully loaded with melanin [2,3].  
In epidermal melanocytes, melanosomes undergo microtubule and actin-dependent 
transport towards the periphery before transfer to neighbouring keratinocytes [4-6]. Rab27a is 
a member of the small GTPase Rab27 subfamily, which controls transport and exocytosis of 
lysosome-related organelles (LRO) in specific cell types (reviewed by [7]). Mutations in the 
RAB27A gene are associated with the ashen phenotype and Griscelli syndrome type II in mice 
and humans, respectively [8-11]. Melanocytes derived from ashen mice or its human 
counterpart Griscelli type II, display defects in melanosome transport towards the cell 
periphery, resulting in accumulation of mature melanosomes in the perinuclear area [9,11]. 
Rab27a in its active, GTP-bound state localises to the membrane of melanosomes. There it 
acts as a receptor for the actin-dependent Myosin Va motor protein mediated by the 
melanocyte-specific Rab27a effector, Melanophilin/Slac2-a [12-16]. Loss of Rab27a 
expression causes loss of function of the Rab27a-Melanophilin-Myosin Va tripartite complex, 
leading to defects in normal actin-dependent melanosome transport and capturing in the 
peripheral actin thus affecting skin colour.  
Another member of the family of Rab GTPases associated to LRO is Rab7, which  is 
involved in microtubule-based transport of late endosomes/lysosomes [17-22], MHC class II 
compartments [20], cytolytic granules (Jordens et al, unpublished results) and phagosomes 
[23-26]. Through its effector Rab7-interacting lysosomal protein (RILP), the minus-end 
microtubule-based motor complex dynein/dynactin is recruited to the Rab7-containing 
compartments [20]. Consequently, minus-end transport increases and compartments 
accumulate around the microtubule-organising centre (MTOC). Proteomics and immuno-
fluorescence analyses showed that Rab7 can interact with the melanosomal membrane as well 
[27]. Moreover, Hirosaki and co-workers demonstrated that Rab7 is involved in the transport 
of the melanosome-specific proteins Tyrosinase and Tyrosinase-related protein 1, both 
involved in melanin synthesis, from the trans-Golgi network to melanosomes passing through 
endosome-delineated compartments [28].  
The role of the dynein motors in retrograde melanosome transport in Xenopus leavis 
melanophores and human melanocytes is well established [4,29-31]. Anterograde 
melanosome transport in frog melanophores is facilitated by kinesin II [32] and in human 
melanocytes by conventional kinesin [33]. Kinesin, dynein and Myosin Va can directly 
interact with each other, suggesting that they could form a multiprotein motor complex [6,33-
35]. Although the regulation of these complexes is still poorly understood, experimental data 
on melanosome movement in Xenopus melanophores suggests that melanosome distribution 
results from competition between microtubule-based motors and myosins, in the so-called 
‘tug-of-war’[4]. How the activity of the different motors is regulated is unclear, yet Rab 
GTPases might be critical. 
At least five Rab proteins have been implicated in motor recruitment to their specific 
compartments [12-16,20,36-40]. Here we have studied the role of two of them in one 
pathway, the intracellular transport of melanosomes. We show that the Rab7-RILP-dynein 
motor cascade is controlling transport of early melanosomes. The most mature melanosomes 
lack Rab7 and maintain located to the actin-rich cell extremities by the Rab27a-Melanophilin-
MyosinVa cascade. This is the first example of two Rab proteins controlling two motor 
proteins in transport of one organelle, the melanosome. 
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Figure 1. Rab7 and Rab27a both associate to melanosomes 
Primary melanocytes were electroporated with wild type GFP-Rab7 (A; left panel) or GFP-Rab27a (A; right 
panel). For colocalisation with melanosomes, cells expressing GFP-Rab7 or GFP-Rab27a were formaldehyde 
fixed and labelled with the melanosomal NKI-beteb antibody (B). Arrows indicate colocalisation. GFP-Rab7 (C) 
and GFP-Rab27a (D) expressing cells were labelled for Tyrosinase and Mel-5, respectively labeling early and 





Rab7 and Rab27a co-localise on melanosomes 
The small GTPases Rab7 and Rab27a have been found associated to melanosomal 
membranes in human and mouse melanocytes [27,28,41,42]. To visualise the relative 
distribution of Rab7 and Rab27a in melanocytes, we expressed GFP-Rab7 or GFP-Rab27a in 
primary human melanocytes. GFP-Rab7 mainly localises to the perinuclear area with some 
vesicles in the periphery and dendrites (figure 1A, left panel). GFP-Rab27a mainly localises 
to the periphery, underneath the plasma membrane and in dendrites, with a striking 
accumulation in the dendrite tips (figure 1A, right panel). Some GFP-Rab27a is observed in 
the perinuclear region as well. To determine to co-distribution with melanosomes, we co-
stained with the melanosomal marker NKI-beteb, recognising the melanosomal silver protein 
(Pmel17) (figure 1B). A significant portion of GFP-Rab7 co-localises with NKI-beteb (figure 
1B, upper panels). As expected, GFP-Rab27a strongly co-localised with NKI-beteb (figure 












































Figure 2. Rab7 localises to early melanosomes, whereas Rab27a is found on more mature melanosomes. 
Primary human epidermal melanocytes were electroporated with GFP-Rab7 (A, B and C) or GFP-Rab27a (D, 
E, F and G). Labelling of ultrathin cryosections was performed with an anti-GFP coupled to 10 nm gold and the 
melanosomal marker NKI-beteb coupled to 15 nm gold. Early stage, multivesicular melanosomes (I and II) are 
positive for GFP-Rab7 (A, B and C), whereas more mature melanosomes (electron dense stage IV) are positive 
for GFP-Rab27a (D, E, F and G). GFP-Rab27a is also present on stage II melanosomes (G). Arrows indicate 
GFP-Rab7 or –Rab27a. Bars: 500 nm. (H) Quantification of melanosomal distribution GFP-Rab7 (n=185) and 
GFP-Rab27a (n=54). 
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Co-staining with the early melanosomal marker Tyrosinase (figure 1C, upper panels) and 
the late melanosomal marker Mel-5 (figure 1C, lower panels), suggests that GFP-Rab7 (left 
panels) mainly localises to earlier melanosomes. In contrast, GFP-Rab27a strongly co-
distributes with the late endosomal marker Mel-5 in the dendrites (figure 1D, lower panels) 
and only partially with Tyrosinase (figure 1D, upper panels). To investigate this in more 
detail, we performed cryo-immuno-electron microscopy on primary human epidermal 
melanocytes expressing GFP-Rab7 or GFP-Rab27a. To identify the structures that represent 
melanosomes, we used a co-labelling with monoclonal NKI-beteb. Note that fully melanised 
stage IV melanosomes, recognised as electron dense structures, show reduced NKI-beteb 
labelling because the epitope is partially masked by melanin. GFP-Rab7 is mainly present on 
early stage II melanosomes but is also detected on stage I and III. However, less frequently 
found on melanin-laden stage IV melanosomes (figure 2A, B and C). Rab27a is mainly 
present on stage III, but is also present on stage IV melanosomes (figure 2D, E, and F) and 
early stage II melanosomes (figure 2D, E and G). Quantification of the EM (figure 2H) shows 
that ± 70 % of the GFP-Rab7 is observed on early stage I and II melanosomes and only ± 30 
% on stage III and IV. GFP-Rab27a shows a reciprocal distribution and is primarily found on 
stage III and IV melanosomes (± 78%) with a minor portion present on early stage 
melansomes (± 22%).  
 
Figure 3. Rab27a and Rab7 co-localise on melanosomes 
(A) Primary melanocytes expressing GFP-Rab27a and mRFP-Rab7 show partial co-localization in the 
periphery (in sets). (B) RILP-HA expression induces clustering of Rab7-positive compartments and co-
localization of GFP-Rab27a and mRFP-Rab7 in the periphery is increased. (C) Quantification is shown of co-
localization of GFP-Rab27a and mRFP-Rab7 in the cell periphery. Mean percentage of co-localization is shown 






































These data suggest that the intermediate stage II and III melanosomes contain both Rab7 
and Rab27a. To determine the extent of co-localisation between Rab27a and Rab7, we co-
expressed GFP-Rab27a and mRFP-Rab7 in primary human melanocytes. A typical lysosomal 
distribution of mRFP-Rab7 in the perinuclear region with several peripheral vesicles is shown 
(figure 3A, right panels). GFP-Rab27a mainly localised to the periphery and the dendrites 
with some GFP-Rab27a in the perinuclear region as well (figure 3A, left panels). Zooming 
into the periphery revealed many vesicles labelling for both GFP-Rab27a and mRFP-Rab7 
(high zooms, figure 3A). Since structures in the perinuclear area cannot be spatially separated, 
only peripheral structures were quantified. Approximately 40% of the peripheral 
melanosomes contained both Rab27a and Rab7 (figure 3A).  
 
Rab7 and Rab27a activities in living cells 
Rab7 and Rab27a co-localise on the intermediate stage melanosomes. The membrane 
localisation in fixed cells, however, does not provide information on activity of the GTPases. 
Therefore, we have used Fluorescent Recovery after Photo bleaching (FRAP) as described 
before [20,25]. Cycling of Rab proteins between the membrane-bound active state and the 
soluble inactive state can be followed in living cells by bleaching a small portion of GFP-Rab 
positive vesicles and measuring the recovery of fluorescence on the same vesicles by time-
lapse microscopy [20,43]. The bleached vesicles are visualised by simultaneous incubation 
with LysoTracker Red which labels late endosomal compartments and melanosomes. The 
recovery of fluorescence in the bleach spot at different locations in the cell was plotted in a 
recovery curve (figure 4A), allowing the determination of two factors: the recovery time 
(T1/2), which represents the time in which 50% of the fluorescence in the bleach spot was 
recovered (i.e. the cycling time of the GTPase), and the mobile fraction being the percentage 
of fluorescent GFP-Rab that was recovered and thus able to cycle. This mobile fraction can be 
affected by effector proteins, like for instance RILP, which locks Rab7 in the active, 
membrane-bound state [20].  
The procedure described above was conducted on GFP-Rab7 or GFP-Rab27a positive 
vesicles located in the cell periphery and the tips of melanocytes. Representative recovery 
curves are shown in figure 4A and B. Rab7 recovered slower in the tips of dendrites (t1/2 56.9 
+/- 4.0s versus 24.4 +/- 1.8s; figure 4D), but the curve levelled off at the same percentage of 
recovery, implying a similar mobile fraction (figure 4C). The recovery curves for GFP-
Rab27a are markedly different. Although the recovery rates were similar in the tip and the 
periphery (t1/2 37.2 +/- 4.3s versus 36.7 +/- 4.3s; figure 4D), the mobile fraction was 
dramatically decreased in vesicles present at the tip of dendrites (figure 4C). Thus, whereas 
Rab7 and Rab27a activities are more or less similar in the periphery, Rab27a is significantly 
more active in the tips of the dendrites. These data suggest that the GTPase cycle of Rab7 and 
Rab27a show spatial differences within the same cell.  
 
RILP controls early melanosomal distribution  
The role of the Rab27a and its effector Melanophilin/Slac2a in actin-dependent 
melanosome transport in human and mouse melanocytes is well established [12,14-16,41]. 
However, the involvement of Rab7 in melanosomal transport has only been recently 
suggested [27,28]. Several studies showed the involvement of dynein/dynactin and kinesin 
motors in the transport of melanosomes [4,29-31,33,44,45]. Although phosphorylation plays 
an important role in the regulation of motor activities [46,47], the exact mechanisms of motor 
targeting is still largely unclear.  
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Figure 4. Cycling of Rab27a and Rab7 in living cells 
(A) Representative recovery curves of fluorescence in the bleached spot in GFP-Rab7 and (B) GFP-Rab27a 
(right) expressing cells (triangles= tip; squares=periphery). The fluorescence was related to the initial 
fluorescence (set at 100%). The different colours represent the different locations in the cell. (C) Quantification 
of the half-time of recovery (T½) and (D) mobile fraction (M) deduced from the recovery curves. Shown are the 
mean ± standard errors.  
 
We and others have shown that Rab7 and its effector RILP control dynein-dynactin 
mediated microtubule-based transport of lysosome-related organelles (LRO) [20,23-25]. 
Since Rab7 is localised to early melanosomes, it may control transport of these structures 
along the microtubules. To determine to what extent melanosomes are subject to dynein-
mediated microtubule-based transport, dynein-mediated transport was obstructed by 
overexpression of p50dynamitin. Overexpression of p50dynamitin causes dissociation of the dynein-
associated dynactin complex and subsequent inhibition of minus-end directed transport 
[48,49]. Consequently, the plus-end directed microtubule-dependent kinesin motor activity, 
known to participate in anterograde melanosome transport in melanocytes, becomes dominant 
and melanosomes will be transported towards the plus-end of microtubules into the periphery 
[32,33,44]. Overexpression of GFP-p50dynamitin significantly affected melanosome distribution 
as visualised by beteb staining (figure 5A). Most of the earlier perinuclear-localised 
melanosomes stained by anti-Tyrosinase moved towards the periphery (figure 5B). The 
position of the later stage melanosomes positive for Mel-5, however, is not significantly 




























Figure 5. Melanosomes depend on microtubule-based transport. 
(A) Primary human melanocytes overexpressing GFP-p50dynamitin to disrupt dynein motor function labelled for 
NKI beteb. Perinuclear melanosomes are relocated toward the periphery. (B) Quantification of melanosome 
distribution shown as mean percentage of normal and dispersed melanosomes in control cells and cells 
expressing p50dynamitin (control N = 38, GFP- p50dynamitin N=22). (C) Melanocytes expressing GFP-p50 stained 
for the early melanosomal marker Tyrosine (upper panels) or the late marker Mel-5 (lower panels). Inset in 
Tyrosinase panel shows control cells. Bars 10 µm. 
 
To test whether Rab7/RILP controls the minus-end transport of the melanosomes, we 
ectopically expressed GFP-RILP in human melanocytes which has been shown to cause 
clustering of Rab7-positive compartments in the perinuclear area [18,20]. In melanocytes 
expressing RILP, perinuclear clustering of NKI-beteb positive vesicles was observed (figure 
6A and B), indicating that RILP controls at least part of the melanosomal transport. Rab27a-
positive melanosomes that are not yet captured in the actin cytoskeleton via Myosin Va, could 
still be subjected to the Rab7-RILP-dynein motor complex. To test whether these more 
mature melanosomes are controlled by the Rab7/RILP pathway, the experiment was repeated 
using GFP-Rab27a as a marker. Again, clustering of Rab27a vesicles was induced by RILP 
expression, although to a lesser extent (figure 6C). This finding is consistent with the fact that 
a substantial portion of the Rab27a-positive melanosomes lacks Rab7 and is not subject to the 
effects of the RILP-dynein pathway. 
To visualise the effect of RILP on the melanosomes positive for both Rab7 and Rab27a, 
GFP-Rab27a was co-expressed with mRFP-Rab7 and HA-tagged RILP. As described above, 
overexpression of RILP causes almost all Rab7-positive compartments to move towards the 
MTOC (figure 3B), whereas most Rab27a-positive melanosomes remained localised to the 
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periphery show a significantly higher co-localisation with Rab27a (figure 3C). This suggests 
that on these particular melanosomes, Rab27a is dominant over Rab7. Apparently, Rab27a 
and Rab7 compete during the transport of melanosomes, which indicates that (at least) two 
different Rab GTPases and their associated motor activities control the transport of one 
compartment, the melanosome.  
 
Discussion 
Lysosome-related organelles (LRO) move in a bi-directional manner along microtubules 
by dynein and kinesin motor proteins [4,50,51]. How timing of transport is controlled is 
largely unclear. The dynein-motor is recruited by the Rab7 effector RILP to these structures 
[20]. The involvement of one other motor protein has been shown in LRO motility, which is 
the actin-based motor Myosin Va [12-16]. Again a Rab protein, the melanosome-specific 
Rab27a, controls the recruitment of this motor protein through interactions with the Rab27a-
effector Melanophilin/Slac2a. Thus, besides regulating vesicle fusion, Rab GTPases also 
control protein-motor driven vesicle transport; two functions that are most likely connected 
(Jordens et al., in press). In fact, the large family of Rab proteins is ideal for timed and 
spatially controlled motility of intracellular structures, because of their compartment-specific 
distribution. In our study, we have tested two Rab proteins that control different motor 






















Figure 6. The Rab7 effector RILP controls melanosomal distribution.  
(A) Primary human melanocytes expressing GFP-RILP (left panel) were labelled with NKI/beteb (right panel) 
(B) Quantification of melanosome distribution shown as mean percentage of normal and clustered melanosomes 
in control cells and cells expressing GFP-RILP (control N = 27, GFP-RILP N=17 ). (C) Melanocytes co-
expressing GFP-Rab27 (left panel) and RILP-HA (right panel). Expression of RILP partially clusters Rab27-





























In the skin, melanosomes undergo several stages of maturation before they are fully 
matured and arrive in the periphery, where they are trapped in the actin network by Myosin 
Va and ultimately transferred to the neighbouring keratinocytes [1-3]. Rab7 and Rab27a co-
distribute on the intermediate stage II and III melanosomes. Rab27a, but not Rab7, is 
excluded from the earliest melanosomes and Rab7, unlike Rab27a, is excluded from the 
mature stage IV melanosomes. Similarly, Weibel Pallade bodies, which are also controlled by 
Rab27a, acquire Rab27a during maturation [52].  
Melanosomes are known to move along microtubules via kinesin and dynein in a bi-
directional manner [45]. Gross et al [4] have shown that in frog melanophores Myosin Va 
activity counteracts the dynein-dynactin activity possibly by Myosin Va-driven shortening of 
minus-end (dynein-driven) motility. We show that the situation is more complex in human 
melanocytes. Early and intermediate melanosomes containing both Rab7 and Rab27a are 
susceptible to the action of the Rab7-effector RILP and subsequent dynein-mediated transport 
to the microtubule minus-end. Only the most mature form of melanosomes (stage IV) is no 
substrate for this motor activity, simply because it lacks Rab7. A fraction of melanosomes, 
labelled by Rab27a but also containing Rab7, was unresponsive to RILP action possibly 
because Rab27a was acting dominant over Rab7, or –in motor protein terms- Myosin Va 
interactions with the actin cytoskeleton could not be overcome by the action of the dynein 
motor. In fact, Rab27a-Myosin Va interactions with the cortical actin cytoskeleton may be 
important for local retention of melanosomes and to prevent microtubular minus-end directed 
dynein motor-mediated transport. Sequestration of vesicles underneath the plasma membrane 
in the actin network is a general feature observed for secretory lysosomes, like those found in 
nerve terminals and cytotoxic T cells.  
Both the dynein-dynactin motor and the Myosin Va motor are targeted to specific 
compartments by the action of two Rab GTPases that have to be activated before the effector 
proteins can recruit the motor proteins. We have used Fluorescent Recovery After Photo 
bleaching (FRAP) to measure the cycling time of Rab7 and Rab27a. Importantly, we 
measured differences in the Rab cycle times on vesicles within the same cell when using 
FRAP. Rab7 cycles somewhat faster in the periphery than in the cell tip, possibly because the 
regulatory proteins for Rab7, like GAPs and GEFs are differently active on these 
compartments. A striking difference, however, is observed for Rab27a, which is largely 
immobile in the tip of the cell. Melanohilin/Slac2a binding to Rab27a possibly inhibits GTP 
hydrolysis (and thus cycling), analogous to the effects observed for RILP binding to Rab7 
[20]. Consequently, the Myosin Va motor sequestering to the Rab27a-effector protein 
complex maintains the melanosome associated to the actin cytoskeleton, rendering it 
unsusceptible to microtubule-based transport. 
In the Tug-of-war model postulated by Gross et al [4], Myosin Va counter acts kinesin-
mediated transport less than dynein-mediated transport, thereby favouring the peripheral 
localisation of melanosomes. When Myosin Va activity is absent [9,53] melanosomes still 
move bi-directional by the actions of kinesin and dynein, but the overall distribution of 
melanosomes is shifted toward the perinuclear area. This suggests that on most early 
melanosomes dynein motor activity is dominant over kinesin motor activity, similar to what 
has been observed for lysosomes [51].  
In summary we show that on early and intermediate stage melanosomes Rab7 is active, 
whereas Rab27a is not present or has a relatively low activity. As a result, Rab7/RILP/dynein 
activity retains these melanosomes in the perinuclear area. When melanosomes mature, 
Rab27a activity will increase. This will lead to enhanced Melanophilin/Slac2a binding, which 
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will shift the motor balance towards Myosin Va motor activity. Since Myosin Va activity 
counteracts dynein activity and favours kinesin activity, melanosomes could be transported 
towards the periphery. In this way, mature melanosomes will be captured in the peripheral 
actin network via Myosin Va, rendering them unsusceptible for the actions of 
Rab7/RILP/dynein (figure 7). Two Rab proteins thus control two different motor proteins 



























Figure 7. Model of the two Rab GTPases and the two motor proteins involved in the transport of one vesicle, 
the melanosome. 
Melanosomes are transported along microtubules to the cortical actin network in the tips of the melanocytes, 
while progressing from an early stage I to a mature stage IV melanosome. Bi-directional microtubule-dependent 
transport is controlled by the dynein motor (for minus-end motility) and kinesin motors (for plus-end transport to 
the tips). Rab7 and RILP control dynein motor recruitment onto early melanosomes. The most mature 
melanosomes (stage IV) are devoid of Rab7 and maintain in the tip of the cells by Rab27a and its effector 
Melanophilin/Slac2a that recruits the actin-based Myosin Va motor. Rab7 and Rab27a couple melanosome 
transport to respectively microtubule- and actin-based motor activities and control transport in subsequent 




Materials and Methods 
 
Cell Culture 
The primary human epidermal melanocytes used for confocal and immuno-electron 




Full length Rab27a was amplified by PCR from cDNA derived from human epidermal 
melanocytes and cloned into the pEGFP-C1 vector (CloneTech). Full length RILP and Rab7 
were subcloned in the pEGFP-C1 vector (CloneTech). Full length RILP was subcloned into 
pcDNA3 (Invitrogen) with a C-terminal HA-tag. cDNA encoding GFP-p50dynamitin was a kind 
gift of C. Hoogenraad [56]. Rab7 and RILP were subcloned into mRFP cloned in frame in the 
pEGFP-C1 vector after replacing EGFP for mRFP. All constructs were sequence verified. 
 
Electroporation 
Electroporations were performed as described [14]. Briefly, primary melanocytes were 
collected in an Amaxa certified cuvette (Amaxa GmbH, Germany). A mixture of 100 µl 
nucleofector solution (Amaxa GmbH, Germany) and 1 µg plasmid DNA was added. The cells 
were electroporated in the nucleofector electroporator (Amaxa GmbH, Germany) with the 
U_16 specific nucleofector program.  
 
Antibodies 
The following antibodies were used: rabbit polyclonal anti-GFP antibody [57], mouse 
monoclonal NKI beteb antibody, recognizing the melanosomal silver protein (Monosan, The 




Primary human epidermal melanocytes expressing either GFP-Rab7 or GFP-Rab27a were 
fixed in 2% paraformaldehyde with 0.2% glutaraldehyde in PHEM buffer for 2 hours at room 
temperature. After washing in PBS, the cells were pelleted and embedded in 12% gelatine. 
The pellet was divided into 1-mm3 cubes, cryoprotected in 2.3 M sucrose and snap frozen in 
liquid nitrogen. Ultra thin cryosections were labelled with monoclonal NKI beteb antibody 
(1:200) and visualised using a rabbit anti-mouse IgG bridging antibody and 15-nm protein A-
gold particles. The second labelling was performed with the polyclonal anti-GFP (1:1000; gift 
from J Fransen, Nijmegen; [57]) followed by 10-nm protein A-gold incubation. Sections were 
contrasted with uranyl acetate and analyzed by a Philips EM 410 electron microscope 
(Eindhoven, The Netherlands). 
 
Confocal analyses and Fluorescence recovery after photo bleaching 
For living cell analyses, cells were seeded on coverslips at least 24 h before the 
experiment. For immuno-fluorescence, cells were fixed in 3.7% formaldehyde for 20 minutes 
at room temperature and permeabilised in PBS containing 0.1% Triton-X100. Analyses were 
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performed using a Leica TCS SP2 confocal laser-scanning microscope equipped with an 
Argon/ Krypton laser (Leica Microsystems, Heidelberg, Germany). Green fluorescence was 
detected at λ > 515 nm after excitation at λ = 488 nm. For dual analyses, green fluorescence 
was detected at λ = 520-560 nm. Red fluorochromes were excited at λ = 568 nm and detected 
at λ > 585 nm.  
FRAP experiments were performed as described [20,43]. Briefly, primary melanocytes 
expressing either GFP-Rab7 or GFP-Rab27 were seeded on coverslips. The cells were 
analysed in a culture chamber at 37oC by CLSM (Leica TCS2). A small set of vesicles was 
bleached for one second by a high intensity laser beam and the fluorescence recovery in the 
bleached spot was quantified. To identify the bleached vesicles, cells were incubated with 
LysoTracker Red. The experiments were performed in multiple at various days. The recovery 
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Summary and Discussion 
 
Major histocompatibility complex (MHC) class II molecules are crucial in protecting our 
body against pathogens. They are synthesized in the endoplasmatic reticulum (ER) where they 
form a trimer with the invariant chain (Ii). This complex is transported via the Golgi to the 
MHC class II containing compartment (MIIC), a specialized compartment where peptide 
loading occurs. After internalisation, antigens are degraded into peptides during their transport 
through the endosomal pathway. When they arrive in the specialised MIIC, they are loaded 
onto the MHC class II molecules, a process facilitated by the chaperone HLA-DM. MHC 
class II-peptide complexes are then transported to the plasma membrane where the antigenic 
peptide can be recognised by CD4+ T cells [1]. 
This thesis mainly focused on the transport of MIIC, and other lysosome-related 
organelles. MHC class II transport towards the plasma membrane is tightly regulated and 
depends on both the cell type and the activation state of the cells. In Mel Juso cells, which are 
not professional antigen presenting cells (APCs), but have all the requirements for efficient 
antigen presentation, MIICs are transported to and fuse with the plasma membrane [2,3]. In 
dendritic cells a different process is observed. Upon activation, MIICs start to form tubular 
structures, extending into the direction of the contact site with the T cell. However, under 
these conditions many non-tubulated vesicles exist as well [4-6]. Both ways of transport have 
one thing in common, they require microtubules.  
 
In Chapter 2, we studied the transport of GFP-tagged MHC class II in Mel Juso cells. 
Real time imaging showed that most of the MIIC accumulated in the perinuclear area, where 
little movement is observed. A small portion of the MIICs is found in the periphery where 
they move in a peculiar stop-and-go fashion, rapidly changing direction. We identified the 
mediators of this transport, which are the plus-end directed motor, kinesin, and the minus-end 
directed motor complex, dynein-dynactin. Both motors act on the same MIIC, which explains 
their bi-directionality. Dynein activity usually overrules kinesin, retaining the MIIC in the 
perinuclear area around the minus-end of the microtubules close to the microtubule 
organizing centre (MTOC). When kinesin activity overrides dynein activity, MIICs are 
transported into the periphery. Yet the MIIC is not directly transported to the plasma 
membrane and alters its direction frequently. This suggests that during this transport the two 
motor activities are regulated, possibly to prevent ‘immature’ MIIC to reach the plasma 
membrane. 
Multiple highly processive kinesin motor protein variants have been identified with 
differences in cargo specificity [7,8]. Two kinesin motors have been described to be involved 
in the transport of late endosomal and lysosomal compartments, Kinesin-I and –II [9-11]. 
Kinesin activity is at least partially regulated by phosphorylation, which leads to an increase 
in its membrane association and a higher processivity of the motor [12-15]. Moreover, 
recently it was found that Kinesin-II interacts with the p150Glued subunit of dynactin via the 
kinesin-associated protein (KAP) [16], implying that bi-directional movement may be 
controlled by one protein complex containing both motor proteins. 
Thus far, only one dynein isoform has been shown to posses a processive motor domain, 
which is cytoplasmic dynein 1 [17,18]. Again regulation can occur via phosphorylation or 
dephosphorylation of dynein itself or its activator dynactin [19-22]. However, interference 
with the motor activity of dynein affects multiple cellular processes and therefore more 
specific and local regulation is required. Moreover, since bi-directional moving vesicles are 
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never torn apart by two oppositely directed motor activities [23], there must be a regulator 
that coordinates the activity of both dynein and kinesin.  
 
Small GTPases are ideal regulators. They are able to switch between an active and an 
inactive state and have a high compartment specificity, which enables them to act locally. In 
Chapter 3 we investigated the role of the small GTPase Rab7 in the transport of late 
endosomal/lysosomal compartments. Rab7 is present on late endosomal/lysosomal 
compartments, including MIIC, and is known to regulate their transport [18,24-26]. Via a 
Yeast Two-Hybrid screen with Rab7 as bait, we identified an at that time unidentified protein: 
Rab7 interacting lysosomal protein (RILP) [27,28]. RILP interacts with the active membrane-
bound Rab7 and locks Rab7 in the active GTP-bound state. Effector proteins like RILP often 
interact with the GTP-bound state and prolong the active state of their target GTPase. How 
the interaction between effector and its GTPase is terminated is largely unclear. It might be 
competition with GTPase activating proteins (GAPs) or other interacting factors that change 
the conformation of the GTPase. In the case of Rab7, no GAPs or Guanine Exchange Factors 
(GEFs) have been reported yet.  
Besides locking Rab7 in the active state, RILP also induces the recruitment of the minus-
end motor complex, dynein-dynactin, onto the late endosomes and lysosomes (Chapter 3). 
Although for other Rabs and their effectors direct interactions with motor proteins have been 
shown (Introduction), we were unable to show a direct interaction between either Rab7 or 
RILP with any component of the dynein/dynactin motor complex. We used immuno-electron 
microscopy to show that on the lysosomes the dynactin subunit p50dynamitin was mostly found 
in close proximity of RILP. This indicates that there might be an interaction, although 
possibly via other proteins. A likely intermediate is β3 spectrin, which is present on late 
endosomes and lysosomes (our unpublished results) and has been shown to interact with the 
ARP1 subunit of dynactin [29]. Moreover, via RNAi we showed that spectrin β3 is required 
for late endosomal/lysosomal retention in the perinuclear area (unpublished results), 
presumably via its interaction with dynein-dynactin. Spectrin β3 has been shown to bind 
specifically to acidic phospholipids [30], thus it might be that RILP regulates the lipid content 
of late endosomal/lysosomal membranes and thereby stimulates dynein-dynactin recruitment 
via rearrangements in the spectrin network. Interestingly, Zerial and co-workers recently 
identified a new kinesin member, KIF16B, which has a lipid binding domain. They showed 
that an effector of Rab5, the PI3 kinase Vps34, locally produces PI(3)P, which results in the 
recruitment of KIF16B to the endosome [31]. Thus altering the lipid composition of 
compartments might be a general way to manipulate motor protein recruitment.  
Increased dynein-dynactin recruitment to late endosomes and lysosomes induced by 
expression of RILP overrides the kinesin activity on these compartments. As a result, all late 
endosomes and lysosomes are transported to the very minus-end of the microtubules and 
accumulate around the MTOC. Expression of the C-terminal half of RILP, RILP-ΔN, results 
in the opposite phenotype –late endosomes and lysosomes disperse into the periphery of the 
cell and accumulate underneath the plasma membrane. A similar phenotype was observed for 
dynein-dynactin inhibition (Chapter 2). The C-terminal half of RILP contains the Rab7-
binding domain (aa 284-312) (Chapter 4), but lacks a domain required for motor binding. 
Therefore RILP-ΔN competes with endogenous RILP for Rab7, preventing the perinuclear 
retention of late endosomes and lysosomes normally facilitated by dynein-dynactin activity. 
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Interestingly, not all late endosomes and lysosomes (including MIIC) fuse with the plasma 
membrane upon arrival in the cell extremities. Especially in the case of MIIC, we could not 
detect changes in cell surface MHC class II molecules when minus-end transport was 
abrogated (unpublished results). Apparently, another regulatory step occurs close to the 
plasma membrane. For several lysosome-related organelles (LRO), including melanosomes 
and cytolytic granules, it has been shown that actin-based transport is required next to 
microtubule-based transport [32]. Again various Rab proteins are involved in this actin-based 
transport, including Rab27a, Rab3 and Rab8 [32,33].  
An illustrative example of the cooperation between actin-based and microtubule-based 
motors is found in melanosomes. Melanosomes are lysosome-related organelles and like 
lysosomes they move along microtubules in a bi-directional way via the alternating action of 
kinesin and dynein. In the periphery, melanosomes are captured in the peripheral actin via the 
small GTPase Rab27a and its effector protein Melanophilin/Slac2a [34-38]. Melanophilin 
interact with the actin motor Myosin Va and this tripartite structure has been shown to link 
melanosomes to peripheral actin prior to their transfer to the surrounding keratinocytes.   
Since melanosomes are related to lysosomes, we reasoned that Rab7 could also be 
involved in the transport of melanosomes. Moreover, it has been shown that delivery of TRP-
1, which is involved in melanosomal biogenesis, to the melanosomes is Rab7-dependent 
[39,40]. In chapter 6, we show that Rab7 is mainly present on early stage melanosomes, 
whereas Rab27a is present on more mature melanosomes. Their distribution overlapped on 
the intermediate stage melanosomes, which suggests maturation dependent activity of 
different Rab proteins. We showed that Rab7 and RILP are able to target a major part of the 
melanosomes to the MTOC. In addition, when both Rab7 and Rab27a are overexpressed we 
observed that many Rab7-positive compartments moved to the MTOC upon co-expression of 
RILP. The majority of the Rab7-positive compartments remaining in the periphery contained 
Rab27a as well. This suggests that there is a competition between Rab7 and Rab27a and their 
associated motors, dynein and myosin Va respectively.  
Fluorescent Recovery after Photo bleaching (FRAP) enabled us to measure the local 
activities of both Rab7 and Rab27a. Interestingly, the amount of Rab27a in the GTP-bound 
active state was extremely high in the tips of the melanocytes and less in the perinuclear area. 
The Rab7 activity did not show these extreme differences. This might explain why Rab27a 
overrules Rab7 in the periphery and therefore melanosomes in the periphery containing both 
Rab27a and Rab7 remain associated to the actin via Melanophilin/Myosin Va.  
Thus Rab7 keeps melanosomes in the perinuclear area during their early stages of 
maturation via the action of RILP and dynein. This might be required to keep the immature 
melanosomes close the Golgi in order to receive biogenetically-related proteins, like Trp1. As 
the melanosomes mature, they acquire Rab27a and ultimately are captured in the peripheral 
actin via the action of Rab27a effector Melanophilin/Slac2a and Myosin Va.  
Most likely many other proteins will be involved in the transport of mature melanosomes. 
For instance, activation of specific kinesin molecules might play a role in maturation of 
melanosomes, since kinesin is thought to cooperate with Myosin Va in the dispersion of 
melanosomes [41]. Recently, also Rab8 has been implicated in the actin-based transport of 
melanosomes, although its exact role has to be determined [33]. Rab3 and Rabphilin3a are 
found associated to melanosomes as well [42]. Interestingly, in endocrine cells Rab27a shares 
the effector Granulophilin with Rab3, indicating that Rab27a also functions in dense-core 
granule secretion [43]. Rab3 and Rab27a, however, have opposite effects on secretion. 
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Moreover, Fukuda has shown that several other effectors are shared among Rab3, Rab8 and 
Rab27a [44], again indicating a possible interplay between different Rabs in one pathway.  
 
Other lysosomal-related organelles that depend on Rab7 are phagosomes. Phagosomes are 
formed after the internalisation of pathogens by interaction with the endosomal system. By 
the sequential recruitment of endosomal proteins, phagosomes mature into phagolysosomes 
[45]. Normally, pathogens are killed and degraded in the phagolysosome. However, some 
pathogens, like Salmonella, M. Tuberculosis and M. Leprae, can actively inhibit fusion with 
proteolytic lysosomes. Hence, they create their own intracellular environment in which they 
are able to survive and replicate [46].  
Rab7 is required for the intracellular survival of Salmonella and phagosomes also require 
the action of kinesin and dynein for microtubule-based transport [47,48]. In Chapter 5 we 
described the involvement of the Rab7/RILP pathway in intracellular survival of Salmonella. 
Upon ectopic expression of RILP in cells infected with Salmonella, dynein-dynactin motors 
were massively recruited onto the Salmonella-containing vacuole (SCV). In addition, we 
observed an increase in fusion of SCV with mature lysosomes. Most likely, dynein facilitates 
the targeting of phagosomes towards the mature lysosomes. Moreover, RILP locks Rab7 in 
the active GTP-bound conformation which may also stimulate fusion with lysosomes. As 
result, the intracellular survival of Salmonella was dramatically reduced (Chapter 5). Thus by 
modulating the Rab7/RILP/dynein pathway, the intracellular survival of intracellularly 
growing pathogens, like Salmonella, was influenced. Interestingly, Salmonella has been 
shown to actively secret certain factors, like SifA, SopD, and SopE [49,50]. SopE is identified 
as a GEF for CDC42, involved in the actin rearrangements during uptake [51]. An obvious 
question would be whether any of the secreted factors interfere with the host cell Rab7 
pathway to block downstream events involved in the fusion with mature lysosomes. Recently, 
SifA has been shown to block RILP recruitment to the SCV and modulates the ‘normal’ fusion 
with lysosomes [52]. Most likely, other pathogen factors will target this pathway as well. 
 
The exact role of RILP in the lysosomal pathway is not completely clear yet. However, 
some additional information was obtained from the isolation of a splice variant of RILP, 
RILPsv (Chapter 4). RILPsv lacks aa 315-342 (Exon VII), yet still contains the Rab7 
interaction domain [53,54]. Like full-length RILP, RILPsv is able to lock Rab7 in the active 
conformation. However, one striking difference is observed, RILPsv fails to recruit the 
dynein-dynactin complex to late endocytic structures. As a result, upon overexpression of 
RILPsv, lysosomes do not cluster around the MTOC but smaller separated clusters were 
formed. The relative localisation to the Golgi nicely illustrates the difference between RILP 
and RILPsv. The lysosomal cluster in RILP expressing cells is located directly around the 
MTOC in between the Golgi, whereas the clusters in RILPsv expressing cells were localized 
outside the Golgi area further away from the MTOC. This implies that beside the N-terminal 
portion of RILP, also Exon VII is required for the RILP-mediated dynein-dynactin 
recruitment.  
Interestingly, although RILPsv does not efficiently recruit the minus-end motor complex it 
still causes lysosomal clustering. This is most likely due to the capacity of RILPsv to homo- 
and hetero-oligomerise with RILP (Chapter 4; [54,55]). The recent published crystal 
structure confirms that the Rab7-interacting domain of RILP forms a dimer. Two other 
proteins are reported with similar capacities, mVps18p and hVamp6p, both of which are 
involved in late endosomal and lysosomal fusion as well [56,57]. They contain a clathrin 
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homology (CLH) domain, which is sufficient for homo-oligomerisation and is required for 
induction of late endosomal/lysosomal clustering. mVps18p and hVam6p are mammalian 
homologues of proteins of the vacuolar homotypic fusion complex (HOPS) in yeast. They act 
in the tethering process preceding the actual fusion between late endocytic structures [58-61]. 
Interestingly, RILP-ΔN contains the Rab7-binding domain as well as the required for 
dimerisation, but no lysosomal clustering is observed. This suggests that the N-terminus 
probably interacts with other proteins involved in clustering of lysosomal compartments. 
Preliminary data suggest that these proteins are members of the HOPS complex. 
As already suggested above, Rab7 is most likely part of a complex of proteins involved in 
the transport and fusion of late endosomes and lysosomes, similar to the multi-protein Rab5 
complex on early endosomes [62]. This complex will include GEFs, effectors, SNAREs, 
tethering factors, and GAPs. Several Rab7-binding proteins have been isolated, such as the 
PI3-kinase Vps34 [63] and two Rab7 effectors are identified thus far, RILP and Rabring7 
[27,28,64]. Rabring7, like RILP, induces the clustering of Rab7-positive compartments. 
Rabring7 has a Zinc-finger motive, which is known to be involved in protein-protein 
interactions [64]. RILP as described above, couples fusion to transport of late endosomes and 
lysosomes, which will make the fusion process significantly more efficient.  
Although the motor is not yet identified, it has been suggested that Rab5 activity besides 
the plus-end motor KIF16B, is also linked to a minus-end directed motor activity [65]. Since 
many Rab proteins have been shown to link to motor proteins (Introduction), this may 
become a common feature of the Rab GTPases to enhance delivery of cargo to their targets by 




This thesis provides new insights in the regulation of late endosomal and lysosomal 
transport. We show the involvement of the Rab7/RILP/dynein pathway in the intracellular 
retention of late endosomal and lysosomal compartments like MIIC, phagosomes and 
melanosomes. The key question remains what regulates transport in the opposite (+ end) 
direction. Is it regulated directly or depending on the inactivation of the Rab7/RILP pathway? 
The rapid redistribution of late endocytic structures into the periphery upon disruption of 
dynein motor function supports the latter case. Thus by stimulating the Rab7/RILP pathway, 
contents of lysosomes can be kept intracellular. It has been shown that the cytokine IL-10 
largely reduces cell surface expression of MHC class II molecules by inhibiting transport of 
MIIC to the membrane [66], analogous to the effect of RILP. Several tumours secrete IL-10, 
most likely to reduce antigen presentation [67,68]. Interestingly, RILP mRNA levels are 
highly upregulated in monocytes treated with IL-10 (our unpublished data). This suggests that 
RILP-dependent retention of MIIC is, at least in part, responsible for the reduced antigen 
presentation by MHC class II molecules. Moreover, we have shown that activation of the 
Rab7/RILP pathway reduces the intracellular survival of Salmonella (Chapter 5). Thus the 
Rab7/RILP pathway might be an interesting target for manipulation in many different 
diseases in which transport and fusion of late endocytic structures like MIIC, phagosomes or 
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 Het immuunsysteem beschermt ons lichaam tegen de invasie van lichaamsvreemde 
eiwitten en schadelijke indringers, zoals bijvoorbeeld bacteriën. Cellen die de bacteriën 
opruimen omsluiten de bacterie in een membraan waardoor de bacterie in de cel opgenomen 
wordt. Hierbij wordt een afzonderlijk compartiment binnen in de cel gevormd dat dieper de 
cel in getransporteerd wordt via de zogenaamde endosomale route. Gedurende dit transport 
worden er continu eiwitten toegevoegd door fusie met andere compartimenten die zich in de 
cel bevinden, waardoor de samenstelling steeds veranderd. Door deze toevoegingen verzuurd 
het interne milieu van het compartiment wat optimaal is voor de afbraak van bijvoorbeeld 
bacteriën tot kleine fragmenten eiwit (peptiden). Dit relatief zure compartiment (laat 
endosoom/lysosoom) wordt vanaf dit stadium het MHC klasse II compartiment (MIIC) 
genoemd.  
 Vanuit de productie route van de cel, uit het endoplasmatisch reticulum, worden de MHC 
klasse II moleculen aangevoerd naar het MIIC. In het MIIC vindt vervolgens de associatie 
plaats van de bacteriële fragmenten (antigenen) met de MHC klasse II moleculen. Hierna 
wordt het compartiment naar het cel oppervlak wordt getransporteerd waardoor de klasse II 
moleculen met het bacteriële fragment aan het celopervlak gepresenteerd kunnen worden. De 
combinatie van de MHC klasse II moleculen met het bacteriële peptide wordt vervolgens 
herkent door cellen van het immuunsysteem, de T cellen. Als deze cellen herkenning 
registreren, sporen deze andere cellen van het immuunsysteem aan om antilichamen te maken 




Dit proefschrift bestudeert hoe de regulatie van het transport van het MIIC plaatsvindt. In 
de cel zijn naast het MIIC namelijk nog veel meer compartimenten met variërende 
samenstellingen die door de cel bewegen. Omdat elk compartiment een bepaald einddoel in 
de cel heeft, moet het transport op een gerichte manier plaatsvinden. De cel heeft daarvoor 
twee soorten wegen aangelegd. De snelwegen voor snel transport over langere afstanden, deze 
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worden microtubules genoemd en de locale binnenwegen worden gevormd door het actine 
netwerk. De microtubules lopen vanuit het midden van de cel, dichtbij de celkern 
(Microtubule organizing center) naar het cel oppervlak en vormen zo een uitgebreid netwerk 
door de hele cel. Transport langs de microtubules vindt plaats via motor eiwitten, die letterlijk 
over de microtubuli lopen terwijl ze een compartiment meedragen. Deze motoren lopen of in 
de richting van het celoppervlak of naar het midden van de cel, hetgeen gericht transport van 
compartimenten mogelijk maakt. Er zijn twee verschillende soorten motoren, kinesine die in 
de richting van het cel oppervlak loopt en dyneine, die compartimenten naar het midden van 
de cel brengt.  
 Als we nu het transport van de MIIC in levende cellen onder de microscoop volgen, valt op 
dat de compartimenten niet in een richting bewegen (Hoofstuk 2), maar steeds van richting 
veranderen. Wij hebben ontdekt dat dit komt doordat kinesine en dyneine tegelijkertijd 
associëren met het MIIC en als het ware met elkaar strijden om de richting van transport van 
het MIIC. Omdat de MHC klasse II moleculen geassocieerd met de bacteriële fragmenten 
uiteindelijk op het cel oppervlak moeten komen om herkent te worden door de cellen van het 
immuunsysteem, moet dit transport gecoördineerd worden. Om moleculen te vinden die de 
activiteit van deze motoren kunnen coördineren, hebben we gezocht naar potentiële kandidaat 
moleculen die geassocieerd zijn met het membraan van het MIIC. Een hiervan was Rab7. 
Rab7 is een onderdeel van een familie van eiwitten die functioneren als schakelaars in de cel. 
Als Rab7 aangeschakeld is (actieve staat), associeert het met het membraan van het MIIC, 
terwijl Rab7 zich los in de cel (in het cytoplasma) bevindt als het uitgeschakeld is (inactieve 
staat). Bij het aanschakelen van Rab7 verandert de vorm van Rab7, waardoor er 
bindingsplaatsen ontstaan voor andere moleculen die zich in de cel bevinden. Alleen 
moleculen die precies ‘passen’ (zogenaamde effector moleculen) kunnen binden, hetgeen een 
hoge specificiteit als gevolg heeft.  
 Wij hebben een dergelijk effector eiwit dat bindt aan de actieve staat van Rab7 
gekarakteriseerd, RILP (Rab7-interacting lysosomal protein). Tevens hebben wij ontdekt dat 
de binding van RILP aan Rab7 als gevolg heeft dat er meer dyneine motoren naar het 
membraan van het MIIC worden getrokken (Hoofdstuk 3). Hierdoor krijgen dyneine motoren 
de overhand over kinesine en beweegt het MIIC naar het midden van de cel. Het omgekeerde 
gebeurt echter als Rab7 uitgeschakeld wordt. In dat geval associeert Rab7 niet met het 
membraan van het MIIC, waardoor RILP niet kan binden en de dyneine motor niet wordt 
aangetrokken. Hierdoor wint kinesine van dyneine en als resultaat beweegt het MIIC naar het 
celoppervlak. Op deze manier kan Rab7 dus door aan en uit te schakelen het transport van de 
MIICs reguleren en daardoor de herkenning van bacteriële fragmenten aan het oppervlak door 
het immuunsysteem.  
  
 Hoofdstuk 4 beschrijft een variant van het RILP eiwit (RILPsv), dat een stukje van het 
gehele molecuul mist. Dit gebeurt door zogenaamde splicing van het DNA dat codeert voor 
het RILP eiwit, waarbij en gedeelte van het DNA ertussen uit wordt geknipt en RILP 
daardoor dit onderdeel mist. Wij hebben gevonden dat RILPsv nog wel aan de actieve staat 
van Rab7 kan binden, maar de dyneine motoren worden niet aangetrokken. Dit betekent dus 
dat het onderdeel dat RILPsv mist, een belangrijke functie heeft in het aantrekken van de 
dyneine motoren. Tevens weten we welk gedeelte van RILP van belang is bij de binding aan 
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Rab7, doordat we zelf RILP in stukjes kunnen onderverdelen. Op deze manier kunnen we 
analyseren welk onderdelen van RILP welke functies hebben.  
  
 In hoofdstuk 6 laten we zien dat naast het MIIC ook het transport van andere zure 
compartimenten in de cel gereguleerd kan worden door Rab7. Een voorbeeld hiervan zijn de 
zogenaamde melanosomen. Melanosomen zijn compartimenten in gespecialiseerde cellen die 
fungeren als kleine fabriekjes waar pigment (melanine) aangemaakt wordt. Als gevolg van 
UV straling worden dit proces aangewakkerd en worden de met melanine gevulde 
melanosomen naar het celoppervlak getransporteerd. Hier worden deze compartimenten in 
zijn geheel uitgescheiden door de cel en opgenomen door de huidcellen, waardoor deze 
huidcellen een donkere kleur krijgen (pigmentatie). Wij hebben laten zien dat Rab7 via het 
effector molecuul RILP een regulerende rol speelt in het transport van de melanosoom naar 
het celoppervlak. Wederom gebeurt dit via de aantrekking van de dyneine motor.  
 Bij het melanosomale transport speelt tevens een andere schakelaar uit dezelfde categorie 
een belangrijke rol, Rab27a. Net als Rab7, kan Rab27a aan en uitgeschakeld worden. Tevens 
associeert Rab27a in de actieve staat met het membraan, in dit geval het membraan van de 
melanosomen. Andere onderzoekers hebben gevonden dat Rab27a ook een effector eiwit 
heeft, Melanophilin, dat tevens aan de actieve staat van Rab27a bindt. Melanophilin zorgt 
voor de aantrekking van een andere soort motor, Myosine Va. Deze motor associeert met en 
beweegt via het actine netwerk. Actine bevindt zich voornamelijk vlak onder het 
celoppervlak, waardoor Rab27a met Melanophilin en Myosine Va zorgen dat de 
melanosomen onder het celoppervlak worden gevangen. Dit proces is vereist voor het 
efficiënt uitscheiden van de melanosomen. Dus de schakelaars Rab7 en Rab27a reguleren 
samen het transport van de melansosomen.  
  
 Hoofdstuk 5 laat een bijzonder geval van een bacterie zien die binnen in de cel kan 
overleven, zonder afgebroken te worden. Dit is de welbekende Salmonella bacterie. 
Salmonella wordt net als andere bacteriën de cel binnen gehaald, maar kan zelf actief tegen 
gaan dat het niet wordt afgebroken doordat het niet fuseert met de late lysosomale 
compartimenten dichtbij de kern, die de enzymen bevatten die nodig zijn voor het afbreken 
van de bacteriën. Het blijkt nu dat als we in deze cellen Rab7 geforceerd aanschakelen en dus 
RILP en de dyneine motor naar het membraan halen, Salmonella toch fuseert met de late 
lysosomen en daardoor alsnog wordt afgebroken. Dit duidt op een mogelijke actieve 
verstoring van het Rab7/RILP/dyneine complex door Salmonella, waardoor de werking van 
dit complex wordt verhinderd en het Salmonella-bevattend compartiment daardoor niet 
fuseert met de compartimenten die voor de afbraak zorgen.  
  
 Samenvattend geeft dit proefschrift nieuwe inzichten in de regulatie van het transport van 
verschillende zure compartimenten en laten we zien dat de schakelaar Rab7 en zijn effector 
eiwit RILP hierin een belangrijke rol spelen. Hierdoor vormen Rab7 en RILP nieuwe 
mogelijke targets voor het aanpakken van verschillende ziekten veroorzaakt door een 
verstoord transport van zure compartimenten. Hierbij moeten we niet alleen denken aan 
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